学术周报 · IF≥10 或专科旗舰刊
消化内科领域文献阅读汇编
2026年第45周 (2026-11-06) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Alimentary pharmacology & therapeutics | 12 | IF 6.8 |
| The American journal of gastroenterology | 12 | IF 8.5 |
| Gastrointestinal endoscopy | 8 | IF 8.0 |
| Pharmacological research | 4 | IF 12.2 |
| Gastroenterology | 4 | IF 29.7 |
| Journal of hepatology | 4 | IF 40.1 |
| Drugs | 3 | IF 14.7 |
| Journal of advanced research | 2 | IF 17.1 |
| EClinicalMedicine | 2 | IF 12.8 |
| Endoscopy | 2 | IF 11.8 |
1炎症性肠病/IBD (16篇)
临床研究 (10篇)
Therapeutic options for inflammatory bowel disease (IBD) have expanded rapidly with the introduction of selective interleukin (IL)-23 inhibitors, Janus kinase inhibitors, sphingosine-1-phosphate receptor modulators, and several emerging therapeutic classes. Consequently, the major clinical challenge has shifted from developing effective therapies to determining how best to position them within increasingly complex treatment algorithms. To review the contemporary and emerging therapeutic landscape in IBD, focusing on mechanism-based treatment positioning, disease modification, refractory disease, and novel therapeutic strategies that may overcome the current therapeutic ceiling. We performed a comprehensive review of PubMed, Ovid MEDLINE, Embase, and major international conference proceedings to identify pivotal clinical trials, long-term extension studies, comparative effectiveness studies, real-world evidence, and emerging therapeutic developments in IBD. Comparative studies have strengthened the positioning of selective iL-23 inhibitors as foundational therapies in IBD, while oral small molecules continue to expand with novel mechanisms and improved convenience. Emerging strategies targeting TL1A, fibrosis and advanced combination therapy offer the potential to further improve outcomes, particularly in refractory disease. However, important challenges remain regarding optimal treatment sequencing, patient selection, long-term safety and disease modification. Contemporary IBD management is increasingly defined by mechanism-based therapeutic positioning rather than simply expanding treatment options. Ongoing advances in comparative effectiveness research, novel therapeutic targets, and treatment strategies have the potential to further individualise care and improve long-term patient outcomes.
中文摘要:随着选择性IL-23抑制剂、Janus激酶抑制剂、鞘氨醇-1-磷酸受体调节剂及若干新兴治疗类别的引入,炎症性肠病(IBD)的治疗选择迅速扩展。主要临床挑战已从开发有效疗法转向如何在日益复杂的治疗算法中最佳定位这些疗法。本文综述IBD当代与新兴治疗格局,重点关注基于机制的治疗定位、疾病修饰、难治性疾病以及可能突破当前治疗天花板的新型治疗策略。研究对PubMed、Ovid MEDLINE、Embase及主要国际会议论文集进行了全面检索,以识别关键临床试验、长期扩展研究、比较有效性研究、真实世界证据及IBD新兴治疗进展。比较研究加强了选择性IL-23抑制剂作为IBD基础治疗的定位,口服小分子药物则凭借新机制和便利性持续扩展。靶向TL1A、纤维化及进阶联合治疗等新兴策略有望进一步改善结局,尤其在难治性疾病中。治疗顺序优化、患者选择、长期安全性及疾病修饰方面仍存在重要挑战。当代IBD管理正日益由基于机制的治疗定位所界定,而非仅由治疗选择扩展所决定。比较有效性研究、新治疗靶点及治疗策略的持续进展,有望进一步推动个体化诊疗并改善患者长期结局。
Criteria to define difficult-to-treat (DTT) inflammatory bowel disease (IBD) have recently been proposed, yet the inclusion and participation of patients with DTT-IBD in randomized controlled trials (RCTs) are heterogeneous and poorly defined. To explore inclusion and representation of patients with DTT-IBD in RCTs. We reviewed RCTs of advanced therapies (ATs) in ulcerative colitis (UC) and Crohn's disease (CD). DTT-IBD was defined as active disease despite exposure to ATs with ≥ 2 different mechanisms of action. Secondary analyses assessed eligibility and participation of patients exposed to ≥ 1 or ≥ 2 ATs irrespective of mechanism of action, and in CD only, active disease after ≥ 2 intestinal resections and fistulizing disease. We included 179 RCTs, 93 in UC and 86 in CD, comprising 54,258 patients. In UC, 72% (67/93) of studies included patients with prior exposure to ATs and 16.1% (15/93) included participants exposed to agents with ≥ 2 mechanisms of action (DTT); among the 10 trials reporting patient-level data, DTT-UC accounted for 16.2% (814/5019). In CD, 73.3% (63/86) of RCTs included patients with prior exposure to ATs, and 10.5% (9/86) reported patients with DTT-CD due to exposure to multiple classes of ATs. Patients with multifailure DTT-CD accounted for 22.4% (773/3455) of the reported study populations. Subgroup-specific efficacy outcomes for DTT-IBD were not reported, except for one small trial that enrolled only DTT-UC. Few RCTs of advanced medications include patients with DTT-IBD. In most trials, participants with DTT-IBD represent a minority of the study population, and subgroup-specific data are lacking.
中文摘要:近期提出了定义难治性(DTT)炎症性肠病(IBD)的标准,但DTT-IBD患者在随机对照试验(RCT)中的纳入和参与情况存在异质性且界定不清。为探讨DTT-IBD患者在RCT中的纳入和代表性,我们回顾了溃疡性结肠炎(UC)和克罗恩病(CD)中先进疗法的RCT。DTT-IBD定义为尽管暴露于≥2种不同作用机制的先进疗法仍存在活动性疾病。次要分析评估暴露于≥1种或≥2种先进疗法(不论作用机制)患者的合格性和参与情况,并仅在CD中评估≥2次肠切除后仍存在活动性疾病及瘘管性疾病。共纳入179项RCT,其中UC 93项、CD 86项,涉及54,258例患者。在UC中,72%(67/93)的研究纳入了既往暴露于先进疗法的患者,16.1%(15/93)纳入了暴露于≥2种作用机制药物(DTT)的参与者;在报告患者水平数据的10项试验中,DTT-UC占16.2%(814/5019)。在CD中,73.3%(63/86)的RCT纳入了既往暴露于先进疗法的患者,10.5%(9/86)报告了因暴露于多类先进疗法而属于DTT-CD的患者。多次治疗失败的DTT-CD患者占已报告研究人群的22.4%(773/3455)。除一项仅纳入DTT-UC的小型试验外,未报告DTT-IBD的亚组特异性疗效结局。很少有先进药物RCT纳入DTT-IBD患者。在多数试验中,DTT-IBD参与者仅占研究人群的少数,且缺乏亚组特异性数据。
Reliable biomarkers to distinguish ulcerative colitis (UC) from Crohn's disease (CD) remain limited. To assess the diagnostic accuracy of anti-integrin αvβ6 autoantibodies for differentiating UC from CD and to compare their performance with anti-neutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA). In this prospective cross-sectional study in patients with UC and CD, serum anti-integrin αvβ6 autoantibodies, ASCA, and ANCA were measured and clinical data were collected. The primary outcome was the accuracy of anti-integrin αvβ6 antibodies in distinguishing UC from CD. Secondary analyses compared their performance with ASCA and ANCA status and across IBD subgroups. A total of 224 patients were included (UC: n = 106, CD: n = 118, male: 63.8%, median age: 43.5 years). Patients with indeterminate colitis were excluded. At a cut-off of 2.44 U/mL, anti-integrin αvβ6 autoantibodies demonstrated a diagnostic accuracy of 86.5%, with a sensitivity of 85.8% and specificity of 87.1%. In a multivariate logistic regression analysis, these autoantibodies were independently associated with UC (OR 36.18, 95% CI 17.0-83.0, p = 4.86 × 10-19) and demonstrated superior diagnostic performance compared to ANCA and ASCA status (Akaike information criterion 184.8 vs. 252.4). Positivity rates followed a gradient across the Montreal classification, increasing from ileal (L1: 7.9%) and ileocolonic (L3: 8.1%) CD towards colonic CD (L2: 43.8%) and UC: 85.8% (p = 2.04 × 10-31). Anti-integrin αvβ6 autoantibodies demonstrate high diagnostic accuracy and outperform conventional serological markers in distinguishing UC from CD. Importantly, this study provides the first direct comparison with ANCA and ASCA status within the same patient cohort.
中文摘要:区分溃疡性结肠炎(UC)与克罗恩病(CD)的可靠生物标志物仍有限。评估抗整合素αvβ6自身抗体鉴别UC与CD的诊断准确性,并与抗中性粒细胞胞质抗体(ANCA)和抗酿酒酵母抗体(ASCA)的表现进行比较。这项前瞻性横断面研究纳入UC和CD患者,检测血清抗整合素αvβ6自身抗体、ASCA和ANCA,并收集临床数据。主要结局为抗整合素αvβ6抗体区分UC与CD的准确性。次要分析将其表现与ASCA和ANCA状态比较,并在IBD各亚组间比较。共纳入224例患者(UC 106例,CD 118例,男性63.8%,中位年龄43.5岁)。未定型结肠炎患者被排除。以2.44 U/mL为界值,抗整合素αvβ6自身抗体的诊断准确性为86.5%,敏感性85.8%,特异性87.1%。多因素logistic回归分析中,这些自身抗体与UC独立相关(OR 36.18,95% CI 17.0-83.0,p=4.86×10^-19),诊断表现优于ANCA和ASCA状态(赤池信息准则184.8对252.4)。阳性率在蒙特利尔分型中呈梯度变化,从回肠型(L1:7.9%)和回结肠型(L3:8.1%)CD向结肠型CD(L2:43.8%)及UC(85.8%)升高(p=2.04×10^-31)。抗整合素αvβ6自身抗体在鉴别UC与CD方面具有较高诊断准确性,并优于传统血清学标志物。该研究在同一患者队列中首次直接比较了ANCA和ASCA状态。
The expanding use of targeted therapies in inflammatory bowel disease has made treatment sequencing increasingly relevant, yet evidence on anti-TNF effectiveness after prior biologics with different mechanisms of action (MOA) remains limited. Our objective is to evaluate the durability of anti-TNF treatment in this scenario. Multicentre study based on data from the ENEIDA registry. Patients who received second-line anti-TNF therapy after a first biologic with a different MOA for active luminal disease were identified. Using propensity score matching, each case was matched with three controls from two cohorts: patients treated with second-line anti-TNF after another anti-TNF and patients receiving first-line anti-TNF therapy. Treatment durability and short- and long-term clinical effectiveness were assessed. Sixty-six Crohn's disease patients and 117 UC patients receiving anti-TNF after other MOA were included. In CD, second-line anti-TNF therapy after a different MOA (62% ustekinumab) was associated with a higher risk of treatment discontinuation compared with first-line anti-TNF therapy (HR 1.55; 95% CI, 1.05-2.30), without significant differences in short- or long-term clinical effectiveness. In UC, anti-TNF therapy after a different MOA (90% vedolizumab) was associated with lower treatment durability compared with first-line anti-TNF therapy (HR 1.69; 95% CI, 1.31-2.19) and with anti-TNF after another anti-TNF agent (HR 1.91; 95% CI, 1.48-2.48), its remission rates significantly lower at both short- and long-term follow-up (p < 0.001). Anti-TNF therapy used after a different MOA is associated with reduced effectiveness and durability compared with its use as first-line therapy or after another anti-TNF agent, especially in UC.
中文摘要:靶向治疗在炎症性肠病中的使用不断扩大,使治疗顺序问题日益重要,但关于既往使用不同作用机制生物制剂后anti-TNF疗效的证据仍有限。本研究旨在评估这一情景下anti-TNF治疗的持续性。研究为基于ENEIDA登记数据库的多中心研究,纳入因活动性腔内病变接受第一种不同作用机制生物制剂后,以anti-TNF作为二线治疗的患者。通过倾向评分匹配,每例患者与来自两个队列的各三例对照匹配:其一是使用另一种anti-TNF作为二线治疗的患者,其二是接受一线anti-TNF治疗的患者。评估治疗持续性以及短期和长期临床有效性。共纳入66例克罗恩病患者和117例溃疡性结肠炎患者,这些患者在采用其他作用机制药物后接受anti-TNF治疗。在克罗恩病中,不同作用机制药物后(62%为乌司奴单抗)使用二线anti-TNF,与一线anti-TNF治疗相比,治疗停用风险更高(HR 1.55;95% CI 1.05-2.30),短期或长期临床有效性无显著差异。在溃疡性结肠炎中,不同作用机制药物后(90%为维得利珠单抗)使用anti-TNF,与一线anti-TNF治疗相比治疗持续性更低(HR 1.69;95% CI 1.31-2.19),与另一种anti-TNF后使用anti-TNF相比也更低(HR 1.91;95% CI 1.48-2.48),其短期和长期随访缓解率均显著更低(p < 0.001)。不同作用机制药物后使用anti-TNF,与一线使用或另一种anti-TNF后使用相比,有效性和持续性降低,尤其在溃疡性结肠炎中更为明显。
Frailty is an important predictor of adverse outcomes in inflammatory bowel diseases (IBD); however, it has not been established which is the best way to measure frailty in IBD patients. To compare four frailty scales in elderly IBD patients and identify factors associated with this condition. Multicentre cohort study in IBD outpatients ≥ 60 years old using four frailty scales: Fried Frailty Phenotype (FFP), FRAIL scale, Clinical Frailty Score (CFS) and SHARE-FI. Clinical-demographic data and comorbidity indices (Charlson and CIRS-G) were obtained. The agreement between scales was evaluated, and logistic regression analysis was conducted to assess the factors associated with frailty. Six hundred and twelve patients (56.4% Crohn's disease) were enrolled from March to June 2024. Prevalence of frailty varied from 4.4% (FRAIL), 4.6% (CFS), 12.4% (SHARE-FI) up to 16.8% (FFP). The agreement between all the scales used was Fleiss' Kappa 0.25. Frailty was independently associated with polypharmacy and CIRS-G ≥ 3 on multivariate analysis of the four scales. Other factors, such as higher age, female gender, poor family support, disease duration of IBD, and clinical IBD activity were statistically associated with higher risk of frailty according to three of the four scales used. The prevalence of frailty in elderly IBD patients varies depending on the scale used. Polypharmacy and CIRS-G ≥ 3 are associated with a higher risk of frailty, regardless of the frailty assessment tool used. Further prospective studies are needed to identify the impact of frailty in elderly IBD patients and improve treatment strategies.
中文摘要:衰弱是炎症性肠病(IBD)不良结局的重要预测因素,但IBD患者衰弱的较佳测量方法尚未确定。研究比较四种衰弱量表在老年IBD患者中的应用,并识别与该状态相关的因素。该多中心队列研究纳入60岁及以上IBD门诊患者,使用Fried衰弱表型(FFP)、FRAIL量表、临床衰弱评分(CFS)和SHARE-FI四种量表。收集临床人口学资料及共病指数(Charlson和CIRS-G)。评估量表间一致性,并采用logistic回归分析评估与衰弱相关的因素。2024年3月至6月共纳入612例患者,其中克罗恩病占56.4%。衰弱患病率从4.4%(FRAIL)、4.6%(CFS)、12.4%(SHARE-FI)至16.8%(FFP)不等。所用量表间一致性为Fleiss Kappa 0.25。四种量表的多因素分析均显示,衰弱与多重用药及CIRS-G≥3独立相关。根据四种量表中的三种,较高年龄、女性、家庭支持较差、IBD病程和临床IBD活动度等因素与较高的衰弱风险存在统计学关联。老年IBD患者衰弱患病率随所用量表不同而变化。无论采用何种衰弱评估工具,多重用药和CIRS-G≥3均与较高的衰弱风险相关。仍需进一步前瞻性研究明确衰弱对老年IBD患者的影响并改进治疗策略。
Achieving mucosal healing has become a central therapeutic objective in treat-to-target strategies for Crohn's disease (CD). Capsule endoscopy, including small-bowel capsule endoscopy (SBCE) and pan-enteric capsule endoscopy (PCE), enables comprehensive mucosal evaluation and supports treatment optimization. This systematic review and meta-analysis aimed to evaluate the role of SBCE and PCE within treat-to-target strategies in patients with small-bowel or ileocolonic CD. A systematic search of PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and Google Scholar was conducted from inception to November 2025. Randomized clinical trials and observational studies using capsule endoscopy to monitor mucosal activity and guide therapy were included. The primary outcome was the proportion of patients achieving mucosal healing after targeted medical therapy. Pooled proportions were estimated using random-effects models, and heterogeneity was assessed using the I2 statistic. Nine studies comprising 321 patients were included. The weighted mean age was 31.3 years, and 46% of patients were male. Active disease was detected in 76.3% of patients at baseline, leading to treatment modification in 71% overall and in 93% of patients with active disease. After a weighted mean follow-up of 33.5 weeks, the pooled proportion of patients achieving mucosal healing was 27% (95% CI, 18%-38%), with substantial heterogeneity (I2 = 71%). Mucosal response was observed in 43% of patients, whereas 34% showed no response. Capsule retention was observed in 1 case. Capsule endoscopy enables comprehensive assessment of mucosal activity across the GI tract and supports proactive, individualized treatment optimization within treat-to-target strategies. Further prospective studies are needed to standardize outcome definitions and to clarify their impact on long-term clinical outcomes.
中文摘要:实现黏膜愈合已成为克罗恩病(CD)治疗达标策略的核心治疗目标。胶囊内镜,包括小肠胶囊内镜(SBCE)和全消化道胶囊内镜(PCE),能够全面评估黏膜并支持治疗优化。本系统综述与荟萃分析旨在评估SBCE和PCE在小肠型或回结肠型CD患者治疗达标策略中的作用。系统检索PubMed/MEDLINE、Cochrane对照试验中心注册库、ClinicalTrials.gov和Google Scholar,检索时间自建库至2025年11月。纳入使用胶囊内镜监测黏膜活动并指导治疗的随机临床试验和观察性研究。主要结局为接受靶向药物治疗后达到黏膜愈合的患者比例。采用随机效应模型估计合并比例,并使用I2统计量评估异质性。共纳入9项研究、321例患者。加权平均年龄为31.3岁,男性占46%。基线时76.3%的患者检出活动性疾病,总体71%的患者因此调整治疗,活动性疾病患者中该比例为93%。加权平均随访33.5周后,达到黏膜愈合的合并比例为27%(95% CI,18%-38%),异质性较大(I2=71%)。43%的患者出现黏膜应答,34%无应答。观察到1例胶囊滞留。胶囊内镜可全面评估全胃肠道的黏膜活动,并在治疗达标策略中支持主动、个体化的治疗优化。仍需进一步前瞻性研究以标准化结局定义并明确其对长期临床结局的影响。
Multiomic and multimodal datasets with detailed clinical annotations offer significant potential to advance understanding of inflammatory bowel diseases (IBDs), refine diagnostics, and enable personalized therapeutic strategies. In this multicohort study, an extensive multiomic and multimodal analysis of 1002 clinically annotated patients with IBD and non-IBD controls was performed, incorporating whole-exome and RNA sequencing of normal and inflamed gut tissues, serum proteomics, and histopathological assessments from images of H&E-stained tissue sections. Transcriptomic profiles of normal and inflamed tissues revealed distinct site-specific inflammatory signatures in Crohn's disease and ulcerative colitis. Leveraging serum proteomics, an inflammatory protein severity signature that reflects underlying intestinal molecular inflammation was developed. Furthermore, foundation model-based deep learning accurately predicted histologic disease activity scores and enabled Crohn's disease vs ulcerative colitis classification from images of H&E-stained intestinal tissue sections, offering a robust tool for clinical evaluation. This integrative, publicly available multiomics resource for IBD research highlights the potential of combining multiomics and advanced computational approaches to improve understanding and management of IBD.
中文摘要:带有详细临床注释的多组学和多模态数据集,对推进炎症性肠病理解、改进诊断和实现个体化治疗策略具有重要潜力。这项多队列研究对1002例有临床注释的IBD患者及非IBD对照开展了广泛的多组学和多模态分析,纳入正常与炎症肠道组织的全外显子组和RNA测序、血清蛋白质组学,以及H&E染色组织切片图像的组织病理学评估。正常与炎症组织的转录组谱显示,克罗恩病和溃疡性结肠炎具有不同的部位特异性炎症特征。利用血清蛋白质组学,研究建立了反映肠道分子炎症基础的炎症蛋白严重程度特征。基于基础模型的深度学习能够准确预测组织学疾病活动评分,并可从H&E染色肠道组织切片图像中区分克罗恩病与溃疡性结肠炎,为临床评估提供了稳健工具。这一公开可用的IBD多组学整合资源显示,多组学与先进计算方法结合可提升对IBD的理解和管理。
Inflammatory bowel diseases often require long-term treatment with advanced therapies, including biologics and small molecules. The use of these agents must be carefully balanced against the risks of uncontrolled gastrointestinal inflammation and the potential for treatment-related adverse events. This review synthesizes contemporary evidence on malignancy, infection, venous thromboembolism, and major adverse cardiovascular events in inflammatory bowel diseases, integrating risks attributable to underlying disease and those conferred by specific drug classes, with the goal of improving how clinicians communicate these risks to patients. Chronic intestinal inflammation increases the risk of colorectal cancer, small bowel adenocarcinoma, intestinal lymphoma, anal cancer in fistulizing Crohn's disease, and cholangiocarcinoma in those with primary sclerosing cholangitis, alongside modest excesses in select extraintestinal malignancies. Thiopurines increase the risk of lymphoma, particularly when combined with anti-tumor necrosis factor agents, and nonmelanoma skin cancer. Corticosteroid use is the major driver of serious infection, venous thromboembolism, and major adverse cardiovascular events, whereas combination anti-TNF-thiopurine therapy, Janus kinase inhibitors, and S1P receptor modulators are associated with therapy-specific and context-specific infectious and thrombotic risks, which remain low in absolute terms for most patients. Across outcomes, we emphasize absolute risk and patient-level modifiers, and provide pictorial tools that depict clinically meaningful risks to support shared decision-making and individualized, evidence-based risk communication with patients.
中文摘要:炎症性肠病常需长期使用先进治疗,包括生物制剂和小分子药物。使用这些药物时,须在未控制的胃肠道炎症风险与治疗相关不良事件风险之间仔细权衡。该综述整合了炎症性肠病中恶性肿瘤、感染、静脉血栓栓塞和主要不良心血管事件的最新证据,将基础疾病本身带来的风险与特定药物类别带来的风险一并考虑,旨在改善临床医生向患者传达这些风险的方式。慢性肠道炎症增加结直肠癌、小肠腺癌、肠道淋巴瘤、瘘管型克罗恩病中的肛癌以及原发性硬化性胆管炎患者中的胆管癌风险,并使部分肠外恶性肿瘤风险轻度升高。硫嘌呤增加淋巴瘤风险,与抗肿瘤坏死因子药物联用时尤为明显,并增加非黑色素瘤皮肤癌风险。糖皮质激素使用是严重感染、静脉血栓栓塞和主要不良心血管事件的主要驱动因素;抗TNF药物与硫嘌呤联合治疗、Janus激酶抑制剂和S1P受体调节剂则与治疗特异性和情境特异性的感染及血栓风险相关,对多数患者而言其绝对风险仍低。围绕各项结局,强调绝对风险和患者层面的效应修饰因素,并提供描绘具有临床意义风险的图示工具,以支持共享决策和个体化、循证的风险沟通。
The incidence of pediatric inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), is increasing worldwide. Thus, a thorough understanding of the development and presentation of pediatric IBD is essential. This study aims to establish and characterize a comprehensive population-based cohort of all patients with pediatric IBD in the North Denmark Region spanning 4 decades. We identified all children (n = 468) diagnosed with IBD in the North Denmark Region (589,936 inhabitants) during 1978-2020, establishing the Pediatric NorDIBD cohort. Patient characteristics were manually gathered from medical records. We examined developments in incidence, disease presentation, and family history of IBD over time. A total of 244 children with UC and 224 children with CD were diagnosed during 1978-2020. Incidence rate of pediatric IBD had increased 272%. The proportion of CD had increased. The median age at diagnosis was 15.4 years for both UC and CD and increased over time. In UC, the proportions of children diagnosed with pancolitis increased over time. For CD, most children were diagnosed with ileocolonic (39.3%) or colonic (40.2%) disease, and the proportion presenting with ileocolonic and penetrating CD increased over time. The 13% of patients who had a first-degree relative with IBD were younger at diagnosis. The newly established unselected population-based pediatric NorDIBD cohort shows an increase in both incidence and extensiveness of newly diagnosed pediatric IBD over the last 4 decades and provides a foundation for future research into the long-term outcomes of pediatric IBD.
中文摘要:儿童炎症性肠病(IBD)包括溃疡性结肠炎(UC)和克罗恩病(CD),全球发病率不断上升。因此,全面理解儿童IBD的发生与表现十分必要。本研究旨在建立并描述北丹麦地区跨越40年的全部儿童IBD患者基于人群的完整队列。我们识别了1978—2020年北丹麦地区(589,936名居民)所有诊断为IBD的儿童(n=468),建立Pediatric NorDIBD队列。患者特征从病历中人工收集。我们考察了发病率、疾病表现和IBD家族史随时间的变化。1978—2020年共有244名UC儿童和224名CD儿童被诊断。儿童IBD发病率上升272%。CD所占比例上升。UC和CD诊断时中位年龄均为15.4岁,并随时间增加。UC中,诊断为全结肠炎的儿童比例随时间上升。CD中,多数儿童诊断为回结肠型(39.3%)或结肠型(40.2%),回结肠型和穿透型CD比例随时间上升。13%的患者有一级亲属患IBD,这些患者诊断时更年轻。新建立的非选择性、基于人群的儿童NorDIBD队列显示,过去40年新诊断儿童IBD的发病率和病变范围均增加,并为未来儿童IBD长期结局研究提供了基础。
Interleukin (IL)-23 inhibition is now an established therapeutic strategy in inflammatory bowel disease (IBD), supported by the efficacy of selective IL-23p19 monoclonal antibodies in both Crohn's disease (CD) and ulcerative colitis (UC). Advances in peptide engineering have also enabled direct oral targeting of the IL-23 receptor (IL-23R), introducing an alternative approach to inhibition of the same inflammatory pathway. This narrative review examines the biological rationale for targeting the IL-23-IL-23R axis and the clinical evidence establishing selective IL-23p19 inhibition in IBD. Particular attention is given to the clinical development of icotrokinra, an oral macrocyclic peptide IL-23R antagonist. Phase 3 studies in psoriasis have established the efficacy of oral IL-23R antagonism, while the phase 2b ANTHEM-UC study has provided clinical evidence of efficacy in IBD, with improvements in clinical and endoscopic outcomes accompanied by translational evidence of pathway suppression. Ongoing phase 3 programmes in UC and CD will determine whether oral IL-23R antagonism can achieve durable clinical and endoscopic efficacy and establish its place alongside existing IL-23p19 monoclonal antibodies. If successful, this approach could represent a broader shift towards highly selective oral targeting of extracellular inflammatory pathways that have traditionally required biological therapy.
中文摘要:白细胞介素(IL)-23抑制现已成为炎症性肠病(IBD)的成熟治疗策略,选择性IL-23p19单克隆抗体在克罗恩病(CD)和溃疡性结肠炎(UC)中的疗效为此提供了支持。肽工程的进展使直接口服靶向IL-23受体(IL-23R)成为可能,为抑制同一炎症通路提供了另一种途径。本叙述性综述考察靶向IL-23–IL-23R轴的生物学依据,以及确立选择性IL-23p19抑制用于IBD的临床证据。重点讨论口服大环肽IL-23R拮抗剂icotrokinra的临床开发。银屑病3期研究已证实口服IL-23R拮抗的疗效,2b期ANTHEM-UC研究则提供了其在IBD中有效的临床证据,临床与内镜结局改善的同时伴有通路抑制的转化研究证据。正在进行的UC与CD 3期项目将判定口服IL-23R拮抗能否取得持久的临床与内镜疗效,并确立其与现有IL-23p19单克隆抗体并行的地位。若获得成功,这一途径可能代表更广泛的转变,即对传统上需要生物制剂治疗的细胞外炎症通路实现高选择性口服靶向。
基础研究 (6篇)
Inflammatory bowel disease (IBD) arises from a dynamic interplay between epithelial dysfunction, immune activation, microbial dysbiosis and tissue remodelling. Although hypoxia was initially regarded as a consequence of intestinal inflammation, it is now recognized as an active regulator of epithelial, immune and stromal responses that coordinate disease progression. Here, we propose that hypoxia acts as a biological organizer linking oxygen sensing to the transition from intestinal homeostasis to chronic inflammation and structural tissue damage. We use this term in a mechanistic rather than a hierarchical sense: oxygen availability is a shared upstream constraint on epithelial, immune, microbial and stromal programmes, not a single initiating event. This review integrates evidence connecting oxygen sensing with epithelial barrier integrity, immunometabolism, microbial ecology and stromal remodelling, with emphasis on advances in single-cell transcriptomics, spatial biology and microbiome research. Physiological low-oxygen gradients support epithelial metabolism, barrier integrity and immune tolerance, whereas persistent inflammatory hypoxia drives oxidative stress, metabolic reprogramming and maladaptive epithelial-immune-microbial interactions. Hypoxia also contributes to spatially distinct epithelial, immune and stromal niches that may sustain chronic inflammation and fibrotic progression. Microbial metabolites, including short-chain fatty acids and succinate, together with iron metabolism and ferroptosis, further link oxygen sensing to tissue injury, adaptation and repair. These findings position hypoxia-responsive signalling as a pharmacologically actionable network rather than a downstream consequence of inflammation. Targeting selected components may promote mucosal healing and limit structural disease progression, although successful translation will require cell- and isoform-selective modulation, adequate tissue exposure and careful assessment of long-term safety.
中文摘要:炎症性肠病(IBD)源于上皮功能障碍、免疫激活、微生物群失调和组织重塑之间的动态相互作用。缺氧最初被视为肠道炎症的结果,现在被认识到是协调疾病进展的上皮、免疫和基质反应的主动调节因素。我们提出缺氧作为连接氧感知与肠道稳态向慢性炎症和结构性组织损伤转变的生物学组织者。此处的「组织者」是机制意义上的,而非层级意义上的:氧可利用性是上皮、免疫、微生物和基质程序的共同上游限制,而不是单一启动事件。本综述整合了氧感知与上皮屏障完整性、免疫代谢、微生物生态和基质重塑相关的证据,重点介绍单细胞转录组学、空间生物学和微生物组研究的进展。生理性低氧梯度支持上皮代谢、屏障完整性和免疫耐受,而持续性炎症性缺氧驱动氧化应激、代谢重编程和适应不良的上皮-免疫-微生物相互作用。缺氧还促成空间上不同的上皮、免疫和基质生态位,可能维持慢性炎症和纤维化进展。微生物代谢物,包括短链脂肪酸和琥珀酸,连同铁代谢和铁死亡,进一步将氧感知与组织损伤、适应和修复联系起来。这些发现将缺氧反应信号定位为药理学上可干预的网络,而非炎症的下游结果。靶向选定组分可能促进黏膜愈合并限制结构性疾病进展,但成功转化需要细胞和异构体选择性调节、足够的组织暴露以及长期安全性的审慎评估。
Methotrexate (MTX) is a gold standard therapy for inflammatory diseases but has mixed therapeutic success in inflammatory bowel disease (IBD). The gut microbiota impact MTX efficacy and toxicity by metabolizing MTX and altering its bioavailability, yet how inflammation alters this metabolism, and how the resulting metabolites act on the host, remain poorly understood. Here, we find that gut microbes, notably Clostridium asparagiforme, metabolize MTX via carboxypeptidase G2 (CPDG2) to produce deoxyaminopteroic acid (DAMPA). In intestinal epithelial cells, DAMPA preserves mitochondrial health through mitochondrial signal transducer and activator of transcription 3 (STAT3) signaling and enhances mitophagy. DAMPA administration attenuates intestinal inflammation in vivo, and remodels colonic mitochondrial pathways. IBD mouse models show reduced microbial CPDG2 and DAMPA, while patients with IBD show reduced CPDG2 gene abundance and suppressed DAMPA-enriched mitochondrial pathways, potentially explaining MTX outcomes in IBD. Together, these findings reframe microbial MTX metabolism from passive drug detoxification to active regulation of host mitochondrial and inflammatory homeostasis.
中文摘要:甲氨蝶呤(MTX)是炎症性疾病的金标准治疗,但在炎症性肠病(IBD)中的治疗成败不一。肠道菌群通过代谢MTX并改变其生物利用度影响MTX疗效和毒性,但炎症如何改变这一代谢、产生的代谢物如何作用于宿主仍知之甚少。本研究发现肠道微生物尤其是天冬酰胺梭菌(Clostridium asparagiforme)通过羧肽酶G2(CPDG2)代谢MTX,生成脱氧氨基蝶呤酸(DAMPA)。在肠上皮细胞中,DAMPA通过线粒体信号转导与转录激活因子3(STAT3)信号维持线粒体健康并增强线粒体自噬。给予DAMPA可在体内减轻肠道炎症,并重塑结肠线粒体通路。IBD小鼠模型显示微生物CPDG2和DAMPA减少,IBD患者则表现为CPDG2基因丰度降低及DAMPA富集的线粒体通路受抑制,这可能解释MTX在IBD中的治疗结局。这些发现将微生物MTX代谢从被动药物解毒重新定义为对宿主线粒体和炎症稳态的主动调节。
Endoplasmic reticulum (ER) stress and mitochondrial dysfunction are key pathogenic drivers in inflammatory bowel disease (IBD). Chronic ER stress impairs epithelial barrier integrity and stimulates inflammatory pathways, causing cell death. Simultaneously, mitochondrial dysfunction results in excessive reactive oxygen species production, bioenergetic failure, and defective mitophagy, further disrupting intestinal homeostasis. Notably, these two organellar stress responses are physically and functionally linked via mitochondria-ER contacts (MERCs), which form signaling platforms-mitochondria-associated ER membranes. These platforms coordinate calcium transfer and redox signaling while integrating autophagy and the unfolded protein response (UPR). This review comprehensively summarizes the current molecular mechanisms by which ER stress and mitochondrial dysfunction aid IBD pathogenesis, emphasizing calcium homeostasis imbalance, oxidative stress, disrupted mitochondrial quality control, and autophagy-UPR integration. Furthermore, this article highlights the functional interplay between the ER and mitochondria, as well as the MERCs that structurally connect them. Additionally, it discusses emerging diagnostic biomarkers and therapeutic strategies based on these mechanisms, aiming to offer theoretical insights and novel perspectives for IBD research and clinical intervention.
中文摘要:内质网应激与线粒体功能障碍是炎症性肠病(IBD)的关键致病驱动因素。慢性内质网应激损害上皮屏障完整性并激活炎症通路,导致细胞死亡。同时,线粒体功能障碍造成活性氧过量产生、生物能量衰竭和线粒体自噬缺陷,进一步破坏肠道稳态。这两类细胞器应激反应通过线粒体-内质网接触(MERCs)在物理和功能上相互联系,后者形成信号平台——线粒体相关内质网膜。这些平台协调钙转移和氧化还原信号,同时整合自噬与未折叠蛋白反应(UPR)。该综述全面总结内质网应激和线粒体功能障碍促进IBD发病的当前分子机制,重点涉及钙稳态失衡、氧化应激、线粒体质量控制受损以及自噬-UPR整合。文章还强调内质网与线粒体之间的功能相互作用,以及将其在结构上连接的MERCs。文中还讨论基于这些机制的新兴诊断生物标志物和治疗策略,旨在为IBD研究和临床干预提供理论见解与新视角。
The regulatory mechanisms that maintain colonic immune homeostasis remain incompletely understood. Here we show that genetic deletion of Zbtb44, a previously uncharacterized member of the ZBTB transcription factor family, leads to spontaneous colitis and rectal prolapse. Zbtb44-/- T cells expressed increased IFN-γ, a pro-inflammatory cytokine strongly associated with human inflammatory bowel disease. Mechanistically, Zbtb44 undergoes SUMOylation, which facilitates its interaction with a conserved SUMO-interacting motif in T-bet, enabling binding to the IFN-γ promoter and enhancer to restrain chronic IFN-γ production. Together, these findings demonstrate that Zbtb44 is a key regulator of colonic inflammation, a role that could be exploited therapeutically.
中文摘要:维持结肠免疫稳态的调控机制仍不完全清楚。Zbtb44是ZBTB转录因子家族中此前未被表征的成员,其基因缺失会导致自发性结肠炎和直肠脱垂。Zbtb44-/- T细胞表达增多的IFN-γ,这是一种与人类炎症性肠病密切相关的促炎细胞因子。机制上,Zbtb44发生SUMO化,这促进其与T-bet中一个保守的SUMO相互作用基序结合,使其能够结合IFN-γ启动子和增强子,从而限制慢性IFN-γ产生。这些发现表明,Zbtb44是结肠炎症的关键调控因子,这一作用可用于治疗开发。
Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), is a chronic, relapsing inflammatory disorder of the intestine driven by disruption of mucosal immune balance. In this context, mucosal inflammation, oxidative stress, and damage to the epithelial barrier reinforce one another and form a self-perpetuating cycle. Oral nanozymes that combine catalytic removal of reactive oxygen species with in vivo imaging readouts provide a potential platform for site-focused intervention and imaging-based evaluation of IBD. This review focuses on how oral nanozymes are designed to couple imaging and therapy and summarizes recent progress in two overarching directions: single-modality imaging-guided strategies and multimodal imaging-guided strategies. Within the single-modality group, current studies are discussed mainly as computed tomography (CT)-guided strategies and optical/photoacoustic (PA)-guided strategies according to their dominant signal-generation mechanisms. Multimodal imaging-guided strategies, by contrast, integrate structural and functional information on a single platform to support more informative preclinical assessment of IBD. This paper also discusses current limitations in oral delivery, characterization of enzyme-like activity, imaging assessment, and long-term biosafety, thereby outlining key design principles for the next generation of oral nanozymes for visual theranostics in IBD.
中文摘要:炎症性肠病(IBD)包括溃疡性结肠炎(UC)和克罗恩病(CD),是肠道慢性复发性炎症性疾病,由黏膜免疫平衡破坏驱动。黏膜炎症、氧化应激和上皮屏障损伤相互强化,形成自我延续的循环。口服纳米酶将活性氧的催化清除与体内成像读出结合,为IBD的病灶靶向干预和基于成像的评估提供潜在平台。综述聚焦口服纳米酶如何设计以实现成像与治疗耦合,并总结两个总体方向的最新进展:单模态成像引导策略和多模态成像引导策略。单模态组中,按主要信号产生机制,现有研究主要讨论为CT引导策略和光学/光声(PA)引导策略。多模态成像引导策略则在一个平台上整合结构与功能信息,以支持更具信息量的IBD临床前评估。文中还讨论口服递送、类酶活性表征、成像评估和长期生物安全性方面的当前局限,进而勾勒用于IBD可视化诊疗的下一代口服纳米酶的关键设计原则。
Tumor necrosis factor (TNF) is a key driver of intestinal epithelial inflammation. The baculoviral inhibitor of apoptosis protein repeat-containing 3 (BIRC3) gene encodes the cellular inhibitor of apoptosis protein 2 (cIAP2), a known regulator of TNF signaling. Although genetic variants in components of the TNF signaling pathway have been reported, no human BIRC3 variants have been previously identified. We screened exomes obtained from Crohn's disease (CD) patients from multiple centers for BIRC3 variants. We used cellular, mouse organoids, induced pluripotent stem cells-derived intestinal organoids, knock-in and knockout mouse models, and knockout zebrafish, as well as transcriptome analysis of various samples to determine pathogenicity of BIRC3 variants. Rare and damaging BIRC3 variants were identified in 14 patients from 10 unrelated families with CD diagnosed between infancy and adulthood. Functional studies showed that BIRC3 deficiency caused impaired receptor-interacting protein kinase 1 (RIPK1) ubiquitylation, leading to RIPK1 autophosphorylation resulting in increased epithelial cell death. The p.H312Y cIAP2 variant identified in both our index and in another independent patient was mislocalizaed, and a knock-in mouse model of this BIRC3 variant (cIAP2H312Y/+) had exacerbation of chemically induced colitis, whereas ciap1-/+ zebrafish developed spontaneous colitis. Transcriptome analysis of mice organoids and zebrafish showed that BIRC3 deficiency led to inappropriate sustained activation of TNF-responsiveness genes in the absence of stimuli. Small molecule pharmacologic inhibition of RIPK1 or caspases attenuated intestinal inflammation in BIRC3-deficient intestinal organoids and cIAP2H312Y/+ mice. We establish BIRC3 deficiency as a cause of monogenic CD in both pediatric- and adult-onset patients and identify RIPK1 as a therapeutic target.
中文摘要:TNF是肠道上皮炎症的关键驱动因子。BIRC3基因编码细胞凋亡抑制蛋白2(cIAP2),后者是TNF信号通路的已知调节因子。尽管TNF信号通路组分的遗传变异已有报道,此前未发现人类BIRC3变异。我们对来自多个中心的克罗恩病(CD)患者外显子进行筛查以寻找BIRC3变异。我们采用细胞、小鼠类器官、诱导多能干细胞来源的肠道类器官、敲入和敲除小鼠模型、敲除斑马鱼,以及多种样本的转录组分析,确定BIRC3变异的致病性。在10个无亲缘关系的家系中,14例于婴儿期至成年期诊断为CD的患者中鉴定出罕见且有害的BIRC3变异。功能研究显示,BIRC3缺陷导致受体相互作用蛋白激酶1(RIPK1)泛素化受损,引起RIPK1自身磷酸化,进而增加上皮细胞死亡。在先证者及另一名独立患者中均发现的p.H312Y cIAP2变异发生错定位,该BIRC3变异的敲入小鼠模型(cIAP2H312Y/+)化学诱导结肠炎加重,而ciap1-/+斑马鱼发生自发性结肠炎。小鼠类器官和斑马鱼的转录组分析显示,BIRC3缺陷导致在无刺激情况下TNF反应基因不适当的持续激活。小分子药物抑制RIPK1或caspase可减轻BIRC3缺陷肠道类器官和cIAP2H312Y/+小鼠的肠道炎症。我们确立BIRC3缺陷是儿童期和成年期发病患者单基因CD的原因,并确定RIPK1为治疗靶点。
2病毒性肝炎 (8篇)
临床研究 (6篇)
Paediatric chronic hepatitis C (PCHC) is often asymptomatic and underdiagnosed, and its contemporary global burden remains incompletely characterised. We estimated global, national, and socioeconomic trends in PCHC using Global Burden of Disease (GBD) 2023 estimates, and hepatitis C virus (HCV)-related liver cancer as a limited Supplementary analysis. We analysed GBD 2023 estimates of prevalence, mortality, and disability-adjusted life years (DALYs) for PCHC in people younger than 20 years from 1990 to 2023. Results were summarised globally, across seven official GBD super-regions, and for 204 countries and territories using annual point estimates and supplied 95% uncertainty intervals. Because HCV-related liver cancer estimates were unavailable for children younger than 10 years, analyses of this endpoint were restricted to ages 10-19 years. Global PCHC prevalence was 0.380% (95% uncertainty interval [UI] 0.314-0.452) in 2023, representing a decline from 0.443% (0.376-0.514) in 1990, with an absolute change of -0.062 percentage points and a relative change of -14.1%. Mortality declined from 0.0890 (0.0504-0.1538) to 0.0595 (0.0303-0.1023) deaths per 100,000 population younger than 20 years, and the DALY rate declined from 7.49 (4.36-12.92) to 5.06 (2.62-8.40) per 100,000. The highest prevalences clustered in Central Asia, South-East Asia, and sub-Saharan Africa. The PCHC burden has declined globally, particularly mortality and DALYs, but prevalence has fallen only modestly. The continued high burden in Central Asia, South-East Asia, and sub-Saharan Africa, and marked country heterogeneity highlight the need to integrate antenatal screening, follow-up of perinatally exposed infants, and access to curative treatment for children aged 3 years or older into hepatitis elimination programmes in order to reach the 2030 elimination targets. National Institutes of Health.
中文摘要:儿童慢性丙型肝炎(PCHC)常无症状且诊断不足,其当代全球疾病负担仍未得到充分描述。研究利用全球疾病负担(GBD)2023估计值评估PCHC的全球、国家和社会经济趋势,并将丙型肝炎病毒(HCV)相关肝癌作为有限的补充分析。分析纳入GBD 2023中1990至2023年20岁以下人群PCHC的患病率、死亡率和伤残调整生命年(DALYs)估计值,结果按全球、七个GBD官方超级区域以及204个国家和地区汇总,采用年度点估计及提供的95%不确定性区间。由于10岁以下儿童缺乏HCV相关肝癌估计值,该终点分析限于10至19岁。2023年全球PCHC患病率为0.380%(95%不确定性区间[UI] 0.314-0.452),低于1990年的0.443%(0.376-0.514),绝对变化为-0.062个百分点,相对变化为-14.1%。死亡率由每10万名20岁以下人群0.0890(0.0504-0.1538)例死亡降至0.0595(0.0303-0.1023)例,DALY率由每10万人7.49(4.36-12.92)降至5.06(2.62-8.40)。患病率最高者集中于中亚、东南亚和撒哈拉以南非洲。全球PCHC负担下降,死亡率和DALYs尤为明显,但患病率仅小幅下降。中亚、东南亚和撒哈拉以南非洲的持续高负担及明显的国家间异质性,提示需将产前筛查、围产期暴露婴儿随访以及3岁及以上儿童获得治愈性治疗纳入肝炎消除规划,以实现2030年消除目标。美国国立卫生研究院。
People who inject drugs (PWID) may engage in sexual behaviours that increase their HIV and hepatitis C virus (HCV) risk, including sex work and male-with-male sexual activity. We undertook a global systematic review to assess whether PWID who engage in these behaviours have higher HIV and HCV acquisition risks. In this systematic review and meta-analysis, we searched MEDLINE, Embase, and PsycINFO for studies among PWID published between 01/01/2000 and 09/06/2026 that included estimates of the association between male-with-male sex or sex work and our primary outcomes of HIV or HCV incidence. Studies that estimated incidence by longitudinally re-testing people at risk of infection or by using assays for recent infection were eligible for inclusion. We also contacted authors for unpublished estimates. We pooled estimates using random-effects meta-analysis. We used I2 to assess heterogeneity, and we used Egger's test to assess publication asymmetry. This review is registered with Prospero (CRD42020220884). We included 57 studies comprising 164 estimates. Among men, recent male-with-male sex was associated with higher HIV acquisition (pooled incidence rate ratio (IRR):2.35; 95% CI: 1.51-3.66; I2: 51%).) but not HCV (IRR: 1.28; 95% CI: 0.95-1.72; I2: 21%). Recent sex work had a 1.72-fold (95% CI: 1.30-2.28; I2: 65%) and 1.59-fold (95% CI: 1.29-1.96; I2: 60%) higher HIV and HCV acquisition risk among all PWID, respectively. When stratified, sex work was associated with higher HIV acquisition among women (IRR: 2.30; 95% CI: 1.44-3.68; I2: 68%) but not men (IRR: 1.43; 95% CI: 0.92-2.22; I2: 51%), and was associated with HCV acquisition among men (IRR: 1.51; 95% CI: 1.22-1.87; I2: 0%), but not women (IRR: 1.26; 95% CI: 0.90-1.77; I2: 55%). For lifetime behaviours, only male-with-male sex was associated with HIV acquisition (IRR: 2.44; 95% CI: 1.18-5.02; I2 = 87%). Results from Egger's tests did not provide evidence of asymmetry bias for our pooled estimates, while I2 measures suggested considerable heterogeneity for many outcomes. PWID who also engage in sex work or male-with-male sex were found to have higher HIV or HCV acquisition risks. Future research should aim to understand the mechanisms driving these associations. Medical Research Council Greater Western Four Partnership Doctoral Training Partnership, Wellcome Trust, Canadian Institutes of Health Research and Medical Research Council.
中文摘要:注射吸毒者(PWID)可能参与增加其HIV和丙型肝炎病毒(HCV)感染风险的性行为,包括性工作和男男性行为。我们开展全球系统综述,评估参与这些行为的PWID是否具有更高的HIV和HCV感染风险。在这项系统综述和荟萃分析中,我们检索MEDLINE、Embase和PsycINFO中2000年1月1日至2026年9月6日发表的PWID研究,这些研究纳入了男男性行为或性工作与主要结局HIV或HCV发病率之间关联的估计值。通过纵向重复检测感染风险人群或使用近期感染检测方法估计发病率的研究符合纳入条件。我们还联系作者获取未发表的估计值。采用随机效应荟萃分析合并估计值,使用I2评估异质性,使用Egger检验评估发表不对称。该综述已在Prospero注册(CRD42020220884)。共纳入57项研究,包含164个估计值。在男性中,近期男男性行为与更高的HIV感染风险相关(合并发病率比(IRR):2.35;95% CI:1.51-3.66;I2:51%),但与HCV感染风险无关(IRR:1.28;95% CI:0.95-1.72;I2:21%)。近期性工作使全部PWID的HIV和HCV感染风险分别升高1.72倍(95% CI:1.30-2.28;I2:65%)和1.59倍(95% CI:1.29-1.96;I2:60%)。分层分析中,性工作与女性更高的HIV感染风险相关(IRR:2.30;95% CI:1.44-3.68;I2:68%),与男性无关(IRR:1.43;95% CI:0.92-2.22;I2:51%);性工作与男性HCV感染风险相关(IRR:1.51;95% CI:1.22-1.87;I2:0%),与女性无关(IRR:1.26;95% CI:0.90-1.77;I2:55%)。对于终生行为,仅男男性行为与HIV感染风险相关(IRR:2.44;95% CI:1.18-5.02;I2=87%)。Egger检验结果未提供合并估计值存在不对称偏倚的证据,I2提示许多结局存在相当大的异质性。参与性工作或男男性行为的PWID具有更高的HIV或HCV感染风险。未来研究应致力于理解驱动这些关联的机制。资助来源:Medical Research Council Greater Western Four Partnership Doctoral Training Partnership、Wellcome Trust、Canadian Institutes of Health Research和Medical Research Council。
The opioid epidemic has led to an infectious diseases syndemic, with injection drug use responsible for driving rising rates of HIV, viral hepatitis, and serious bacterial and fungal infections. Opioid use continues to cause devastating mortality, with over 80,000 opioid-involved overdose deaths in the USA in 2022. Despite the proven effectiveness of opioid agonist therapy, specifically methadone and buprenorphine, treatment coverage remains inadequate, with profound gaps in opioid use disorder (OUD) continuum of care. Injection-related infections, particularly skin and soft tissue infections, bacteremia, osteomyelitis, and infective endocarditis, have increased substantially since the early 2000s and carry a high risk of morbidity and mortality. Risk is further compounded by criminalization, stigma, incarceration, and comorbid psychiatric conditions. Emerging concerns such as xylazine-associated necrotic wounds illustrate the dynamic intersection of substance use and infectious disease. While direct-acting antivirals have made hepatitis C curable, barriers to treatment persist, and uptake of HIV prevention strategies, including pre-exposure prophylaxis, remains low among people who inject drugs. Integration of addiction treatment into infectious disease and hospital care improves outcomes, yet systemic and policy barriers limit access. Innovative models such as syringe service programs, mobile units, and inpatient addiction consult services demonstrate the feasibility of integrated, patient-centered care. Evidence gaps remain regarding optimal antibiotic strategies for serious infections in people with OUD, and research and policy must address exclusionary practices, stigma, and fragmented systems of care. A synergistic approach integrating OUD treatment, infectious disease management, risk reduction, and trauma-informed care is essential to reduce preventable deaths and improve long-term health outcomes.
中文摘要:阿片类药物流行已形成感染性疾病协同流行,注射吸毒推动HIV、病毒性肝炎以及严重细菌和真菌感染的发生率上升。阿片类药物使用仍在造成沉重死亡负担,2022年美国与阿片类药物相关的过量死亡超过80000例。阿片受体激动剂治疗,尤其是美沙酮和丁丙诺啡,已被证实有效,治疗覆盖仍不足,阿片类药物使用障碍(OUD)照护连续体存在明显缺口。注射相关感染,特别是皮肤软组织感染、菌血症、骨髓炎和感染性心内膜炎,自2000年代初以来大幅增加,并带来较高的发病和死亡风险。犯罪化、污名、监禁以及合并精神疾病进一步放大了风险。赛拉嗪相关坏死性伤口等新出现的问题,说明物质使用与感染性疾病之间存在动态交叉。直接抗病毒药物已使丙型肝炎可治愈,治疗障碍仍然存在,注射吸毒人群对HIV预防策略包括暴露前预防的接受度仍低。将成瘾治疗整合进感染性疾病和医院照护可改善结局,系统性和政策障碍限制了可及性。注射器服务项目、移动单元和住院成瘾会诊服务等创新模式,证明了以患者为中心的整合照护具有可行性。关于OUD患者严重感染的最佳抗生素策略仍存在证据缺口,研究和政策必须处理排斥性做法、污名和碎片化照护系统。将OUD治疗、感染性疾病管理、风险降低和创伤知情照护结合起来形成协同路径,对减少可预防死亡和改善长期健康结局至关重要。
Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis, with highly heterogeneous outcomes ranging from viral control to persistent viraemia and progressive liver disease. The Human Leukocyte Antigen (HLA) system plays a central role in antiviral immunity, yet its contribution to HDV disease remains poorly defined. We aimed to identify HLA genetic polymorphisms associated with virological control and disease severity. High-resolution genotyping of classical (A, B, C, DPB1, DQB1, DRB1) and non-classical (E, G) HLA was performed in 72 anti-HDV-positive patients. A group of healthy donors (N = 150) was used as a reference. Patients were stratified by longitudinal HDV RNA status into viraemic (persistent viraemia, N = 36) and non-viraemic (undetectable viraemia, N = 36) groups. Clinical data, including liver fibrosis stage, were collected. T cell receptor (TCR) β-chain sequencing was performed in isolated CD3+ T cells from viraemic patients and compared to a group of healthy donors (HD; N = 44). The HLA-A*11:01 allele was exclusively observed in viraemic patients (p-value < 0.001, FDR = 0.02; allele frequency = 0.15). Multivariate analysis confirmed its independent association with persistent viraemia and advanced fibrosis. Notably, its frequency did not differ between our cohort and the overall reference population. Furthermore, viraemic HLA-A*11:01 carriers exhibited significantly higher TCRβ chain clonality, consistent with a restricted and potentially ineffective antiviral T-cell response. HLA-A*11:01 identifies a subgroup of HDV patients at high risk of persistent viral replication and advanced fibrosis. The integration of HLA genotyping into risk stratification algorithms may help to early identify patients requiring intensified monitoring and timely therapeutic intervention.
中文摘要:丁型肝炎病毒(HDV)感染是最严重的病毒性肝炎,结局高度异质,从病毒控制到持续性病毒血症和进行性肝病不等。人类白细胞抗原(HLA)系统在抗病毒免疫中起核心作用,但其对HDV疾病的影响仍不清楚。研究旨在识别与病毒学控制和疾病严重程度相关的HLA基因多态性。对72例抗-HDV阳性患者进行经典(A、B、C、DPB1、DQB1、DRB1)和非经典(E、G)HLA高分辨率基因分型,并以150名健康供者作为参照。按纵向HDV RNA状态将患者分为病毒血症组(持续性病毒血症,N=36)和无病毒血症组(病毒血症检测不到,N=36),收集包括肝纤维化分期在内的临床数据。对病毒血症患者分离的CD3+ T细胞进行T细胞受体(TCR)β链测序,并与健康供者组(HD;N=44)比较。HLA-A*11:01等位基因仅见于病毒血症患者(p值<0.001,FDR=0.02;等位基因频率=0.15)。多变量分析证实其与持续性病毒血症和晚期纤维化独立相关。该等位基因频率在本队列与总体参照人群之间无差异。病毒血症的HLA-A*11:01携带者TCRβ链克隆性显著更高,符合受限且可能无效的抗病毒T细胞应答。HLA-A*11:01可识别具有持续性病毒复制和晚期纤维化高风险的HDV患者亚组。将HLA基因分型纳入风险分层算法可能有助于早期识别需要加强监测和及时治疗干预的患者。
Virus-specific T-cell dysfunction is a hallmark of chronic hepatitis B (CHB), and its reversal may represent a potential strategy for achieving an HBV cure. A deeper understanding of the T-cell correlates of viral persistence and infection control is needed to clarify the role of CD8 T cells in CHB pathogenesis and to identify novel therapeutic targets for effective T-cell reconstitution. Core- and polymerase-specific CD8 T cells from untreated, highly viremic, HBeAg-negative patients with CHB were analyzed by RNA sequencing and compared with those from patients who achieved a functional cure after nucleos(t)ide analogue treatment (rNUC) or acute hepatitis B (rACU). Histone acetylation levels, cytokine production, and cytotoxic activity were evaluated in T cells from patients with CHB following histone deacetylase inhibition. A 101-gene "resolution signature", shared by both resolution groups and distinguishing them from patients with CHB, was identified, along with 41 genes whose dysregulation was not reversed in rNUC patients. Although most dysregulated genes exhibited similar expression patterns in core- and polymerase-specific CD8 T cells from patients with CHB, approximately 30% showed discordant behavior. Targeting aberrant transcriptional regulation with entinostat significantly increased histone acetylation levels and improved T-cell function. Mechanisms underlying dysfunction in core- and polymerase-specific CD8 T cells are only partially shared between these two subsets, with no clear hierarchy in exhaustion severity between polymerase- and core-specific cells. A chronicity-associated, transcriptional scar-like signature persisted even after HBsAg loss. The resolution signature shared by polymerase- and core-specific CD8 T cells from rNUC and rACU patients identifies histone deacetylase inhibition as a promising immunotherapeutic strategy for CHB. There is an urgent need to identify new therapeutic strategies that can achieve durable control of infection in people with chronic hepatitis B (CHB), as impairment of HBV-specific CD8 T cells is a major driver of viral persistence. In this study, transcriptional profiling of virus-specific T cells associated with functional cure identified epigenetic regulation of transcription as a potential target for restoring T-cell function in patients with CHB. In vitro treatment with entinostat significantly increased histone acetylation levels and improved T-cell function, supporting its potential use as an immunotherapeutic strategy to achieve HBV cure.
中文摘要:病毒特异性T细胞功能障碍是慢性乙型肝炎(CHB)的标志,逆转这种功能障碍可能是实现HBV治愈的潜在策略。要阐明CD8 T细胞在CHB发病中的作用并识别有效重建T细胞功能的新治疗靶点,需要更深入理解与病毒持续和感染控制相关的T细胞特征。研究对未治疗、高病毒载量、HBeAg阴性CHB患者的核心抗原和聚合酶特异性CD8 T细胞进行RNA测序,并与经核苷(酸)类似物治疗后获得功能性治愈(rNUC)或急性乙型肝炎(rACU)患者相应细胞比较。在CHB患者T细胞中评估组蛋白去乙酰化酶抑制后的组蛋白乙酰化水平、细胞因子产生和细胞毒活性。鉴定出一个101基因的「缓解特征」,为两个缓解组共有并可将它们与CHB患者区分,同时发现41个基因的失调在rNUC患者中未被逆转。尽管CHB患者核心抗原和聚合酶特异性CD8 T细胞中大多数失调基因表达模式相似,约30%表现不一致。用entinostat靶向异常转录调控可显著提高组蛋白乙酰化水平并改善T细胞功能。核心抗原和聚合酶特异性CD8 T细胞功能障碍机制仅部分共享,聚合酶特异性和核心特异性细胞在耗竭严重程度上无明确层级。一种与慢性化相关的、转录瘢痕样特征即使在HBsAg消失后仍持续存在。rNUC和rACU患者聚合酶和核心特异性CD8 T细胞共有的缓解特征提示,组蛋白去乙酰化酶抑制是治疗CHB有前景的免疫治疗策略。迫切需要识别能在CHB患者中实现持久感染控制的新治疗策略,因为HBV特异性CD8 T细胞受损是病毒持续的主要驱动因素。本研究通过对与功能性治愈相关的病毒特异性T细胞进行转录谱分析,发现转录的表观遗传调控是恢复CHB患者T细胞功能的潜在靶点。体外entinostat处理显著提高组蛋白乙酰化水平并改善T细胞功能,支持其作为实现HBV治愈的免疫治疗策略的潜在用途。
Universal hepatitis C virus (HCV) screening is now recommended during pregnancy, although rates of screening, confirmatory viral load testing, and HCV treatment during pregnancy and postpartum remain poorly described. This was a retrospective chart review study of birthing parents and infants who delivered at the University of California, San Francisco and Zuckerburg San Francisco General Hospital between January 1, 2014, and December 31, 2024, using the Epic electronic health record system. Maternal outcomes included HCV antibody screening, confirmatory HCV viral load testing, referral to HCV specialty care, and receipt of antiviral therapy. Infant screening and additional obstetric and neonatal outcomes were also reported. During the study period, 41,951 pregnant women delivered at our 2 sites of whom 13,950 received HCV screening (33.3%) by antibody or RNA testing. Screening rates increased over time from 15.2% in 2014 to 69.1% in 2024 ( P < 0.001). Among 328 (2.4%) with a positive screening test, 293 (89.3%) tested positive via HCV antibody and 203 (69.3%) of these completed follow-up HCV RNA testing and 110 (54.2%) had confirmed viremia. Of these, 52 (47.3%) received subspecialty referral and 43 of 52 (82.7%) received antiviral therapy (2 during pregnancy, 41 postpartum). Overall, 67 of 110 (60.9%) viremic patients were lost to follow-up. Among 115 infants born to viremic mothers, 30 (26.1%) received HCV screening at a median age of 19.2 months (interquartile range 13.4-22.0). Three infants (10.0%) screened HCV antibody positive; 2 had undetectable RNA, and 1 experienced spontaneous viral clearance at 19 months. Despite increasing screening over time, substantial gaps persist in HCV screening, follow-up testing, and linkage to care for pregnant patients and their infants. High loss to follow-up and low infant screening rates highlight the urgent need to strengthen peripartum HCV care pathways to support maternal and pediatric cure and advance HCV elimination goals.
中文摘要:目前推荐在孕期进行普遍性丙型肝炎病毒(HCV)筛查,但孕期及产后的筛查率、确诊性病毒载量检测和HCV治疗情况仍缺乏充分描述。本研究为回顾性病历审查,纳入2014年1月1日至2024年12月31日在加利福尼亚大学旧金山分校及Zuckerburg旧金山总医院分娩的产妇和婴儿,数据来自Epic电子健康记录系统。母亲结局包括HCV抗体筛查、确诊性HCV病毒载量检测、转诊至HCV专科照护以及接受抗病毒治疗。婴儿筛查及额外的产科和新生儿结局亦被报告。研究期间,两个院区共有41951名孕妇分娩,其中13950名(33.3%)接受了抗体或RNA检测的HCV筛查。筛查率随时间从2014年的15.2%升至2024年的69.1%(P < 0.001)。在328名(2.4%)筛查阳性者中,293名(89.3%)经HCV抗体检测为阳性,其中203名(69.3%)完成了随访HCV RNA检测,110名(54.2%)确认存在病毒血症。上述患者中,52名(47.3%)获得专科转诊,52名中的43名(82.7%)接受了抗病毒治疗(2名在孕期,41名在产后)。总体而言,110名病毒血症患者中有67名(60.9%)失访。115名病毒血症母亲所生婴儿中,30名(26.1%)接受了HCV筛查,中位年龄为19.2个月(四分位距13.4-22.0)。3名婴儿(10.0%)筛查HCV抗体阳性;2名RNA检测不到,1名在19个月时发生自发病毒清除。尽管筛查率随时间上升,孕妇及其婴儿在HCV筛查、随访检测和照护衔接方面仍存在显著缺口。高失访率和低婴儿筛查率突出表明,亟需加强围产期HCV照护路径,以支持母亲和儿科治愈并推进HCV消除目标。
基础研究 (2篇)
Viral proteases are critical targets in antiviral drug development due to their essential role in the viral lifecycle and high conservation across viral strains. This review summarizes the recent progress of antiviral drugs based on protease structures, with a focus on the structural characteristics and inhibitor design strategies targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Enterovirus 71 (EV71), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV). Based on the three-dimensional structure of proteases, various types of protease inhibitors such as peptidomimetic, non-peptidic, and natural product-derived inhibitors are discussed. Given the critical challenge of drug resistance in antiviral therapies, we address the mechanisms of protease inhibitor resistance and explore advanced strategies, including allosteric inhibition, dual-target inhibition, and Proteolysis-Targeting Chimeras (PROTAC) to overcome drug resistance. This review also explores the cutting-edge applications of artificial intelligence (AI) for viral protease-based antiviral drug discovery, providing valuable insights for the rational design and development of antiviral drugs.
中文摘要:病毒蛋白酶在病毒生命周期中必不可少且在不同毒株间高度保守,因此成为抗病毒药物开发的重要靶点。本文综述基于蛋白酶结构的抗病毒药物近期进展,重点讨论针对严重急性呼吸综合征冠状病毒2、肠道病毒71型、丙型肝炎病毒和人类免疫缺陷病毒蛋白酶的结构特征及抑制剂设计策略。围绕蛋白酶三维结构,讨论拟肽类、非肽类及天然产物来源抑制剂等类型。抗病毒治疗中的耐药问题构成关键挑战,本文梳理蛋白酶抑制剂耐药机制,并探讨变构抑制、双靶点抑制和蛋白水解靶向嵌合体等克服耐药的进阶策略。本文还讨论人工智能在基于病毒蛋白酶的抗病毒药物发现中的前沿应用,为抗病毒药物的理性设计与开发提供参考。
Hepatitis C virus (HCV) is a major etiological agent of liver diseases and remains a serious global health threat. Herein, we report a dual-modal HCV biosensing platform for ultrasensitive HCV RNA detection by integrating near-infrared fluorescence and colorimetric readouts. In this system, the presence of HCV RNA initiates a catalytic assembly circuit (CAC) that forms a Y-shaped DNA structure, exposing two double-stranded DNA activators with complete protospacer adjacent motif (PAM) to trigger CRISPR/Cas12a nuclease activity. The combination of CRISPR/Cas12a-driven signal amplification and hemin-binding aptamer-functionalized single-walled carbon nanotubes (HeApt-SWCNTs) enables highly sensitive target quantification. Upon exposure to hydrogen peroxide (H2O2), ferric ion in hemin catalyzes a Fenton-like reaction, generating hydroxyl radicals (·OH) that quench SWCNT fluorescence and oxidize 3,3',5,5'-tetramethylbenzidine (TMB) to its blue oxidized form (oxTMB). In the presence of target HCV RNA, CRISPR/Cas12a-mediated HeApt cleavage inhibits ·OH generation, resulting in SWCNT fluorescence recovery and suppresses TMB oxidation. Under optimal conditions, detection limits of 0.23 fM and 4.1 fM are achieved for the fluorescence and colorimetric modes, respectively. This integrated CAC-Cas12a-HeApt-SWCNTs (CCHS) biosensing strategy offers high specificity, dual-mode signal reliability, and broad potential for early diagnosis of HCV and other RNA viruses.
中文摘要:丙型肝炎病毒(HCV)是肝病的主要病因之一,持续构成严重全球健康威胁。我们报道了一种双模态HCV生物传感平台,通过整合近红外荧光与比色读出实现HCV RNA的超灵敏检测。在该系统中,HCV RNA存在时启动催化组装回路(CAC),形成Y形DNA结构,暴露两个具有完整原间隔序列邻近基序(PAM)的双链DNA激活子,从而触发CRISPR/Cas12a核酸酶活性。CRISPR/Cas12a驱动的信号放大与血红素结合适配体功能化单壁碳纳米管(HeApt-SWCNTs)结合,实现高灵敏靶标定量。暴露于过氧化氢(H2O2)时,血红素中的铁离子催化类芬顿反应,生成羟自由基(·OH),淬灭SWCNT荧光并将3,3',5,5'-四甲基联苯胺(TMB)氧化为蓝色氧化型(oxTMB)。靶标HCV RNA存在时,CRISPR/Cas12a介导的HeApt切割抑制·OH生成,导致SWCNT荧光恢复并抑制TMB氧化。在优化条件下,荧光模式与比色模式的检测限分别为0.23 fM和4.1 fM。该整合CAC-Cas12a-HeApt-SWCNTs(CCHS)生物传感策略具有高特异性、双模态信号可靠性,并为HCV及其他RNA病毒的早期诊断提供广泛潜力。
3胆管炎/PSC (5篇)
临床研究 (5篇)
Acute cholangitis (AC) is a potentially fatal biliary tract infection most commonly caused by gallstones. While modern-day treatments with antibiotics and biliary decompression have drastically decreased mortality rates, AC still requires prompt intervention. Diagnosis of AC traditionally relied on the presence of the Charcot triad, which has since proven to incompletely capture the complexity of this condition. Modern-day diagnosis, severity grading, and management guidelines provide a more holistic approach. Tokyo Guidelines (TG) are widely used, though newer guidelines, namely the BILE criteria, have recently emerged. These criteria include demonstration of inflammation, cholestasis, and biliary obstruction. Ultrasound is first-line imaging modality with computed tomography or magnetic resonance cholangiopancreatography often used for diagnostic dilemmas. Treatment is dependent on severity, though guidelines generally recommend early decompression (most commonly with endoscopic retrograde cholangiopancreatography [ERCP]) for moderate to severe cases. The optimal timing of biliary drainage remains unclear, with mixed evidence from observational studies and no universal definition of what constitutes "early" vs "urgent" drainage. Laparoscopic cholecystectomy should be performed during index hospitalization, when possible, with multiple studies demonstrating lower morbidity and mortality rates when compared with interval procedures. The prognosis of AC is favorable if treated swiftly and appropriately; in turn, mortality rates increase with severity and delays in diagnosis. AC can be challenging to diagnose and the precise timing of biliary drainage and cholecystectomy is debated. This comprehensive review reflects the most recent evidence and recommendations on severity grading, resuscitation, and timing of ERCP and cholecystectomy to assist clinicians who manage these complex patients.
中文摘要:急性胆管炎(AC)是一种可能致命的胆道感染,最常见由胆结石引起。现代抗生素治疗和胆道减压已大幅降低死亡率,但AC仍需及时干预。AC的诊断传统上依赖Charcot三联征,但该三联征已被证明不能完整涵盖本病的复杂性。现代诊断、严重程度分级和管理指南提供了更整体的处理思路。东京指南(TG)应用广泛,近期也出现了新的BILE标准。这些标准包括炎症、胆汁淤积和胆道梗阻的证据。超声是一线影像学检查,计算机断层扫描或磁共振胰胆管成像常用于诊断困难时。治疗取决于严重程度,指南一般建议中重度病例尽早减压,最常用内镜逆行胰胆管造影(ERCP)。胆道引流的最佳时机仍不明确,观察性研究证据不一致,且对何为「早期」与「紧急」引流缺乏统一定义。条件允许时,应在本次住院期间行腹腔镜胆囊切除术,多项研究显示与间隔手术相比,其并发症发生率和死亡率更低。若治疗迅速且恰当,AC预后良好;死亡率随严重程度升高和诊断延迟而增加。AC诊断可能具有挑战性,胆道引流和胆囊切除术的精确时机仍有争议。本综述反映关于严重程度分级、复苏以及ERCP和胆囊切除术时机的最新证据与建议,以帮助临床医生管理这类复杂患者。
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease associated with progressive fibrosis, cirrhosis, liver transplantation, and premature mortality. Despite effective therapies, important challenges remain in the diagnosis and management of PBC, including identification of antimitochondrial antibody-negative disease, assessment of response to ursodeoxycholic acid (UDCA), risk stratification, treatment of patients with inadequate response, management of cholestatic pruritus, and prevention of recurrent disease after liver transplantation. The aim of this guideline was to develop evidence-based recommendations addressing these key areas of clinical care. The American Gastroenterological Association (AGA) and the American Association for the Study of Liver Diseases (AASLD) convened a multidisciplinary panel to develop clinical practice recommendations for adults with PBC. Systematic reviews were performed for 6 prioritized clinical questions. The Grading of Recommendations Assessment, Development and Evaluation framework was used to prioritize clinical outcomes and assess evidence, and its Evidence to Decision Framework was used to develop recommendations. The guideline panel agreed on 6 recommendations. These recommendations address the use of PBC-specific antinuclear antibodies in antimitochondrial antibody-negative suspected PBC, UDCA as first-line therapy, liver stiffness measurement for prognostication, peroxisome proliferator-activated receptor agonists for patients with inadequate response or intolerance to UDCA, linerixibat for moderate to severe pruritus, and UDCA prophylaxis post-transplantation to reduce disease recurrence. The certainty of evidence ranged from moderate to very low. The guideline emphasizes early diagnosis, optimization of first-line therapy, risk-based treatment escalation, symptom management, and prevention of post-transplantation disease recurrence to improve patient outcomes and quality of life.
中文摘要:原发性胆汁性胆管炎(PBC)是一种慢性胆汁淤积性肝病,与进行性纤维化、肝硬化、肝移植和过早死亡相关。尽管已有有效治疗,PBC的诊断和管理仍存在重要挑战,包括识别抗线粒体抗体阴性患者、评估对熊去氧胆酸(UDCA)的反应、风险分层、对反应不足患者的治疗、胆汁淤积性瘙痒的管理以及肝移植后疾病复发的预防。本指南旨在制定循证推荐,以解决这些临床照护的关键领域。美国胃肠病学会(AGA)和美国肝病研究学会(AASLD)召集多学科专家组,为成人PBC制定临床实践推荐。针对6个优先临床问题进行了系统评价。采用推荐分级的评估、制定与评价框架对临床结局进行优先级排序并评估证据,并使用其证据到决策框架制定推荐。指南专家组就6条推荐达成一致。这些推荐涉及:在抗线粒体抗体阴性但疑似PBC时使用PBC特异性抗核抗体;将UDCA作为一线治疗;通过肝脏硬度测量进行预后判断;对UDCA反应不足或不耐受的患者使用过氧化物酶体增殖物激活受体激动剂;使用linerixibat治疗中度至重度瘙痒;以及移植后使用UDCA预防以降低疾病复发。证据确定性从中等到极低不等。该指南强调早期诊断、优化一线治疗、基于风险的治疗升级、症状管理以及预防移植后疾病复发,以改善患者结局和生活质量。
Cholestatic pruritus is a debilitating symptom with substantial placebo responses. We aimed to quantify this response and identify trial-level moderators in randomized controlled trials of contemporary therapies. We performed a systematic review and meta-analysis of placebo-controlled trials evaluating ileal bile acid transporter inhibitors or PPAR agonists (searched through March 2026, with a supplementary search on 11 July 2026). Primary outcomes included the standardized mean change (SMC) of pruritus intensity, placebo response rate and mean difference (MD) in Numerical Rating Scale (NRS) and Worst-Itch NRS (WI-NRS) scores. Secondary outcomes included PBC-40 and 5-D Itch scores. We used random-effects models with Hartung-Knapp adjustment and meta-regression. Thirteen trials (n = 548) were analysed. Across placebo groups, pruritus intensity decreased significantly from baseline during follow-up periods of up to 52 weeks. The pooled SMC was -0.49 (95% CI, -0.72 to -0.27) overall, and -0.57 (95% CI, -0.81 to -0.33) for moderate-to-severe pruritus. Pooled response rates were 30.0% (overall) and 27.4% (moderate-to-severe). In moderate-to-severe patients, NRS showed a significant mean reduction of -1.62, whereas the WI-NRS change (-0.65) was not statistically significant. Significant reductions occurred in the PBC-40 itch domain (-2.02) and overall score (-9.13), while 5-D Itch changes were non-significant. None of the evaluated moderators were statistically significant. The magnitude of placebo-associated improvement differed across outcome instruments and may affect estimates and interpretation of treatment effects in cholestatic-pruritus trials. These findings may inform endpoint selection and assumptions used in future trial design. PROSPERO registration number: CRD420261385974.
中文摘要:胆汁淤积性瘙痒是使人衰弱的症状,安慰剂反应明显。旨在量化当代疗法随机对照试验中的该反应并识别试验层面的调节因素。系统检索并荟萃分析了评估回肠胆汁酸转运体抑制剂或PPAR激动剂的安慰剂对照试验(检索至2026年3月,并于2026年7月11日补充检索)。主要结局包括瘙痒强度标准化均值变化(SMC)、安慰剂反应率以及数值评定量表(NRS)与最严重瘙痒NRS(WI-NRS)评分的均数差(MD)。次要结局包括PBC-40和5-D瘙痒评分。采用随机效应模型并作Hartung-Knapp校正和meta回归。共分析13项试验(n=548)。在最长52周的随访期间,安慰剂组瘙痒强度较基线显著下降。总体合并SMC为-0.49(95% CI,-0.72至-0.27),中重度瘙痒为-0.57(95% CI,-0.81至-0.33)。合并反应率总体为30.0%,中重度为27.4%。在中重度患者中,NRS平均显著降低-1.62,而WI-NRS变化(-0.65)无统计学意义。PBC-40瘙痒域(-2.02)和总分(-9.13)显著下降,5-D瘙痒变化无统计学意义。所评估的调节因素均无统计学意义。安慰剂相关改善幅度因结局工具而异,可能影响胆汁淤积性瘙痒试验中治疗效应的估计与解读。这些发现可为未来试验设计的终点选择和假设提供参考。PROSPERO注册号:CRD420261385974。
Pruritus is a common and burdensome symptom in patients with primary sclerosing cholangitis (PSC). To determine the prevalence of pruritus in PSC, its clinical associations, and its impact on quality of life. Patients with PSC were assessed for pruritus using the Worst Itch Numerical Rating Scale (WI-NRS) and 5-D Itch scale, and for quality of life using SF-36 and PSC-PRO. Participants reporting moderate to severe pruritus (WI-NRS ≥ 4) within 6 months of enrollment completed longitudinal assessments for up to 6 months. Those with inflammatory bowel disease (IBD) completed the Simple Clinical Colitis Activity Index (P-SCCAI). Median age was 43 years, 61% were male and 75% had IBD. Moderate to severe itch over the prior 7 days was reported by 24%, increasing to 38% over the prior 6 months. Greater pruritus was associated with cirrhosis (p = 0.01), alkaline phosphatase (p = 0.0001), total bilirubin (p = 0.0006) and lower albumin (p = 0.01). Among patients with IBD, itch severity was associated with colitis activity (p = 0.01). Pruritus associated with impaired quality of life on the SF-36 (rs = -0.47) and PSC-PRO (rs = 0.69). Longitudinally, pruritus varied markedly with 86.5% of patients reporting moderate to severe pruritus in the past 6 months experiencing severe itch at least once over 6 months. Pruritus is common, clinically meaningful and fluctuates over time in PSC. Its strong impact on quality-of-life underscores the need for standardized assessment and development of more effective therapies.
中文摘要:瘙痒是原发性硬化性胆管炎(PSC)患者常见且负担沉重的症状。为确定PSC中瘙痒的患病率、临床相关因素及其对生活质量的影响,研究采用最严重瘙痒数字评定量表(WI-NRS)和5-D瘙痒量表评估PSC患者瘙痒,采用SF-36和PSC-PRO评估生活质量。入组前6个月内报告中度至重度瘙痒(WI-NRS≥4)的参与者在入组后完成最长6个月的纵向评估。合并炎症性肠病(IBD)者完成简易临床结肠炎活动指数(P-SCCAI)。中位年龄43岁,61%为男性,75%合并IBD。24%报告过去7天中度至重度瘙痒,过去6个月该比例升至38%。瘙痒程度更高与肝硬化(p=0.01)、碱性磷酸酶(p=0.0001)、总胆红素(p=0.0006)及较低白蛋白(p=0.01)相关。在IBD患者中,瘙痒严重程度与结肠炎活动度相关(p=0.01)。瘙痒与SF-36(rs=-0.47)和PSC-PRO(rs=0.69)所测生活质量受损相关。纵向观察中瘙痒变化明显,过去6个月报告中度至重度瘙痒的患者中86.5%在6个月内至少一次出现重度瘙痒。瘙痒在PSC中常见、具有临床意义并随时间波动。其对生活质量的显著影响凸显了标准化评估和开发更有效疗法的必要性。
Despite the widespread use of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC), many patients remain at risk of progression. Emerging data suggest that normalization of alkaline phosphatase (ALP) and total bilirubin (TB)-particularly when TB < 0.6 times the upper limit of normal (× ULN)-is associated with improved outcomes compared with ALP reduction to < 1.5 × ULN. This study investigated the association between ALP normalization in response to UDCA and long-term clinical outcomes in a real-world cohort of patients with PBC. We compared complication-free survival in patients achieving an ALP > ULN and < 1.5 × ULN (adequate response) with those with an ALP ≤ ULN on UDCA monotherapy. Complication-free survival was defined as the absence of serious liver-related clinical events. Restricted mean survival time was used to quantify survival time gained. Patients achieving normal ALP and/or TB ≤ 0.6 × ULN demonstrated significantly improved complication-free survival compared with those with an adequate ALP response. Event-free survival was extended by 1.34 years (95% CI: 0.56, 2.11; P = 0.001) for ALP normalization alone, 3.7 years (95% CI: 3.11, 4.29; P < 0.001) for TB ≤ 0.6 × ULN, and 4.51 years (95% CI: 4.13, 4.88; P < 0.001) for those meeting both criteria. The risk of severe clinical events was reduced in patients achieving ALP normalization (hazard ratio [HR] 0.34; 95% CI: 0.15, 0.80; P = 0.01), TB ≤ 0.6 × ULN (HR 0.23; 95% CI: 0.09, 0.55; P = 0.001), or both (HR 0.14; 95% CI: 0.05, 0.38; P < 0.001). High-risk patients, defined by liver stiffness measurement ≥ 10 kPa or clinical, histological, or laboratory evidence of cirrhosis or portal hypertension, derived the greatest benefit. Achieving normal ALP and TB ≤ 0.6 × ULN is associated with significantly improved complication-free survival, particularly in high-risk patients. These findings highlight the potential of biochemical thresholds as a meaningful therapeutic goal in PBC management.
中文摘要:尽管熊去氧胆酸(UDCA)在原发性胆汁性胆管炎(PBC)中广泛应用,许多患者仍面临疾病进展风险。新出现的资料提示,碱性磷酸酶(ALP)和总胆红素(TB)恢复正常,尤其是TB低于正常上限0.6倍(× ULN)时,与ALP降至<1.5×ULN相比,结局更好。本研究在真实世界PBC队列中考察UDCA治疗后ALP恢复正常与长期临床结局的关系。我们比较UDCA单药治疗下ALP>ULN且<1.5×ULN(充分应答)患者与ALP≤ULN患者的无并发症生存。无并发症生存定义为未发生严重肝脏相关临床事件。采用限制平均生存时间量化获得的生存时间。与ALP充分应答者相比,ALP和/或TB≤0.6×ULN达标者的无并发症生存显著改善。仅ALP恢复正常使无事件生存延长1.34年(95% CI:0.56,2.11;P=0.001),TB≤0.6×ULN延长3.7年(95% CI:3.11,4.29;P<0.001),两项标准均达标者延长4.51年(95% CI:4.13,4.88;P<0.001)。ALP恢复正常(风险比[HR]0.34;95% CI:0.15,0.80;P=0.01)、TB≤0.6×ULN(HR 0.23;95% CI:0.09,0.55;P=0.001)或两者均达标(HR 0.14;95% CI:0.05,0.38;P<0.001)的患者严重临床事件风险降低。以肝脏硬度测量≥10 kPa或临床、组织学或实验室证据提示肝硬化或门静脉高压定义的高危患者获益最大。ALP恢复正常且TB≤0.6×ULN与无并发症生存显著改善相关,在高危患者中尤为明显。这些发现提示生化阈值可作为PBC管理中一个有意义的治疗目标。
4肝硬化/门脉高压 (5篇)
临床研究 (4篇)
Since the first Baveno Consensus Conference in 1990, successive conferences held every 5 years have transformed the field of cirrhosis and portal hypertension, evolving from a focus on variceal bleeding to a pathophysiology-based framework centred on risk stratification, clinically significant portal hypertension (CSPH), and the prevention of decompensation. Building on this progress, the Baveno Cooperation, in collaboration with the Vascular Liver Disease Interest Group (VALDIG), convened an expert faculty to review the evidence published since Baveno VII and update clinical guidance for patients with advanced chronic liver disease (ACLD), portal hypertension, and vascular liver diseases. The Baveno VIII Consensus Conference, held in March 2026 in Baveno, Italy, was based on a structured consensus process across nine panels addressing key domains of ACLD, portal hypertension, and vascular liver diseases. Statements and recommendations were developed through iterative review of the evidence and voting among faculty, with strong consensus defined as >80% faculty agreement. A total of 272 statements and recommendations achieved strong consensus. Key areas included non-invasive risk stratification in compensated ACLD (cACLD), modifiers of steatotic liver disease, prevention of first and further decompensation, management of portal hypertensive bleeding and further decompensation, cirrhosis recompensation, and vascular liver diseases, including Budd-Chiari syndrome, portosinusoidal vascular disorder (PSVD) or non-cirrhotic portal fibrosis (NCPF), and portal vein thrombosis (PVT). The central role of CSPH and the expanding use of non-invasive tests were reaffirmed, and several diagnostic and prognostic cut-offs were revised. New to Baveno VIII is the inclusion of selected guidance for paediatric patients. Recommendations from previous conferences that were not specifically revised in Baveno VIII, such as those on hepatic venous pressure gradient (HVPG) measurement, remain valid. Finally, a research agenda identifying 153 priority topics is proposed.
中文摘要:自1990年首届Baveno共识会议以来,每5年召开一次的历届会议推动了肝硬化与门脉高压领域的发展,关注点从静脉曲张出血转向以病理生理为基础的框架,核心包括风险分层、临床显著门脉高压(CSPH)和失代偿预防。在这一进展基础上,Baveno协作组与血管性肝病兴趣组(VALDIG)组织专家团队,回顾Baveno VII以来发表的证据,并更新针对晚期慢性肝病(ACLD)、门脉高压和血管性肝病患者的临床指导。Baveno VIII共识会议于2026年3月在意大利Baveno举行,采用结构化共识流程,九个专家组覆盖ACLD、门脉高压和血管性肝病的关键领域。声明与推荐通过反复证据审查和专家投票形成,强共识定义为专家同意率超过80%。共有272条声明和推荐达成强共识。关键领域包括代偿期ACLD(cACLD)的无创风险分层、脂肪性肝病的修饰因素、首次及进一步失代偿的预防、门脉高压性出血和进一步失代偿的处理、肝硬化再代偿,以及血管性肝病,包括Budd-Chiari综合征、门窦血管病(PSVD)或非肝硬化门纤维化(NCPF)和门静脉血栓(PVT)。会议重申CSPH的核心作用和无创检测的扩展应用,并修订了若干诊断与预后截断值。Baveno VIII新增了对儿科患者的选定指导。既往会议中未在Baveno VIII专门修订的推荐,如肝静脉压力梯度(HVPG)测定相关推荐,仍然有效。会议还提出研究议程,列出153个优先主题。
The non-invasive Baveno VII criteria for clinically significant portal hypertension (CSPH), based on liver stiffness measurement (LSM) and platelet count (PLT), yield indeterminate ("gray-zone") results in approximately 40-50% of patients, and their performance varies across etiologies and elastography techniques. Spleen stiffness measurement (SSM) has been proposed to improve the accuracy of the Baveno-VII CSPH criteria. We developed and validated the ELM score, a machine learning-based model integrating pan-elastographic LSM and SSM with clinical variables to improve accuracy for CSPH diagnosis, while minimizing indeterminate classifications. We analyzed 1,435 patients with compensated advanced chronic liver disease who underwent paired hepatic venous pressure gradient measurements, LSM, SSM, and clinical assessment. LSM and SSM were obtained using vibration-controlled transient elastography, two-dimensional shear-wave elastography, or point shear-wave elastography. Models were trained (n = 943) and internally validated (n = 150) using harmonized elastography measurements and clinical variables. External validation was performed in 342 patients from seven centers. Cut-offs were selected to maximize rule-out and rule-in performance and compared with the Baveno VII criteria, Baveno-SSM criteria, and, in the vibration-controlled transient elastography subgroup, the ANTICIPATE and NICER scores. A random forest-based model achieved the highest performance in the external validation cohort (AUC = 0.91; Brier score = 0.13). Cut-offs of ≤0.45 (rule-out) and ≥0.60 (rule-in) yielded a negative predictive value of 0.91 (95% CI 0.84-0.95) and a positive predictive value of 0.96 (95% CI 0.92-0.98). The ELM score reduced the gray zone to 12.3%, compared with 47.9% for the Baveno VII criteria (p <0.001), 38.6% for the Baveno-SSM dual cut-off criteria (p <0.001), and 19.6% for the Baveno-SSM single cut-off criteria (p <0.05). In the vibration-controlled transient elastography external validation subgroup (n = 275), the ELM score achieved rule-in performance comparable to that of the ANTICIPATE and NICER scores while reducing the gray zone to 12.0%, compared with 38.2% and 26.5%, respectively. The ELM score outperformed the current Baveno VII criteria and substantially reduced the gray zone across elastography modalities, supporting broader and safer non-invasive identification of patients with CSPH who may benefit from non-selective beta-blocker therapy. Clinically significant portal hypertension is central to prognosis in compensated advanced chronic liver disease, yet current non-invasive strategies classify 40-50% of patients as indeterminate. This study introduces a pan-elastography machine-learning model that integrates liver and spleen stiffness with clinical variables to address this limitation. The results are important for hepatologists and healthcare systems because the ELM score reduced the diagnostic gray zone to ∼12% in external validation, compared with 47.9% for Baveno VII, while maintaining high rule-out and rule-in accuracy (NPV up to 0.91 and PPV up to 0.96). In practice, these findings could support earlier non-invasive identification of patients eligible for non-selective β-blocker therapy, more targeted use of HVPG in indeterminate cases, and harmonized risk stratification across elastography modalities, while recognizing that prospective validation and regulatory approval are required before routine clinical implementation.
中文摘要:基于肝脏硬度测量(LSM)和血小板计数(PLT)的Baveno VII无创标准用于临床显著门静脉高压(CSPH),约40–50%患者得到不确定的「灰色带」结果,且其表现随病因和弹性成像技术而变化。脾脏硬度测量(SSM)被提出用于提高Baveno VII CSPH标准的准确性。我们开发并验证了ELM评分,这是一种机器学习模型,整合全弹性成像的LSM和SSM与临床变量,以提高CSPH诊断准确性并尽量减少不确定分类。我们分析了1435例代偿期进展性慢性肝病患者,这些患者接受了配对的肝静脉压力梯度(HVPG)测量、LSM、SSM和临床评估。LSM和SSM通过振动控制瞬时弹性成像、二维剪切波弹性成像或点剪切波弹性成像获得。模型使用统一化的弹性成像测量和临床变量进行训练(n=943)和内部验证(n=150)。外部验证在来自7个中心的342例患者中完成。选择截断值以最大化排除和确认性能,并与Baveno VII标准、Baveno-SSM标准比较,在振动控制瞬时弹性成像亚组中还与ANTICIPATE和NICER评分比较。随机森林模型在外部验证队列中表现最佳(AUC=0.91;Brier评分=0.13)。≤0.45(排除)和≥0.60(确认)的截断值产生阴性预测值0.91(95%置信区间0.84–0.95)和阳性预测值0.96(95%置信区间0.92–0.98)。ELM评分将灰色带降至12.3%,而Baveno VII标准为47.9%(p<0.001),Baveno-SSM双截断值标准为38.6%(p<0.001),Baveno-SSM单截断值标准为19.6%(p<0.05)。在振动控制瞬时弹性成像外部验证亚组(n=275)中,ELM评分的确认性能与ANTICIPATE和NICER评分相当,同时将灰色带降至12.0%,而二者分别为38.2%和26.5%。ELM评分优于当前Baveno VII标准,并在不同弹性成像方式中大幅减少灰色带,支持更广泛、更安全地无创识别可能从非选择性β受体阻滞剂治疗中获益的CSPH患者。CSPH是代偿期进展性慢性肝病预后的核心,但当前无创策略将40–50%患者归为不确定。该研究提出一种全弹性成像机器学习模型,整合肝脏和脾脏硬度与临床变量以应对这一局限。结果对肝病医生和医疗系统有意义,因为ELM评分在外部验证中将诊断灰色带降至约12%,而Baveno VII为47.9%,同时保持高排除和确认准确性(阴性预测值最高0.91,阳性预测值最高0.96)。在实践中,这些发现可支持更早无创识别适合非选择性β受体阻滞剂治疗的患者、在不确定病例中更有针对性地使用HVPG,以及在不同弹性成像方式间实现统一的风险分层,同时应认识到在常规临床实施前仍需前瞻性验证和监管批准。
Although the relationship between cirrhosis and hepatocellular carcinoma is well established, a growing body of evidence suggests patients with cirrhosis also face elevated risks of nonhepatic cancers (NHCs). Liver cirrhosis has been found to confer up to a two-fold increased risk for NHCs compared with the general population. Clinicians have limited guidance when treating patients with both NHCs and liver cirrhosis given there is a glaring paucity of data regarding optimal management strategies for this subset of patients. Hepatic dysfunction limits therapeutic and interventional approaches, alters the pharmacokinetics of common anticancer drugs, and increases the risk of side effects associated with anticancer treatment. Patients with well-compensated cirrhosis whose life expectancy is primarily determined by their NHC can be appropriate candidates for anticancer therapy with careful monitoring. Conversely, patients with decompensated cirrhosis should have their clinical focus shift toward managing liver-related complications or transitioning to palliative care because oncological treatment likely worsens overall prognosis. Prognostic models like Child-Pugh and Model for End-Stage Liver Disease scores can be used in a complementary fashion to identify appropriate patients and individualize treatment decisions. In this narrative review, we will examine the epidemiology of NHCs in patients with cirrhosis, the influence of hepatic dysfunction on therapeutic approaches, and the current strength of evidence on the safety and efficacy of common anticancer modalities in the setting of both compensated and decompensated cirrhosis.
中文摘要:肝硬化与肝细胞癌的关系已经明确,越来越多证据提示肝硬化患者非肝癌风险也升高。与一般人群相比,肝硬化可使非肝癌风险增加至两倍。对同时患有非肝癌和肝硬化的患者,临床医生可获得的指导有限,这一人群最佳管理策略的数据明显不足。肝功能不全会限制治疗和介入手段,改变常用抗癌药物的药代动力学,并增加抗癌治疗相关副作用风险。代偿良好的肝硬化患者若预期寿命主要取决于非肝癌,可在严密监测下成为抗癌治疗的合适人选。失代偿肝硬化患者则应将临床重点转向处理肝脏相关并发症或过渡至姑息治疗,因为肿瘤治疗很可能使总体预后恶化。Child-Pugh和终末期肝病模型评分等预后模型可互补使用,以识别合适患者并个体化治疗决策。本叙述性综述将考察肝硬化患者非肝癌的流行病学、肝功能不全对治疗策略的影响,以及代偿性和失代偿性肝硬化背景下常用抗癌方式安全性和有效性的现有证据强度。
There is an unmet need for simple tools to predict development of hepatic decompensation among patients with compensated cirrhosis. We applied machine learning to several international Data sets to develop and validate a straightforward predictive model of decompensation. We used routinely available clinical and laboratory data from 575 patients with compensated cirrhosis from the training cohorts in Nottingham (United Kingdom) and Modena (Italy), with a median follow-up of 4 years. Based on these data, we developed a predictive model using a random forest classifier and validated it across independent international populations involving over 2,100 patients from Dublin (Ireland), Menoufia (Egypt), Leeds (UK), and Ogaki (Japan). In the training cohorts, 22% of patients developed liver decompensation. Using machine learning, we developed risk of decompensation in cirrhosis (RODIC), a well-calibrated model based on albumin, bilirubin, and the Fib-4 value (area under the receiver operating characteristic curve = 0.86; weighted F1 score = 0.82) which predicts the risk of decompensation within 3 years (access free of charge at: https://antonkaly.pythonanywhere.com/predict ). RODIC showed strong performance across all validation sets, with area under the receiver operating characteristic curve scores ranging from 0.67 to 0.80 and weighted F1 scores from 0.70 to 0.81. Moreover, the model was effective regardless of cirrhosis etiology. For hepatitis C virus-positive patients, RODIC remained reliable irrespective of whether they achieved sustained virologic response. Our validated machine learning model based on readily available clinical, and laboratory features accurately quantitates the risk of liver decompensation in patients with compensated hepatic cirrhosis.
中文摘要:代偿期肝硬化患者发生肝功能失代偿的风险预测仍缺乏简便工具。研究将机器学习用于多个国际数据集,开发并验证一个直观的失代偿预测模型。训练队列来自英国诺丁汉和意大利摩德纳,共纳入575例代偿期肝硬化患者,使用常规可得的临床与实验室数据,中位随访4年。基于这些数据,采用随机森林分类器建立预测模型,并在爱尔兰都柏林、埃及梅努菲亚、英国利兹和日本大垣的独立国际人群中验证,涉及超过2100例患者。训练队列中22%的患者发生肝失代偿。研究开发出肝硬化失代偿风险(RODIC)模型,该模型校准良好,基于白蛋白、胆红素和Fib-4值,预测3年内失代偿风险,受试者工作特征曲线下面积为0.86,加权F1评分为0.82,可通过https://antonkaly.pythonanywhere.com/predict免费访问。RODIC在所有验证集中表现较强,受试者工作特征曲线下面积为0.67至0.80,加权F1评分为0.70至0.81。该模型不受肝硬化病因影响。对于丙型肝炎病毒阳性患者,无论是否获得持续病毒学应答,RODIC均保持可靠。这一经过验证的机器学习模型基于常规可得的临床和实验室特征,可较准确量化代偿期肝硬化患者发生肝失代偿的风险。
基础研究 (1篇)
Cirrhosis prevalence and mortality continue to rise globally, with a >50% increase in cases since 1990, imposing a growing burden through chronic healthcare needs, recurrent hospitalisation, and liver transplantation, which remains the only definitive cure for advanced disease. Long regarded as a fixed end-stage, cirrhosis is now recognised as a dynamic and modifiable disease state. Sustained aetiological control can induce meaningful architectural remodelling, and single-cell and spatial analyses show that cirrhosis is a heterogeneous fibrotic niche shaped by context-specific fibrogenic, immune, and vascular cell phenotypes. Thus, reversibility is determined not simply by fibrosis stage, but by the biological state of the scar and its microenvironment. Nevertheless, recent disappointing antifibrotic trials, particularly in MASH-related cirrhosis, highlight the structural resilience of advanced disease and the limited sensitivity of conventional histological endpoints. Moreover, although structural improvement appears to confer measurable prognostic benefit, regression does not equate to complete restoration of tissue homeostasis, and residual vascular dysfunction and oncogenic risk often persist. Translating emerging mechanistic insights into precise measurement tools and effective therapies for cirrhosis regression now represents a central challenge in hepatology.
中文摘要:肝硬化患病率和死亡率在全球持续上升,自1990年以来病例增加超过50%,通过长期医疗需求、反复住院和肝移植带来日益加重的负担,而肝移植仍是晚期疾病唯一确定的治愈手段。肝硬化长期被视为固定的终末期状态,现在被认为是一种动态且可改变的疾病状态。持续控制病因可诱导有意义的组织结构重塑,单细胞和空间分析显示肝硬化是由情境特异性致纤维化、免疫和血管细胞表型塑造的异质性纤维化微环境。因此,可逆性并非仅由纤维化分期决定,还取决于瘢痕及其微环境的生物学状态。近期抗纤维化试验结果令人失望,尤其是在MASH相关肝硬化中,这凸显晚期疾病的结构韧性和传统组织学终点的敏感性有限。尽管结构改善似乎带来可测量的预后获益,但消退并不等同于组织稳态完全恢复,残余血管功能障碍和致癌风险常持续存在。将新出现的机制认识转化为肝硬化消退的精准测量工具和有效疗法,是当前肝病学的一项核心挑战。
5NAFLD/NASH/代谢肝病 (4篇)
临床研究 (3篇)
Non-alcoholic fatty liver disease (NAFLD) coexists with dyslipidemia or impaired fasting glucose (IFG), but gut microbial and serum metabolic features remain incompletely characterized. We aimed to compare gut microbial beta diversity, taxonomic profiles, predicted microbial functions, and serum metabolites across healthy controls (HCs) and NAFLD subgroups; evaluate omics-based classifiers and exploratory integrated classifiers distinguishing subgroups from HCs; and assess metabolic responses to Dialister invisus supplementation in mice. Fecal microbiota and serum metabolites were profiled by 16S rRNA gene sequencing and targeted UPLC-MS/MS, respectively, in 41 HCs and 222 NAFLD patients. Patients were stratified into three subgroups by dyslipidemia and IFG: NAFLD_N (neither dyslipidemia nor IFG), NAFLD_DLP (dyslipidemia without IFG), and NAFLD_IFG (IFG irrespective of lipid status; HbA1c/OGTT unavailable). Random-forest classifiers were developed for each omics layer and for post hoc integrated multi-omics panels to distinguish each NAFLD subgroup from HCs, with performance evaluated in the held-out set. Dialister invisus was administered to high-calorie diet-fed mice, and metabolic and hepatic outcomes were assessed. NAFLD patients showed lower Dialister invisus abundance and higher abundance of the GTDB placeholder taxon Phascolarctobacterium_A sp900545025, with increased predicted menaquinone biosynthetic potential. Microbial and serum metabolite profiles differed significantly among subgroups. Microbiome classifiers achieved AUROCs of 0.71, 0.58, and 0.73 in the held-out internal evaluation, whereas metabolome classifiers achieved AUROCs of 0.89, 0.83, and 0.93 for NAFLD_N, NAFLD_DLP, and NAFLD_IFG. Post hoc integrated panels yielded descriptive AUROCs of 0.92, 0.89, and 0.96 in that subset. Dialister invisus supplementation reduced body weight, serum ALT, AST, triglycerides, fasting blood glucose, and ipGTT AUC in high-calorie diet-fed mice. This study identifies shared gut microbial and serum metabolic alterations across NAFLD patients irrespective of IFG or dyslipidemia, alongside subgroup-specific signatures. The Dialister invisus findings support its potential role in metabolic regulation and warrant mechanistic investigation.
中文摘要:非酒精性脂肪性肝病(NAFLD)常与血脂异常或空腹血糖受损(IFG)并存,但肠道微生物和血清代谢特征仍未充分阐明。我们比较健康对照(HCs)与NAFLD亚组之间的肠道微生物β多样性、分类学谱、预测微生物功能及血清代谢物;评估基于组学的分类器及探索性整合分类器将各亚组与HCs区分的能力;并评估补充Dialister invisus对小鼠代谢反应的影响。采用16S rRNA基因测序和靶向UPLC-MS/MS分别对41例HCs和222例NAFLD患者进行粪便微生物群和血清代谢物分析。按血脂异常和IFG将患者分为三个亚组:NAFLD_N(既无血脂异常也无IFG)、NAFLD_DLP(有血脂异常但无IFG)和NAFLD_IFG(无论血脂状态如何,存在IFG;HbA1c/OGTT不可用)。为各组学层面及事后整合多组学面板开发随机森林分类器,以将每个NAFLD亚组与HCs区分,并在留出集中评估性能。给高热量饮食喂养小鼠施用Dialister invisus,评估代谢和肝脏结局。NAFLD患者显示Dialister invisus丰度降低,GTDB占位分类单元Phascolarctobacterium_A sp900545025丰度升高,并预测甲萘醌生物合成潜力增加。微生物和血清代谢物谱在各亚组间存在显著差异。微生物组分类器在留出内部评估中AUROC分别为0.71、0.58和0.73,而代谢组分类器对NAFLD_N、NAFLD_DLP和NAFLD_IFG的AUROC分别为0.89、0.83和0.93。事后整合面板在该子集中获得描述性AUROC 0.92、0.89和0.96。补充Dialister invisus降低高热量饮食喂养小鼠的体重、血清ALT、AST、甘油三酯、空腹血糖和ipGTT AUC。本研究识别出NAFLD患者无论是否合并IFG或血脂异常均存在的共同肠道微生物和血清代谢改变,以及亚组特异性特征。Dialister invisus的结果支持其在代谢调节中的潜在作用,值得开展机制研究。
Most individuals with steatotic liver disease (SLD) do not develop advanced liver disease. Multiple risk scores for SLD-associated cirrhosis and hepatocellular carcinoma (HCC) have been proposed, but their utility to inform decisions about surveillance for advanced liver disease is unknown. To compare the clinical utility of SLD risk scores for predicting cirrhosis and hepatocellular carcinoma in patients with noncirrhotic steatotic liver disease. This cohort study used data from the national US Veterans Affairs health system of adults with imaging-confirmed SLD without viral hepatitis or primary liver disease from 2008 and 2020. Nine clinical risk scores were calculated at the time of the first imaging results that demonstrated hepatic steatosis. Individuals were followed up until cirrhosis, HCC, death, or 6 months after last follow-up visit. Data were analyzed between November 1, 2025, and May 11, 2026. Nine risk scores evaluated for prediction of cirrhosis or HCC within 10 years were: (1) ALBI, albumin-bilirubin; (2) aMAP, age-male-albumin-bilirubin-platelet; (3) APRI, the aspartate aminotransferase-to-platelet ratio; (4) BARD, body mass index, age, alanine aminotransferase-to-aspartate aminotransferase ratio, and diabetes; (5) FIB-4, fibrosis-4 index; (6) NFS, nonalcoholic fatty liver disease fibrosis; (7) SAFE, steatosis-associated fibrosis estimator; and 2 additional scores. First diagnosis of cirrhosis and first diagnosis of HCC identified using VA and Medicare diagnosis codes and data from the VA Cancer Registry. Cox proportional hazards models were used to calculate time-dependent 10-year probabilities of each outcome predicted by 9 risk scores. Decision curves were generated for each outcome by calculating the net benefit, a weighted measure of true and false positives over a prespecified range of risk thresholds at which a clinician may reasonably recommend intervention. Nine risk scales were used to quantify the risk of cirrhosis or HCC within 10 years. The analysis included 853 131 patients (median [IQR] age, 61 [51-68] years; 62 168 females [7.3%] and 790 965 males [92.7%]) whose median (IQR) BMI was 31.3 (27.6-35.5) and 275 898 (32.3%) had diabetes; of these, 33 794 (3.96%) developed cirrhosis and 2978 (0.35%) developed HCC within 10 years. The FIB-4, APRI, and SAFE scores demonstrated the greatest discrimination of cirrhosis risk, while the SAFE, Tate, and FIB-4 scores demonstrated the greatest discrimination of HCC risk. The SAFE score demonstrated the greatest net benefit predicting cirrhosis. A score of 29.5 corresponded to a 10-year cirrhosis risk of 2.5% and yielded a net benefit of 0.019, or 1.9 additional individuals who develop cirrhosis per 100 individuals classified as at-risk patients. At a 0.25% 10-year risk of HCC, the SAFE score had a net benefit of 0.0016 (1.6 additional true positives per 1000 individuals). The findings of this cohort study show that the SAFE score may inform decisions to repeat screening for cirrhosis in patients with SLD. Clinical risk scores for HCC demonstrated minimal utility to inform HCC screening decisions for patients with noncirrhotic SLD.
中文摘要:多数脂肪性肝病(SLD)患者不会进展为晚期肝病。已有多种用于SLD相关肝硬化和肝细胞癌(HCC)的风险评分,但其在指导晚期肝病监测决策方面的效用尚不清楚。本研究比较SLD风险评分在无肝硬化SLD患者中预测肝硬化和HCC的临床效用。这项队列研究使用美国退伍军人事务部全国医疗系统2008年至2020年影像学确诊SLD、无病毒性肝炎或原发性肝病成人的数据。在首次影像结果显示肝脂肪变时计算9种临床风险评分。随访至发生肝硬化、HCC、死亡或末次随访后6个月。数据分析时间为2025年11月1日至2026年5月11日。评估10年内肝硬化或HCC预测的9种风险评分为:ALBI(白蛋白-胆红素)、aMAP(年龄-男性-白蛋白-胆红素-血小板)、APRI(天冬氨酸氨基转移酶与血小板比值)、BARD(体重指数、年龄、丙氨酸氨基转移酶与天冬氨酸氨基转移酶比值及糖尿病)、FIB-4(纤维化-4指数)、NFS(非酒精性脂肪性肝病纤维化评分)、SAFE(脂肪变相关纤维化估计器)以及另外2种评分。肝硬化首次诊断和HCC首次诊断通过VA和Medicare诊断代码及VA癌症登记处数据确定。采用Cox比例风险模型计算9种风险评分预测各结局的10年时依概率。针对各结局生成决策曲线,计算在临床医生可能合理建议干预的预设风险阈值范围内净获益,即真阳性和假阳性的加权指标。使用9种风险量表量化10年内肝硬化或HCC风险。分析纳入853 131例患者(中位[IQR]年龄61[51-68]岁;女性62 168例[7.3%],男性790 965例[92.7%]),中位(IQR)BMI为31.3(27.6-35.5),275 898例(32.3%)患糖尿病;其中33 794例(3.96%)在10年内发生肝硬化,2978例(0.35%)发生HCC。FIB-4、APRI和SAFE评分对肝硬化风险的区分度最高,SAFE、Tate和FIB-4评分对HCC风险的区分度最高。SAFE评分预测肝硬化的净获益最高。评分29.5对应10年肝硬化风险2.5%,净获益为0.019,即在每100例被归类为风险患者中,多识别1.9例将发生肝硬化者。在10年HCC风险0.25%时,SAFE评分净获益为0.0016(每1000人多1.6例真阳性)。该队列研究结果表明,SAFE评分可辅助SLD患者重复筛查肝硬化的决策。HCC临床风险评分对无肝硬化SLD患者HCC筛查决策的效用很小。
Metabolic dysfunction-associated steatohepatitis (MASH) is a leading indication for liver transplantation, and fibrosis stage most strongly predicts clinical outcomes. Pharmacologic treatment is now available with resmetirom and semaglutide holding conditional approval. To describe the therapeutic landscape for MASH with a focus on anti-fibrotic impact. Narrative review of Phase 2 and 3 trials, meta-analyses, epidemiological data, and trial registries. Historically, drugs targeting downstream fibrogenic or inflammatory pathways have had limited success in advanced development, whereas those improving metabolic dysfunction have had fared better. Fibrosis improvement by at least one stage was seen with resmetirom in up to 26% versus 14% placebo after 52 weeks and with semaglutide in 37% versus 22% after 72 weeks. Several agents in development (e.g., fibroblast growth factor 21 analogues, as well as dual and triple incretin agonists, pan-peroxisome proliferator-activated receptor agonist) report encouraging Phase 2 results, with Phase 3 trials ongoing. Compensated cirrhosis requires a distinct approach related to its fibrosis heterogeneity and burden of portal hypertension. This requires a delicate balance between efficacy and event rates that is further complicated by current regulatory constraints. Fibrosis improvement in MASH is attainable by available drugs with further promise from emerging therapies. The link between treatment induced histological improvement or improvement in noninvasive tests and reduction in clinical outcomes remains unproven. A rich therapeutic pipeline with the promise of combination regimens and increased focus non-invasive endpoints suggests that the future looks bright for patients living with fibrotic MASH.
中文摘要:代谢功能障碍相关脂肪性肝炎(MASH)是肝移植的主要适应证之一,纤维化分期对临床结局的预测作用最强。resmetirom和semaglutide已获得条件性批准,药物治疗现已可用。本文描述MASH的治疗格局,重点放在抗纤维化作用。对2期和3期试验、荟萃分析、流行病学数据和试验注册库进行叙述性综述。历史上,靶向下游纤维化生成或炎症通路的药物在后期开发中成功有限,而改善代谢功能障碍的药物表现更好。52周后resmetirom使至少一个纤维化分期改善的比例最高达26%,安慰剂为14%;72周后semaglutide为37%对22%。多种在研药物(如成纤维细胞生长因子21类似物、双靶点和三靶点肠促胰素激动剂、泛过氧化物酶体增殖物激活受体激动剂)报告了鼓舞人心的2期结果,3期试验正在进行。代偿期肝硬化因其纤维化异质性和门静脉高压负担需要不同策略,需在疗效与事件发生率之间谨慎平衡,当前监管限制使这一问题更复杂。现有药物可实现MASH纤维化改善,新兴疗法带来更多希望。治疗所致组织学改善或无创检测改善与临床结局降低之间的联系仍未得到证实。丰富的治疗管线、联合方案的希望以及对无创终点的更多关注,提示纤维化性MASH患者的未来较为光明。
基础研究 (1篇)
The terminology of fatty liver disease has evolved from non-alcoholic fatty liver disease (NAFLD) to alternative metabolically oriented frameworks, including metabolic dysfunction-associated fatty liver disease (MAFLD) and, more recently, metabolic dysfunction-associated steatotic liver disease (MASLD). Its complex pathogenesis and the lack of targeted therapeutic agents highlight the urgent need for new research perspectives. This review first systematically proposes a novel model: the "gut microbiota-gluconeogenesis-NAFLD axis". Under insulin-resistant conditions, impaired suppression of hepatic gluconeogenesis may coexist with increased de novo lipogenesis, thereby contributing to hyperglycemia and hepatic lipid accumulation. In contrast, intestinal gluconeogenesis (IGN) acts as a key "anticipatory signal" that actively inhibits hepatic glucose output and improves systemic insulin sensitivity via the gut-brain-liver neural circuit. More importantly, gut microbiota and its metabolites (e.g., short-chain fatty acids, bile acids) bidirectionally regulate IGN activation and GNG remodeling through pathways such as cAMP, FFAR3, and FXR/TGR5, suggesting a potential new mechanism of microbiota-host metabolic interaction. This model expands the traditional "liver-centered" perspective to "gut-liver crosstalk" and provides an integrated framework for understanding the metabolic imbalance in NAFLD. It also points towards precision intervention strategies aimed at enhancing IGN and restoring glucose homeostasis (e.g., prebiotics, traditional Chinese medicine polysaccharides, FMT), which are of considerable translational and scientific importance.
中文摘要:脂肪性肝病的命名已从非酒精性脂肪性肝病(NAFLD)演变为以代谢为导向的框架,包括代谢功能障碍相关脂肪性肝病(MAFLD)以及较新的代谢功能障碍相关脂肪性肝病(MASLD)。其发病机制复杂且缺乏靶向治疗药物,亟需新的研究视角。本综述系统提出一个新模型:「肠道菌群-糖异生-NAFLD轴」。在胰岛素抵抗状态下,肝糖异生抑制受损可与新生脂肪生成增加并存,从而促进高血糖和肝脏脂质蓄积。相反,肠道糖异生(IGN)作为关键的前馈信号,通过肠-脑-肝神经环路主动抑制肝葡萄糖输出并改善全身胰岛素敏感性。肠道菌群及其代谢物(如短链脂肪酸、胆汁酸)通过cAMP、FFAR3和FXR/TGR5等通路双向调节IGN激活与GNG重塑,提示菌群-宿主代谢互作的新机制。该模型将传统的「肝脏中心」视角拓展为「肠-肝对话」,为理解NAFLD的代谢失衡提供整合框架,并指向以增强IGN、恢复葡萄糖稳态为目标的精准干预策略(如益生元、中药多糖、粪菌移植),具有重要的转化与科学意义。
6胰腺炎 (3篇)
临床研究 (1篇)
Chronic pancreatitis strongly impairs patients' quality of life through pain and functional insufficiencies, which may be improved by implementing an evidence-based management algorithm. This study aimed to improve quality of life and reduce pain by increasing guideline adherence, using an evidence-based management algorithm, addressing exocrine and endocrine pancreatic insufficiency, nutritional status, bone health, pain management, and lifestyle. A nationwide stepped-wedge cluster-randomized controlled trial was performed across 26 Dutch centers collaborating in the Dutch Pancreatitis Study Group, representing 6 healthcare regions. Current practice was compared with evidence-based management algorithm-guided care. Patients with a definite diagnosis of chronic pancreatitis, who were actively receiving care from a gastroenterologist or surgeon at the time of algorithm implementation, were included during the current practice phase and followed longitudinally. Coprimary endpoints were pain severity (Izbicki Pain Score) and quality of life (Pancreatitis Quality-of-Life Instrument score), with a clinically relevant effect threshold defined as 10% of the maximum score, based on an expert consensus Delphi meeting. Analyses were performed according to intention-to-treat. Secondary outcomes included protocol adherence and several clinical outcomes. Total study duration was 35 months. Overall, 418 patients with chronic pancreatitis were included. Evidence-based management algorithm-guided care improved Izbicki Pain Scores (estimate: -1.72, 97.5% CI: -3.02 to -0.41, P < 0.001), without reaching the predefined threshold. No significant change in Pancreatitis Quality-of-Life Instrument score was observed (estimate: 0.42, 97.5% CI: -0.44 to 1.27, P = 0.27). Median protocol adherence in patients who completed the follow-up period was 68.8% (IQR, 56.1-83.9). Stratified analyses by baseline scores and adherence did not yield clinically relevant improvements. We found no superiority of an evidence-based management algorithm over standard practice in improving quality of life or pain severity in all patients with chronic pancreatitis. However, by subgroup analyses, increased protocol adherence led to significantly better outcomes, especially in those with severe pain or low quality of life at baseline. These findings highlight both the complexity of, and the need for, dedicated protocol adherence in chronic pancreatitis management.
中文摘要:慢性胰腺炎可通过疼痛和功能不足严重影响患者生活质量,实施基于证据的管理算法可能改善这些结局。本研究旨在通过提高指南依从性来改善生活质量和减轻疼痛,采用基于证据的管理算法,处理胰腺外分泌和内分泌功能不全、营养状态、骨骼健康、疼痛管理及生活方式。研究在荷兰胰腺炎研究组协作的26家荷兰中心开展全国性阶梯楔形整群随机对照试验,覆盖6个医疗区域。研究比较当前实践与基于证据的管理算法引导的照护。纳入在算法实施时正由消化科或外科医生积极治疗、且确诊慢性胰腺炎的患者,在当前实践阶段纳入并纵向随访。共同主要终点为疼痛严重程度(Izbicki疼痛评分)和生活质量(胰腺炎生活质量量表评分),临床相关效应阈值定义为最高分的10%,依据专家共识Delphi会议确定。分析按意向性治疗进行。次要结局包括方案依从性和若干临床结局。总研究时长为35个月。共纳入418例慢性胰腺炎患者。基于证据的管理算法引导的照护改善了Izbicki疼痛评分(估计值:-1.72,97.5% CI:-3.02至-0.41,P < 0.001),但未达到预设阈值。胰腺炎生活质量量表评分未见显著变化(估计值:0.42,97.5% CI:-0.44至1.27,P = 0.27)。完成随访患者的方案依从性中位数为68.8%(IQR,56.1-83.9)。按基线评分和依从性分层分析未获得临床相关改善。研究发现,对于所有慢性胰腺炎患者,基于证据的管理算法在改善生活质量或疼痛严重程度方面并不优于标准实践。但亚组分析显示,提高方案依从性可带来显著更好的结局,尤其是在基线存在严重疼痛或低生活质量者中。这些发现突出了慢性胰腺炎管理中方案依从性的复杂性以及专门提高依从性的必要性。
基础研究 (2篇)
Acute necrotizing pancreatitis (ANP) is a severe inflammatory pancreatic disease characterized by pancreatic necrosis and systemic inflammation, with complex pathogenesis, rapid progression, and poor prognosis. Mitochondrial dysfunction in pancreatic acinar cells represents a pivotal early event in ANP; however, mitophagy, a central component of mitochondrial quality control, remains poorly characterized in terms of its role, regulatory networks, and therapeutic potential in ANP. In this study, we demonstrated that BNIP3 (BCL2 interacting protein 3) expression was significantly downregulated in patients with ANP and negatively correlated with inflammatory severity. Consistently, BNIP3-mediated mitophagy was impaired in the pancreatic tissue of ANP mouse models. Notably, restoration of BNIP3 expression using a novel adeno-associated virus targeting pancreatic tissue (AAV-PAN)-Bnip3 gene therapy vector alleviated pancreatic necrosis and systemic inflammatory injury, promoted mitophagy, and inhibited mitochondrial dysfunction and oxidative stress. Mechanistically, BNIP3-dependent mitophagy facilitated the clearance of damaged mitochondria and prevented mitochondrial DNA (mtDNA) release into the cytosol, thereby suppressing AIM2 (absent in melanoma 2) inflammasome activation and subsequent acinar cell pyroptosis. Furthermore, we identified the transcription factor FOXA2 (forkhead box A2) as a direct upstream regulator that bound to the Bnip3 promoter and positively regulated its expression. FOXA2 was downregulated in ANP, whereas pancreas-specific FOXA2 overexpression activated BNIP3-mediated mitophagy and conferred protection against inflammatory injury. Together, these findings uncovered a previously unrecognized mechanism whereby the FOXA2-BNIP3-AIM2 axis mitigated pancreatic and systemic inflammatory injury in ANP by enhancing mitophagy to restrain mtDNA-dependent AIM2 inflammasome activation, highlighting the FOXA2-BNIP3-AIM2 axis as a promising target for gene therapy.
中文摘要:急性坏死性胰腺炎(ANP)是一种以胰腺坏死和全身炎症为特征的严重炎症性胰腺疾病,发病机制复杂、进展迅速且预后较差。胰腺腺泡细胞线粒体功能障碍是ANP早期的关键事件,而线粒体自噬作为线粒体质量控制的核心环节,其在ANP中的作用、调控网络及治疗潜力仍缺乏系统认识。本研究发现,ANP患者中BNIP3(BCL2相互作用蛋白3)表达显著下调,且与炎症严重程度呈负相关;ANP小鼠模型胰腺组织中BNIP3介导的线粒体自噬同样受损。利用靶向胰腺组织的新型腺相关病毒(AAV-PAN)-Bnip3基因治疗载体恢复BNIP3表达后,可减轻胰腺坏死和全身炎症损伤,促进线粒体自噬,并抑制线粒体功能障碍和氧化应激。机制上,BNIP3依赖性线粒体自噬促进受损线粒体清除,阻止线粒体DNA(mtDNA)释放至胞质,从而抑制AIM2(黑色素瘤缺失因子2)炎症小体激活及随后的腺泡细胞焦亡。研究进一步确定转录因子FOXA2(叉头框蛋白A2)是直接上游调控因子,可结合Bnip3启动子并正向调控其表达。FOXA2在ANP中下调,而胰腺特异性过表达FOXA2可激活BNIP3介导的线粒体自噬并减轻炎症损伤。这些结果揭示了一条此前未被认识的通路,即FOXA2-BNIP3-AIM2轴通过增强线粒体自噬限制mtDNA依赖性AIM2炎症小体激活,从而减轻ANP的胰腺及全身炎症损伤,提示FOXA2-BNIP3-AIM2轴是颇具前景的基因治疗靶点。
Lung macrophages constitute the first line of defense against environmental attack and participate in the pathogenesis of acute lung injury (ALI). In this study, we sought to elucidate the impact of HK3 on the regulation of macrophage phenotype in severe acute pancreatitis (SAP)-associated acute lung injury (PALI). HK3 expression was enhanced in lung macrophages of mice with SAP, and overexpression of HK3 in macrophages using adeno-associated viral vectors exacerbated PALI progression and increased macrophage M1 polarization in lung tissues. Overexpression of HK3 enhanced the glycolytic activity of macrophages, thereby polarizing macrophages toward the M1 phenotype. Retinoic acid receptor alpha (RARA) repressed HK3 transcription by binding to the promoter of HK3. Knockdown of HK3 inhibited the macrophage glycolysis induced by RARA knockdown and alleviated PALI development. NEDD4L mediated ubiquitination and degradation of RARA, and NEDD4L overexpression promoted macrophage glycolysis-induced increase in M1 polarization and inhibited M2 polarization. In peripheral blood CD14+ monocytes, NEDD4L and HK3 mRNA expression correlated positively with APACHE II scores and negatively with PaO₂/FiO₂, whereas RARA mRNA expression showed the opposite associations. In conclusion, NEDD4L-mediated degradation of RARA hinders its transcriptional repression of HK3 to activate macrophage glycolysis and M1 polarization in PALI development.
中文摘要:肺巨噬细胞是抵御环境侵袭的第一道防线,并参与急性肺损伤(ALI)的发病过程。本研究旨在阐明HK3对重症急性胰腺炎(SAP)相关急性肺损伤(PALI)中巨噬细胞表型调控的影响。SAP小鼠肺巨噬细胞中HK3表达升高,利用腺相关病毒载体在巨噬细胞中过表达HK3可加重PALI进展并增加肺组织巨噬细胞M1极化。HK3过表达增强巨噬细胞糖酵解活性,促使巨噬细胞向M1表型极化。维甲酸受体α(RARA)通过结合HK3启动子抑制HK3转录。敲低HK3可抑制RARA敲低诱导的巨噬细胞糖酵解并减轻PALI发展。NEDD4L介导RARA泛素化与降解,NEDD4L过表达促进巨噬细胞糖酵解引起的M1极化增加并抑制M2极化。外周血CD14+单核细胞中,NEDD4L与HK3 mRNA表达与APACHE II评分呈正相关,与PaO₂/FiO₂呈负相关,RARA mRNA表达则呈相反关联。结论:NEDD4L介导的RARA降解削弱其对HK3的转录抑制,从而激活PALI发生中的巨噬细胞糖酵解与M1极化。
7肠易激/IBS/功能性胃肠病 (3篇)
临床研究 (3篇)
People with irritable bowel syndrome (IBS) often restrict their intake of FODMAPs because of associated gas and abdominal discomfort. Psyllium, a gel-forming fibre, reduces colonic gas after inulin ingestion. We aimed to determine whether methylcellulose, a low-cost, non-fermentable gelling agent, widely used in food manufacture, could be formulated to match psyllium's physical properties and similarly moderate colonic fermentation of inulin. 3-way randomised cross-over study giving 15 g inulin with 15 g methylcellulose, psyllium or maltodextrin (placebo) in 22 healthy volunteers. Participants underwent hourly MRI scans for 6 h and serial breath hydrogen measurements for 24 h when a final MRI scan was performed. Methylcellulose and psyllium gels did not significantly alter AUC0-360 min, however, they were associated with less colonic gas after the gels reached the colon (AUC180-360 min, p = 0.02). The gels increased AUC0-240 min of small bowel free water (p < 0.0001 and 0.048, respectively), methylcellulose effect>psyllium (p = 0.0005). Both increased colon chyme wateriness (T1AC, AUC180-360 min, p < 0.0001) and volume of hydrated fibre in colon (AUC180-360 min, p < 0.0001 and 0.0009, respectively). Both parameters were greater after methylcellulose than psyllium (p = 0.01 and 0.02, respectively). 24 h measurements of breath hydrogen were not different between groups (AUC0-24 h, p = 1.0) but were reduced by psyllium in the 0-6-h period p = 0.008. Methylcellulose and psyllium reduce colonic gas produced by inulin after the gels reach the colon. Methylcellulose increases the water content of both the small and large bowel more than psyllium. This additional effect may allow improved tolerance of FODMAPs, particularly in IBS patients with constipation. ClinicalTrials.gov identifier: NCT06291272.
中文摘要:肠易激综合征(IBS)患者常因产气和腹部不适限制FODMAPs摄入。车前子是一种成胶纤维,可减少菊粉摄入后的结肠气体。我们旨在确定甲基纤维素——一种低成本、不可发酵、广泛用于食品制造的胶凝剂——能否配制成与车前子物理性质匹配的制剂,并同样调节菊粉的结肠发酵。三向随机交叉研究,22名健康志愿者接受15 g菊粉联合15 g甲基纤维素、车前子或麦芽糊精(安慰剂)。参与者每小时接受MRI扫描共6 h,并在24 h内连续测呼气氢,最后进行一次MRI扫描。甲基纤维素和车前子凝胶未显著改变AUC0-360 min,但凝胶到达结肠后与较少结肠气体相关(AUC180-360 min,p=0.02)。凝胶增加小肠游离水AUC0-240 min(分别p<0.0001和0.048),甲基纤维素效应大于车前子(p=0.0005)。两者均增加结肠食糜含水量(T1AC,AUC180-360 min,p<0.0001)和结肠水合纤维体积(AUC180-360 min,分别p<0.0001和0.0009)。甲基纤维素后这两个参数均大于车前子(分别p=0.01和0.02)。24 h呼气氢测量组间无差异(AUC0-24 h,p=1.0),但车前子在0-6 h时段降低呼气氢p=0.008。甲基纤维素和车前子在凝胶到达结肠后减少菊粉产生的结肠气体。甲基纤维素比车前子更多增加小肠和大肠含水量。这一额外作用可能改善对FODMAPs的耐受性,尤其适用于便秘型IBS患者。ClinicalTrials.gov注册号:NCT06291272。
The Bristol Stool Form Scale (BSFS) is widely used to assess stool consistency and subtype irritable bowel syndrome (IBS). Post hoc analysis of a randomized trial comparing patient self-reported BSFS with physician-assessed BSFS. Baseline symptom severity and quality-of-life questionnaires were also collected. Agreement was poor across the 7-point scale (κ = -0.01, P = 0.77) and after collapsing into 3 categories (κ = 0.04, P = 0.46), with concordance in only 18/64 cases (28%). Symptom severity and quality-of-life scores were similar between concordant and discordant groups. Patient-reported BSFS may not reliably reflect stool consistency or overall IBS burden, suggesting caution when using BSFS alone for monitoring or subtyping IBS.
中文摘要:布里斯托粪便形态量表(BSFS)广泛用于评估粪便稠度和肠易激综合征(IBS)亚型。这项随机试验的事后分析比较了患者自报BSFS与医生评估的BSFS,同时收集基线症状严重度和生活质量问卷。7点量表的一致性差(κ=-0.01,P=0.77),合并为3类后一致性仍差(κ=0.04,P=0.46),仅18/64例(28%)一致。一致组与不一致组的症状严重度和生活质量评分相似。患者自报BSFS可能不能可靠反映粪便稠度或整体IBS负担,提示单独使用BSFS监测或分型IBS需谨慎。
Chronic gastrointestinal (GI) conditions, including irritable bowel syndrome and other disorders of gut-brain interaction, are prevalent and costly, and fragmented care contributes to suboptimal outcomes. Virtual and multidisciplinary care models may improve outcomes. Objectives: We aimed to (i) characterize patients receiving virtual GI care, (ii) report patient engagement with and patient-reported outcomes after virtual multidisciplinary care, and (iii) report healthcare utilization and costs from a payer perspective among patients vs propensity score-matched controls identified from claims data. We collected descriptive data on patient demographics, clinic provider visits, symptoms, and patient-reported outcomes from 3/2021 to 9/2022. To evaluate healthcare utilization and costs, we conducted difference-in-difference analyses using claims data compared with a propensity score-matched control group. Among 234 patients (71% women, mean age 45.4 ± 13.2 years), 51% received a new GI diagnosis, predominately disorders of gut-brain interaction (63%). Engagement criteria were met by 80% (n = 187), who completed a mean of 10 visits and median time-to-first appointment of 6 days. Dietitians (93%), psychologists (76%), and health coaches (64%) were frequently used. Engaged patients exhibited significant improvements from preclinic to postclinic in irritable bowel syndrome severity (226.7-145.6), symptom control (20.2%-86.6%), quality-of-life dysphoria (27.5-32.8), missed workdays (1.0-0.7), and satisfaction (37.4%-96.3%) (all P < 0.05). Compared with matched controls, a significantly smaller percent of patients had imaging (15% vs 44%; P < 0.0001) and GI-related emergency department visits (4% vs 10%; P = 0.0028), which contributed to reductions in GI-related costs ($443 per member per month; P = 0.047) and all-cause costs ($676 per member per month; P = 0.043), equating to annualized savings of $5,316 and $8,112, respectively. Virtual multidisciplinary GI care was associated with high engagement, improved clinical outcomes, and reduced healthcare utilization and costs.
中文摘要:慢性胃肠道疾病,包括肠易激综合征和其他肠-脑互动障碍,患病率高且费用高,碎片化诊疗导致结局不理想。虚拟和多学科诊疗模式可能改善结局。研究目标为:(i)描述接受虚拟胃肠道诊疗的患者特征;(ii)报告虚拟多学科诊疗后的患者参与度和患者报告结局;(iii)从支付方角度报告患者与从理赔数据中识别的倾向评分匹配对照者之间的医疗利用和费用。研究收集2021年3月至2022年9月患者人口学、门诊就诊、症状和患者报告结局的描述性数据。为评估医疗利用和费用,使用理赔数据进行双重差分分析,并与倾向评分匹配对照组比较。234例患者中(71%为女性,平均年龄45.4±13.2岁),51%获得新的胃肠道诊断,主要为肠-脑互动障碍(63%)。80%(n=187)达到参与标准,平均完成10次就诊,首次预约中位时间为6天。营养师(93%)、心理师(76%)和健康教练(64%)使用频繁。达到参与标准的患者从诊疗前到诊疗后在肠易激综合征严重度(226.7-145.6)、症状控制(20.2%-86.6%)、生活质量中的烦躁不安(27.5-32.8)、缺勤天数(1.0-0.7)和满意度(37.4%-96.3%)方面均有显著改善(均P<0.05)。与匹配对照者相比,接受影像检查(15% vs 44%;P<0.0001)和胃肠道相关急诊就诊(4% vs 10%;P=0.0028)的患者比例显著更低,这促成胃肠道相关费用(每成员每月443美元;P=0.047)和全因费用(每成员每月676美元;P=0.043)下降,分别相当于年化节省5,316美元和8,112美元。虚拟多学科胃肠道诊疗与高参与度、临床结局改善以及医疗利用和费用降低相关。
8消化道早癌筛查 (3篇)
临床研究 (2篇)
Colonoscopy quality and diagnostic outcomes in Lynch syndrome have historically been heterogeneous. Following the introduction of the Lynch syndrome Bowel Cancer Screening Programme (BCSP), we assessed colonoscopy quality and diagnostic yield in Lynch syndrome using the National Endoscopy Database (NED), comparing outcomes between BCSP and non-BCSP providers. We performed a cross-sectional analysis of UK Lynch syndrome colonoscopies from NED between June 2024 and June 2025. Colonoscopy quality indicators and endoscopic detection rates for polyp (PDR) and advanced neoplasia (eANDR; polyps ≥10 mm or cancer; histopathology linkage was unavailable) were calculated and compared between BCSP and non-BCSP providers. Factors associated with neoplasia detection were identified using logistic regression. Among 3196 colonoscopies, most were performed in England (90.2%), with 34.1% undertaken within BCSP. Overall colonoscopy quality was high: 97.6% were complete, 89.0% had adequate bowel preparation, and 96.3% had adequate tolerance. BCSP procedures demonstrated higher rates of completion (98.5% vs. 97.1%; P = 0.02) and adequate bowel preparation (92.7% vs. 86.7%; P < 0.001) than non-BCSP colonoscopies. PDR and eANDR were 46.8% and 4.7%, respectively, and were higher in BCSP than non-BCSP procedures (PDR 53.7% vs. 43.3%; eANDR 5.7% vs. 3.9%). Higher polyp detection was associated with increasing age (odds ratio [OR] 1.03, 95%CI 1.03-1.04), male gender (OR 1.48, 95%CI 1.26-1.73), BCSP status (OR 1.50, 95%CI 1.28-1.77), adequate bowel preparation (OR 1.81, 95%CI 1.40-2.34), and England nation (OR 1.99, 95%CI 1.22-3.36). Our NED evaluation demonstrated high colonoscopy performance in Lynch syndrome, with superior quality and endoscopic yield in BCSP procedures, supporting national integration of surveillance to establish Lynch syndrome-specific quality benchmarks.
中文摘要:既往Lynch综合征结肠镜质量和诊断结局存在异质性。Lynch综合征肠道癌症筛查项目(BCSP)实施后,我们利用国家内镜数据库(NED)评估Lynch综合征结肠镜质量和诊断检出率,并比较BCSP与非BCSP服务提供者的结局。我们对2024年6月至2025年6月NED中英国Lynch综合征结肠镜进行了横断面分析。计算结肠镜质量指标以及息肉检出率(PDR)和进展期肿瘤内镜检出率(eANDR;息肉≥10 mm或癌;无法关联组织病理学),并在BCSP与非BCSP服务提供者间比较。采用逻辑回归识别与肿瘤检出相关的因素。3196例结肠镜中,多数在英格兰实施(90.2%),34.1%在BCSP内完成。总体结肠镜质量较高:97.6%完成,89.0%肠道准备充分,96.3%耐受性充分。BCSP操作的完成率(98.5%比97.1%;P=0.02)和肠道准备充分率(92.7%比86.7%;P<0.001)高于非BCSP结肠镜。PDR和eANDR分别为46.8%和4.7%,BCSP操作高于非BCSP操作(PDR 53.7%比43.3%;eANDR 5.7%比3.9%)。息肉检出较高与年龄增加(比值比[OR] 1.03,95%CI 1.03-1.04)、男性(OR 1.48,95%CI 1.26-1.73)、BCSP状态(OR 1.50,95%CI 1.28-1.77)、肠道准备充分(OR 1.81,95%CI 1.40-2.34)和英格兰地区(OR 1.99,95%CI 1.22-3.36)相关。该NED评价显示Lynch综合征结肠镜执行水平较高,BCSP操作质量和内镜检出率更优,支持将监测纳入国家体系以建立Lynch综合征特异性质量基准。
Polyp detection metrics are key quality indicators for colonoscopy. The widespread monitoring of these metrics is hindered by the need to link endoscopy and histopathology data. This study assessed the feasibility of automated linking of data from the Dutch national endoscopy and pathology databases to enable continuous monitoring of polyp detection metrics. Data from the Dutch Gastrointestinal Endoscopy Audit and Automated National Pathological Anatomy Archive (PALGA) were linked using an automated stepwise linking protocol. Units with adequate linkage were included to evaluate polyp detection metrics across categorized diagnostic colonoscopy indications, interunit variability in these metrics, and the extent to which units achieve established polyp detection performance targets. In total, 182,539 colonoscopies (36 units) were included. The proportion of units with adequate PALGA linkage ranged from 47% to 94%, depending on the indication category. The median adenoma detection rate (ADR) was 59.3% (range: 49.4%-68.3%) for colonoscopies after a positive fecal immunochemical test and 37.5% (range: 26.7%-47.9%) for routine diagnostic colonoscopies (surveillance, familial risk, or symptom-related indications combined). The ADR, adenomas per colonoscopy, and sessile serrated lesion detection rate performance targets for routine diagnostic colonoscopies were achieved by 71%, 90%, and 86% of units, respectively. Automated linkage across the Dutch national endoscopy and pathology databases enables scalable, resource-efficient monitoring of polyp detection metrics. Most units achieve established polyp detection performance targets, although considerable interunit variability was observed. To further leverage the feasibility of the linking process, the availability of structured data is required across all units.
中文摘要:息肉检出指标是结肠镜的关键质量指标。这些指标的广泛监测受限于内镜与组织病理学数据需要链接。本研究评估了将荷兰全国内镜与病理数据库数据进行自动链接以实现息肉检出指标持续监测的可行性。研究采用自动化分步链接方案,将荷兰胃肠道内镜审计数据库与全国病理解剖自动归档系统(PALGA)的数据进行链接。纳入链接充分的单位,用于评估按诊断性结肠镜指征分类的息肉检出指标、这些指标的单位间差异,以及各单位达到既定息肉检出性能目标的程度。共纳入182,539例结肠镜检查(36个单位)。PALGA链接充分单位的比例随指征类别不同为47%至94%。粪便免疫化学检测阳性后结肠镜检查的中位腺瘤检出率(ADR)为59.3%(范围49.4%至68.3%),常规诊断性结肠镜检查(监测、家族风险或症状相关指征合并)为37.5%(范围26.7%至47.9%)。常规诊断性结肠镜检查中,分别有71%、90%和86%的单位达到ADR、每结肠镜检查腺瘤数和无蒂锯齿状病变检出率的性能目标。荷兰全国内镜与病理数据库间的自动链接可实现可扩展、资源高效的息肉检出指标监测。多数单位达到既定息肉检出性能目标,但观察到明显的单位间差异。为进一步发挥链接流程的可行性,所有单位都需要提供结构化数据。
基础研究 (1篇)
Early detection of colorectal polyps is crucial to reduce the morbidity and mortality associated with colorectal cancer. However, during endoscopy, continuous camera motion and the complex clinical environment often degrade key visual cues (e.g., polyp morphology, texture, and boundaries). This leads to cross-frame view shifts, which are characterized by heterogeneous appearances of the same lesion over time, thereby introducing spurious correlations that hinder reliable assessment. To address this, we propose a causality-inspired representation learning framework with spatiotemporal memory for polyp detection in colonoscopy videos (CIRL-Polyp). Specifically, we develop a novel View-Shift-Aware Causal Intervention Module (VACIM) to remove non-causal influences by enforcing prediction invariance under view shift perturbations. To further constrain non-causal factors, we introduce a dual-branch detection framework that processes the original and intervention frame sequences in parallel and enforces prediction consistency across branches, thereby promoting invariance to non-causal variations. In addition, we propose Causal Temporal Consistency Memory (CTCM) to leverage long sequence-dependency features and stabilize causal representations by constructing memory banks across branches and performing temporal consistency-enhanced cross-attention. Comprehensive experiments on two public video datasets and a private dataset demonstrate that CIRL-Polyp outperforms existing methods, which validates the effectiveness and suggests the clinical potential of the proposed framework from a causal perspective.
中文摘要:结直肠息肉的早期检出对降低结直肠癌相关发病率与死亡率至关重要。内镜操作中持续的相机运动和复杂临床环境常削弱关键视觉线索,如息肉形态、纹理和边界,造成跨帧视角偏移;同一病灶随时间呈现异质外观,会引入伪相关并妨碍可靠评估。为此,提出一种面向结肠镜视频息肉检测、融合时空记忆的因果启发式表示学习框架(CIRL-Polyp)。具体而言,设计视角偏移感知因果干预模块(VACIM),通过在视角偏移扰动下强制预测不变性来移除非因果影响。为进一步约束非因果因素,引入双分支检测框架,并行处理原始帧序列与干预帧序列,并约束跨分支预测一致性,从而提升对非因果变化的不变性。提出因果时序一致性记忆(CTCM),通过跨分支构建记忆库并执行时序一致性增强的交叉注意力,利用长序列依赖特征并稳定因果表示。在两项公开视频数据集和一项私有数据集上的综合实验表明,CIRL-Polyp优于现有方法,验证了所提框架的有效性,并从因果角度显示其临床潜力。
9肝病/肝硬化 (3篇)
基础研究 (3篇)
Coal mining substantially alters watershed hydrology processes, yet quantitatively disentangling the dominant mechanisms within hydrological models remains challenging. Here, an enhanced Spatiotemporal Variable Source Mixed Runoff model, termed E-SVSMR, was developed to explicitly represent two key mining-induced perturbations: enhanced slope infiltration caused by mining fractures, parameterized through a soil-fissure dual-permeability system with an equivalent saturated hydraulic conductivity, and riverbed leakage, characterized by a nonlinear discharge-dependent function. The physical framework was initially validated at the hillslope scale via high-fidelity 3D variably-saturated flow modeling (COMSOL) in the Wujiayao catchment (78.7 km²). The physical basis of the framework was first evaluated at the hillslope scale in the Wujiayao catchment using high-resolution three-dimensional variably saturated flow simulations. Results demonstrate that goaf-induced fractures form preferential flow pathways and increase effective infiltration by approximately one order of magnitude. When upscaled to the Luzhuang catchment, the E-SVSMR markedly improved runoff simulation, increasing the Nash-Sutcliffe efficiency from 0.41 in the traditional SVSMR to 0.89. Continuous simulations from 1996 to 2009 indicated a cumulative mining-induced runoff loss of 1.73 × 10⁸ m³. Mechanistic decomposition of a representative storm event further suggested that enhanced slope infiltration accounted for approximately 70% of the runoff reduction, whereas riverbed leakage contributed the remaining 30%. Application to the independent Lingshi catchment further demonstrated the transferability of the model. By correcting the systematic post-1994 runoff overestimation in the baseline model, the E-SVSMR increased the Nash-Sutcliffe efficiency from -2.27 to 0.88, and successfully captured the timing and magnitude of mining-driven hydrological disturbances. Overall, the E-SVSMR provides a physically interpretable and transferable modeling framework for diagnosing mining impacts on runoff generation, with implications for flood forecasting and water-resource management in mining-affected catchments.
中文摘要:煤炭开采显著改变流域水文过程,但在水文模型中定量分离主导机制仍具挑战。构建了增强型时空变源混合产流模型(E-SVSMR),以显式表征两类关键采矿扰动:采矿裂隙引起的坡面入渗增强,通过含等效饱和导水率的土壤—裂隙双重渗透系统参数化;河床渗漏,以非线性流量依赖函数刻画。该物理框架先在五家窑流域(78.7 km²)坡面尺度通过高保真三维变饱和流动模拟(COMSOL)进行验证;随后利用高分辨率三维变饱和流动模拟在五家窑流域坡面尺度评估其物理基础。结果表明,采空区诱发裂隙形成优先流路径,使有效入渗增加约一个数量级。将模型上推至芦庄流域后,E-SVSMR明显改善径流模拟,将纳什效率系数由传统SVSMR的0.41提高至0.89。1996—2009年连续模拟显示累计采矿诱发径流损失为1.73×10⁸ m³。对一次代表性暴雨事件的机制分解进一步表明,坡面入渗增强约占径流减少量的70%,河床渗漏贡献其余30%。在独立灵石流域的应用进一步证明模型的可移植性。通过纠正基准模型1994年后系统性径流高估,E-SVSMR将纳什效率系数由-2.27提高至0.88,并成功捕捉采矿驱动水文扰动的时间与幅度。E-SVSMR为诊断采矿对产流的影响提供了物理可解释且可移植的建模框架,对受采矿影响流域的洪水预报与水资源管理具有意义。
This work proposes an algorithm for seeking generalized feedback Nash equilibria (GFNEs) in noncooperative dynamic games. The focus is on cyber-physical systems with dynamics that are linear, stochastic, potentially unstable, and partially observed. We employ system-level synthesis (SLS) to reformulate the problem as the search for an equilibrium profile of closed-loop responses to noise, which can then be used to reconstruct a stabilizing output-feedback policy. Under this setup, we leverage monotone operator theory to design a GFNE-seeking algorithm capable of enforcing closed-loop stability, operational constraints, and communication constraints onto the control policies. This algorithm is amenable to numerical implementation, and we provide conditions for its convergence. We demonstrate our approach in a simulated experiment on the noncooperative stabilization of a decentralized power grid.
中文摘要:这项工作提出一种用于在非合作动态博弈中寻求广义反馈纳什均衡的算法。研究对象为具有线性、随机、可能不稳定且部分可观测动力学的信息物理系统。采用系统级综合将问题重构为寻找闭环噪声响应的均衡剖面,并据此重建稳定化输出反馈策略。在该框架下,利用单调算子理论设计能够将闭环稳定性、运行约束和通信约束施加到控制策略上的广义反馈纳什均衡寻求算法。该算法适合数值实现,并给出其收敛条件。通过在分散式电网非合作稳定化上的仿真实验展示了该方法。
Global food safety requires reliable biosensors in complex matrices. Yet, conventional single-signal electrochemical biosensors suffer from high inter-electrode variability (RSD <12.14%) and low accuracy (<87.84%) due to common-mode signal fluctuations. This study presents a ratiometric biosensor with a dual-electrode design that enables calculation of the current ratio (IWE2/IWE1) between a formaldehyde dehydrogenase-functionalized sensing electrode and an inert graphene reference to mitigate systemic fluctuations. This self-calibrating configuration reduced variability (RSD of 6.92%), improved accuracy (>97.29%), and minimized interference effects (from 7.54% to 1.52%). Spanning a linear range of 0.02-0.50 mM with a LOD of 0.004 mM, the biosensor achieved 97.22-103.87% recovery in coffee samples (RSD = 0.21%). Validation against the Nash assay showed strong correlation (R2 = 0.995) with comparable accuracy at 0.10-0.50 mM concentrations, yet up to nine-fold higher accuracy at 0.02 mM (p < 0.05), confirming its superior suitability for practical application in food safety monitoring.
中文摘要:全球食品安全需要在复杂基质中使用可靠生物传感器。传统单信号电化学生物传感器受共模信号波动影响,存在电极间变异较大(RSD <12.14%)和准确性较低(<87.84%)的问题。本研究提出一种双电极设计的比率型生物传感器,通过计算甲醛脱氢酶功能化传感电极与惰性石墨烯参比电极之间的电流比(IWE2/IWE1)来降低系统性波动。这种自校准配置将变异降至RSD 6.92%,将准确性提高至>97.29%,并将干扰效应从7.54%降至1.52%。该传感器线性范围为0.02–0.50 mM,LOD为0.004 mM,在咖啡样品中回收率为97.22–103.87%(RSD = 0.21%)。与Nash法验证显示强相关性(R2 = 0.995),在0.10–0.50 mM浓度下准确性相当,但在0.02 mM时准确性最高提高九倍(p < 0.05),确认其更适合食品安全监测的实际应用。
10内镜/ESD/ERCP (3篇)
临床研究 (3篇)
Sedation is commonly used during GI endoscopy to improve patient comfort and procedural tolerance. Midazolam is a widely used agent but may be associated with adverse effects and delayed recovery. Remimazolam, an ultrashort-acting benzodiazepine, has emerged as a potential alternative with rapid onset and recovery. The aim of this review is to compare remimazolam with midazolam for sedation in patients undergoing GI endoscopy. A systematic search was conducted across PubMed, Cochrane CENTRAL Library, Google Scholar, and ClinicalTrials.gov from inception till March 2026. Only randomized controlled trials (RCTs) comparing remimazolam with midazolam for sedation in GI endoscopy and reporting any outcome of interest were considered eligible. Statistical analysis was performed using RStudio (R Foundation for Statistical Computing, Vienna, Austria). A total of 9 RCTs involving 1251 patients were included. Meta-analysis showed no significant difference in sedation success (risk ratio, 1.49; P = .08) between remimazolam and midazolam in patients undergoing GI endoscopy. However, compared with midazolam, remimazolam significantly reduced induction time (mean difference [MD], -4.39 minutes; P = .04), time to full alertness (MD, -4.65 minutes; P = .012), recovery time (MD, -15.66 minutes; P ≤ .001), and discharge time (MD, -7.62 minutes; P = .04), and was associated with significantly higher patient satisfaction (standardized MD, 0.34; P < .01). In addition, remimazolam significantly reduced the risk of hypotension (odds ratio [OR], 0.47; P < .001) and bradycardia (OR, 0.59; P = .037), while other adverse events were comparable between groups. Remimazolam demonstrated sedation success comparable to midazolam in patients undergoing GI endoscopy. However, it was associated with faster induction and recovery times, higher patient satisfaction, and a lower risk of hypotension and bradycardia. These findings suggest that remimazolam may represent a safer and more efficient alternative to midazolam for procedural sedation during GI endoscopy. Nevertheless, substantial heterogeneity observed across several outcomes warrants cautious interpretation of these findings.
中文摘要:胃肠道内镜检查常使用镇静以提高患者舒适度和操作耐受性。咪达唑仑是广泛使用的药物,但可能带来不良反应和恢复延迟。瑞马唑仑是一种超短效苯二氮䓬类药物,具有起效快、恢复快的特点,已成为潜在替代选择。本综述旨在比较瑞马唑仑与咪达唑仑用于胃肠道内镜检查患者镇静的效果。研究系统检索了PubMed、Cochrane CENTRAL Library、Google Scholar和ClinicalTrials.gov,检索时间自建库至2026年3月。仅纳入比较瑞马唑仑与咪达唑仑用于胃肠道内镜镇静并报告相关结局的随机对照试验。统计分析使用RStudio(R Foundation for Statistical Computing,Vienna,Austria)完成。共纳入9项随机对照试验、1251例患者。荟萃分析显示,瑞马唑仑与咪达唑仑在胃肠道内镜检查患者的镇静成功率方面无显著差异(风险比1.49;P = .08)。与咪达唑仑相比,瑞马唑仑显著缩短诱导时间(均数差-4.39分钟;P = .04)、完全清醒时间(均数差-4.65分钟;P = .012)、恢复时间(均数差-15.66分钟;P ≤ .001)和离院时间(均数差-7.62分钟;P = .04),并带来更高的患者满意度(标准化均数差0.34;P < .01)。瑞马唑仑还显著降低低血压(比值比0.47;P < .001)和心动过缓(比值比0.59;P = .037)风险,其他不良事件在两组间相当。在胃肠道内镜检查患者中,瑞马唑仑的镇静成功率与咪达唑仑相当,但起效和恢复更快、患者满意度更高,低血压和心动过缓风险更低。这些结果提示,瑞马唑仑可能作为胃肠道内镜操作镇静中更安全、更高效的咪达唑仑替代选择。部分结局存在明显异质性,对这些结果需谨慎解读。
High-quality, annotated data sets are fundamental to clinical research and artificial intelligence (AI) model development. Existing endoscopic databanks are predominantly retrospective, image-based, or lacking patient consent and structured prospective clinical annotations, limiting scientific reproducibility and regulatory-compliant AI validation. This study establishes a prospective endoscopy video databank with standardized annotations enabling AI development and clinical outcomes research. Since 2022, we have prospectively enrolled consecutive patients undergoing EGD or colonoscopy at a tertiary center (NCT06822616). Endoscopies were recorded in full (1920 × 1080 resolution, 60 frames per second, 10-bit color depth) and deidentified at acquisition. Trained staff documented timestamped anatomical landmarks, lesion characteristics, optical diagnoses, interventions, and disease scores in structured case report forms during procedures. Pathology results and metadata were linked to all events observed during the endoscopies and corresponding timestamped video frames. Up to March 2026, a total of 8658 patients (mean age, 59.3 years; 52.0% female) were enrolled, contributing 10,831 procedures (7909 colonoscopies and 2922 EGDs) performed by 55 endoscopists. Each colonoscopy and EGD captured up to 747 and 455 structured variables, respectively. Individual polyps (n = 10,057) and biopsies (n = 11,346) were annotated with 49 and 45 variables, respectively. Inflammatory bowel disease-specific documentation comprised up to 188 variables per procedure. Pathologic findings were present in 83.7% of records. This prospective databank provides the infrastructure for endoscopy research requiring traceable data sourcing, whether for clinical outcomes research or AI development and validation. The integration of full-length videos, real-time procedural annotation, and histopathologic correlation addresses critical gaps in optimizing clinical outcomes and AI research.
中文摘要:高质量、带注释的数据集是临床研究和人工智能(AI)模型开发的基础。现有内镜数据库多为回顾性、基于图像,或缺乏患者知情同意和结构化前瞻性临床注释,限制了科学可重复性和符合监管要求的AI验证。本研究建立了一个具有标准化注释的前瞻性内镜视频数据库,支持AI开发和临床结局研究。自2022年起,在三级中心前瞻性连续纳入接受EGD或结肠镜检查的患者(NCT06822616)。内镜检查全程录制(1920×1080分辨率,60帧/秒,10位色深),并在采集时去标识化。受训人员在检查过程中于结构化病例报告表中记录带时间戳的解剖标志、病变特征、光学诊断、干预措施和疾病评分。病理结果和元数据与检查期间观察到的所有事件及相应带时间戳的视频帧关联。截至2026年3月,共纳入8658例患者(平均年龄59.3岁;女性52.0%),贡献10831次操作(7909次结肠镜和2922次EGD),由55名内镜医师完成。每次结肠镜和EGD分别最多采集747和455个结构化变量。单个息肉(n=10057)和活检(n=11346)分别标注49和45个变量。炎症性肠病专用记录每次操作最多包含188个变量。83.7%的记录存在病理发现。该前瞻性数据库为需要可追溯数据来源的内镜研究提供基础设施,无论用于临床结局研究还是AI开发与验证。全长视频、实时操作注释和组织病理学关联的整合,弥补了优化临床结局和AI研究中的关键缺口。
Endoscopic submucosal dissection (ESD) for cecal lesions in proximity to the appendiceal orifice (L-PAO) is technically demanding and associated with risks of incomplete resection and post-ESD appendicitis. We aimed to assess the feasibility and safety of appendectomy-integrated laparoscopic and endoscopic cooperative surgery (A-LECS) as a novel organ-preserving strategy. This retrospective, two-center study included four consecutive patients with L-PAO Type 3 lesions (extending into the appendix) treated with A-LECS between June 2024 and July 2025. The procedure consisted of underwater ESD combined with traction to achieve maximal intraluminal dissection, followed by immediate laparoscopic appendectomy and subsequent endoscopic closure of the cecal defect. Technical success was achieved in all cases without conversion to open surgery. The mean ESD procedure time was 116.5 minutes. No procedure-related adverse events, such as perforation, bleeding, or stump appendicitis, occurred. Pathological evaluation confirmed complete resection in all cases (3 SSLs, 1 intramucosal adenocarcinoma). No recurrence was observed in follow-up endoscopy. A-LECS may represent a feasible and safe organ-preserving strategy for challenging L-PAO Type 3 lesions that maintains oncological integrity and reduces the risk of post-procedural appendicitis.
中文摘要:对邻近阑尾开口的盲肠病变(L-PAO)行内镜黏膜下剥离术(ESD)技术难度高,并存在切除不完整和ESD后阑尾炎的风险。本研究旨在评价阑尾切除联合腹腔镜与内镜协作手术(A-LECS)作为一种新型保留器官策略的可行性和安全性。这项回顾性双中心研究纳入2024年6月至2025年7月接受A-LECS治疗的4例连续L-PAO 3型病变(病变延伸至阑尾)患者。手术包括水下ESD联合牵引以完成最大程度腔内剥离,随后立即行腹腔镜阑尾切除,再行内镜下闭合盲肠缺损。所有病例均获得技术成功,无中转开腹。ESD平均手术时间为116.5分钟。未发生穿孔、出血或残端阑尾炎等手术相关不良事件。病理评估证实所有病例均完整切除(3例无蒂锯齿状病变,1例黏膜内腺癌)。随访内镜未见复发。A-LECS可能是一种可行且安全的保留器官策略,适用于具有挑战性的L-PAO 3型病变,可保持肿瘤学完整性并降低术后阑尾炎风险。
11肠易激/IBS (2篇)
临床研究 (2篇)
Irritable bowel syndrome with constipation is a prevalent disorder of gut-brain interaction in children and adolescents, associated with chronic abdominal pain, altered bowel habits, reduced quality of life, and a significant healthcare burden. Despite a wide range of therapeutic approaches, treatment responses remain suboptimal, highlighting the need for effective, evidence-based pharmacological options. This review summarizes current and emerging pharmacological therapies for pediatric irritable bowel syndrome with constipation, with a focus on their mechanisms of action, efficacy, and safety. Traditional treatments such as dietary fiber, probiotics, antispasmodics, laxatives, prokinetics, antidepressants, antibiotics, and antihistamines are reviewed, emphasizing the limited and often inconsistent evidence supporting their use for pain relief and overall symptom improvement. Particular attention is given to newer agents approved for adults with irritable bowel syndrome with constipation, including secretagogues (linaclotide, plecanatide, and lubiprostone) and the retainagogue tenapanor, with a detailed discussion of their pharmacological properties and clinical trial data. Linaclotide is currently the only medication approved by the U.S. Food and Drug Administration for the treatment of irritable bowel syndrome with constipation in children aged 7 years or older. While other novel agents have shown promise in adults, pediatric data remain limited or unavailable. Overall, although pharmacological treatment options for pediatric irritable bowel syndrome with constipation are expanding, high-quality, pediatric specific clinical trials are still needed to guide safe and effective management.
中文摘要:便秘型肠易激综合征是儿童和青少年中常见的肠-脑互动障碍,与慢性腹痛、排便习惯改变、生活质量下降及显著的医疗负担相关。尽管治疗手段广泛,治疗反应仍不理想,需要有效且循证的药物选择。本综述总结儿童便秘型肠易激综合征当前和新兴的药物治疗,重点关注作用机制、疗效和安全性。传统治疗包括膳食纤维、益生菌、解痉药、泻药、促动力药、抗抑郁药、抗生素和抗组胺药,其缓解疼痛和改善总体症状的证据有限且常不一致。文章特别关注已获批用于成人便秘型肠易激综合征的新型药物,包括促分泌剂(利那洛肽、普卡那肽和鲁比前列酮)及滞留剂tenapanor,并详细讨论其药理特性和临床试验数据。利那洛肽是目前唯一获美国食品药品监督管理局批准用于7岁及以上儿童便秘型肠易激综合征治疗的药物。其他新型药物在成人中显示前景,但儿科数据仍有限或缺乏。总体来看,儿童便秘型肠易激综合征的药物治疗选择正在扩展,仍需高质量的儿科特异性临床试验来指导安全有效的管理。
The infant gut microbiome undergoes rapid maturation that shapes lifelong gastrointestinal health. Although adults with irritable bowel syndrome (IBS) show characteristic microbial and metabolic alterations, it remains unclear whether these differences precede disease onset. Here, microbiome composition and function in infancy were prospectively associated with future IBS development. Stool samples collected from the All Babies in Southeast Sweden (ABIS) cohort at a mean age of 12.4 (±1.5) months, were analysed using a nested case-control design. Cases included future IBS and/or pelvic and abdominal pain, with the average time between age at stool collection and diagnosis being 11.8 (±5.2) years and a mean age at diagnosis of 12.8 (±5.2) years. Microbial composition was profiled with 16S rRNA gene sequencing (n = 396). Data were processed with DADA2, taxonomically assigned using SILVA database, and predicted functionally with PICRUSt2. Descriptive statistics were analysed using χ2 or Fisher's exact test, global differences with PERMANOVA, differential abundance with ANCOM-BC2, and pathway enrichment with GSEA. Infants with future IBS risk demonstrated microbial divergence, marked by depletion of short-chain fatty acid producers and expansion of facultative and mucosa-disruptive taxa. Inferred functional profiles exhibited reduced fermentative capacity, greater respiratory potential, accelerated degradation of neuroactive aromatic amines, and case-enrichment of cytochrome bc1 complex respiratory unit. Gut microbiome dysbiosis in infants with IBS risk is present many years prior to diagnosis and includes early disruptions in fermentation, redox balance, and amine metabolism that potentially compromise epithelial resilience and promote visceral hypersensitivity. Early detection of microbiome dysbiosis suggests probiotic-based interventions. Barndiabetesfonden; Swedish Council for Working Life and Social Research; Swedish Research Council; Östgöta Brandstodsbolag; Medical Research Council of Southeast Sweden; JDRF-Wallenberg Foundation; Linköping University; Horizon Europe INITIALISE grant.
中文摘要:婴儿肠道微生物组快速成熟,并塑造终生胃肠健康。尽管成人肠易激综合征(IBS)患者存在特征性的微生物和代谢改变,但这些差异是否先于疾病发生仍不清楚。本研究以前瞻性方式将婴儿期微生物组组成和功能与未来IBS发生相联系。采用巢式病例对照设计,分析瑞典东南部所有婴儿(ABIS)队列在平均12.4(±1.5)月龄采集的粪便样本。病例包括未来发生IBS和/或盆腔及腹部疼痛者,粪便采集年龄与诊断之间的平均时间为11.8(±5.2)年,平均诊断年龄为12.8(±5.2)岁。采用16S rRNA基因测序分析微生物组成(n=396)。数据经DADA2处理,使用SILVA数据库进行分类学注释,并用PICRUSt2进行功能预测。描述性统计采用χ2检验或Fisher精确检验,整体差异采用PERMANOVA,差异丰度采用ANCOM-BC2,通路富集采用GSEA。未来有IBS风险的婴儿表现出微生物分歧,以短链脂肪酸产生菌耗竭以及兼性菌和黏膜破坏相关类群扩增为标志。推断的功能谱显示发酵能力降低、呼吸潜能增强、神经活性芳香胺降解加速,并且细胞色素bc1复合体呼吸单元在病例中富集。有IBS风险的婴儿在诊断前多年即存在肠道微生物组失调,包括发酵、氧化还原平衡和胺代谢的早期紊乱,这些变化可能损害上皮韧性并促进内脏高敏感。微生物组失调的早期检测提示基于益生菌的干预。资助:Barndiabetesfonden;瑞典工作生活与社会研究委员会;瑞典研究委员会;Östgöta Brandstodsbolag;瑞典东南部医学研究委员会;JDRF-Wallenberg基金会;林雪平大学;Horizon Europe INITIALISE grant。
12GERD/食管疾病 (2篇)
临床研究 (1篇)
Eosinophilic esophagitis (EoE) patients deemed treatment-refractory are frequently referred to tertiary centres. We aimed to characterize expert perspectives on patients referred for refractory EoE, including its causes, prevalence, and evaluation. We conducted an anonymous and blinded cross-sectional survey of international EoE experts (n = 52) assessing provider characteristics, referral patterns, perceived causes of treatment failure, diagnostic approaches, and prior therapies. Descriptive statistics and subgroup analyses were performed. Respondents were predominantly gastroenterologists (77%) and practiced in academic settings (87%) with high EoE volume. Experts estimated that true refractoriness to medical and diet therapy was 15% [IQR 10-25], median 31% [20-50], respectively. Patients referred for perceived refractory EoE had been treated with PPIs (80%), topical steroids (55%), and elimination diets (45%); dupilumab (10%) was infrequently trialled. Half of the patients referred had been on combination therapy. After referral, experts focused on assessing medication adherence (98%), dosing (92%), and administration technique (90%), with most repeating endoscopy (85%) and performing oesophageal dilation (42%). The causes of perceived refractory disease were subtherapeutic dosing (34%), incorrect medication administration (30.5%), inappropriate medication choice (26.5%), and dietary non-adherence (26%). Functional and behavioural contributors including co-existing oesophageal hypersensitivity (20%), ARFID (9%), and rumination syndrome (5%) were also reported. Experience in treating EoE patients assessed by less than or greater than 10 years did not affect most results. Among international experts, most referred EoE patients labelled as refractory had received suboptimal medical and dilation therapy. This highlights opportunities to optimize care along guideline recommendations prior to referral.
中文摘要:被判定为治疗难治的嗜酸性食管炎(EoE)患者常被转诊至三级中心。本研究旨在描述专家对因难治性EoE转诊患者的看法,包括原因、比例和评估方式。我们对国际EoE专家(n=52)开展匿名盲法横断面调查,评估医生特征、转诊模式、对治疗失败原因的判断、诊断路径及既往治疗。采用描述性统计和亚组分析。受访者以消化科医生为主(77%),多在学术机构执业(87%),EoE诊疗量高。专家估计对药物治疗和饮食治疗真正难治的比例分别为15%[IQR 10–25]和中位数31%[20–50]。因自认为难治性EoE转诊的患者曾接受PPI(80%)、局部激素(55%)和排除饮食(45%)治疗;度普利尤单抗(10%)试用较少。转诊患者中有一半接受过联合治疗。转诊后,专家重点评估用药依从性(98%)、剂量(92%)和给药技术(90%),多数重复内镜(85%)并实施食管扩张(42%)。自认为难治性疾病的原因包括剂量不足(34%)、给药方法不正确(30.5%)、药物选择不当(26.5%)和饮食依从性差(26%)。还报告了功能和行为因素,包括合并食管高敏感(20%)、回避/限制性摄食障碍(ARFID,9%)和反刍综合征(5%)。按治疗EoE患者经验少于或大于10年分层,多数结果未受影响。在国际专家中,多数被标记为难治的转诊EoE患者接受的药物和扩张治疗并不理想。这提示在转诊前按指南建议优化诊疗存在机会。
基础研究 (1篇)
Barrett's esophagus (BE), a metaplastic transformation driven by gastroesophageal reflux disease (GERD), induces oxidative stress but the underlying redox mechanisms remain poorly understood. Protein persulfidation (PSSH), a redox-sensitive, reversible, and antioxidative post-translational modification regulated by hydrogen sulfide (H2S) metabolism, has not been explored in this context. Here, we identify epithelial PSSH as a key regulator of this premalignant process. We applied proteomics and chemoproteomics in 2 patient cohorts to map and validate PSSH and total proteome profiles across healthy (squamous), GERD-exposed, and metaplastic epithelium. Using in vitro and in vivo models of chronic GERD and BE, we modulated H2S levels genetically and pharmacologically. Mechanistic and functional effects were assessed using tissue biopsies or recombinant human proteins. GERD-induced oxidative loss of H2S and its enhanced catabolism initiated early PSSH proteome remodeling in squamous epithelium, which expanded in BE and affected >1300 proteins in clinical samples, indicating potential biomarkers. This also included altered persulfidation of enzymes regulating accumulation of prostaglandin E2 (PGE2), a well-established driver of BE development and progression. H2S depletion accelerated metaplastic transformation, whereas H2S donors reversed these effects in experimental models. PSSH of 15-hydroxyprostaglandin dehydrogenase reversibly suppressed its activity, protecting the enzyme and, unlike irreversible oxidation, allowing recovery of PGE2 degradation. These findings redefine the origin of PGE2 accumulation in metaplasia and establish sulfide loss and persulfidomic remodeling as central, druggable drivers of epithelial reprogramming and redox imbalance in BE pathogenesis.
中文摘要:Barrett食管(BE)是由胃食管反流病(GERD)驱动的化生性转化,可诱导氧化应激,但其氧化还原机制仍不清楚。蛋白质过硫化(PSSH)是一种受硫化氢(H2S)代谢调控、对氧化还原敏感、可逆且具有抗氧化作用的翻译后修饰,尚未在此背景下得到探讨。本研究将上皮PSSH确定为该癌前过程的关键调控因素。我们在2个患者队列中应用蛋白质组学和化学蛋白质组学,绘制并验证健康鳞状上皮、GERD暴露上皮和化生上皮中的PSSH及总蛋白质组图谱。利用慢性GERD和BE的体外与体内模型,通过遗传学和药理学方式调控H2S水平。采用组织活检或重组人蛋白评估机制与功能效应。GERD诱导的H2S氧化性丢失及其分解代谢增强,在鳞状上皮中启动早期PSSH蛋白质组重塑,该重塑在BE中扩展,并在临床样本中影响超过1300种蛋白质,提示其可能作为生物标志物。这一改变还包括调控前列腺素E2(PGE2)蓄积的酶的过硫化发生变化,而PGE2是BE发生和进展的明确驱动因素。H2S耗竭加速化生性转化,而H2S供体在实验模型中逆转这些效应。15-羟基前列腺素脱氢酶的PSSH可可逆性抑制其活性,保护该酶,并且不同于不可逆氧化,可使PGE2降解得以恢复。这些发现重新定义了化生中PGE2蓄积的来源,并确立硫化物丢失和过硫化蛋白质组重塑是BE发病机制中上皮重编程和氧化还原失衡的核心、可成药驱动因素。
13内镜/ERCP (2篇)
临床研究 (2篇)
Radiation Scatter at Fluoroscopy-Guided Endoscopic Procedures: Building Toward Further Optimization.
Exposure to ionizing radiation by endoscopy personnel during fluoroscopy-guided procedures remains a health hazard. We aimed to evaluate a novel lead flap-enhanced artificial intelligence-enabled fluoroscopy (LE-AIF) system to minimize radiation scatter. We conducted prospective study of 218 patients who underwent fluoroscopy-guided endoscopic procedures using conventional AIF or LE-AIF systems. The primary outcome measure was comparison of radiation scatter to endoscopists. Radiation scatter to endoscopists and anesthesia personnel were significantly lower using LE-AIF. On linear regression analysis, conventional AIF and fluoroscopy duration were associated with radiation scatter. LE-AIF significantly reduced radiation scatter at endoscopic procedures.
中文摘要:内镜人员在透视引导操作中暴露于电离辐射仍是健康危害。我们旨在评估一种新型铅挡板增强的人工智能透视(LE-AIF)系统以减少辐射散射。我们对218例接受透视引导内镜操作并使用常规AIF或LE-AIF系统的患者进行了前瞻性研究。主要结局指标是比较内镜医师受到的辐射散射。使用LE-AIF时,内镜医师和麻醉人员受到的辐射散射显著降低。线性回归分析显示,常规AIF和透视时长与辐射散射相关。LE-AIF显著降低了内镜操作中的辐射散射。
Current ERCP-based methods for removing gallbladder stones usually need two separate procedures. We evaluated a single-step technique combining stent placement, balloon dilation, and immediate stone removal. Patients with both gallbladder and common bile duct stones were enrolled. Bile duct stones were extracted via ERCP, followed by POCS-guided gallbladder stenting, balloon dilation of the cystic duct stent portion to more fully expand the stent and removing gallbladder stones in the same session. Outcomes were technical success and complete stone clearance. From March to November 2025, 14 patients were enrolled. Technical success and complete stone clearance were achieved in 14/14 patients. Six patients developed hyperamylasemia; no pancreatitis occurred. One patient experienced gallbladder perforation, which resolved with conservative management. This single-step endoscopic technique is technically feasible, offering a promising minimally invasive alternative for patients with concurrent gallbladder and common bile duct stones who wish to avoid cholecystectomy.
中文摘要:当前基于ERCP的胆囊结石取出方法通常需要两次独立操作。我们评估了一种单步技术,将支架置入、球囊扩张和即刻取石联合。纳入胆囊结石合并胆总管结石患者。先通过ERCP取出胆管结石,随后在经口胆管镜引导下置入胆囊支架,对胆囊管支架部分行球囊扩张以更充分展开支架,并在同一次操作中取出胆囊结石。结局为技术成功和结石完全清除。2025年3月至11月纳入14例患者。14/14例实现技术成功和结石完全清除。6例出现高淀粉酶血症;未发生胰腺炎。1例发生胆囊穿孔,经保守治疗缓解。这种单步内镜技术在技术上可行,为希望避免胆囊切除术的胆囊结石合并胆总管结石患者提供了一种有前景的微创选择。
14炎症性肠病 (2篇)
临床研究 (1篇)
Regulatory safety warnings for Janus kinase inhibitors, based on increased cardiovascular events in the rheumatoid arthritis populations, have raised concern regarding their use in inflammatory bowel disease (IBD) patients with cardiovascular risk factors. Patients 50 years and older with IBD initiating upadacitinib were studied. Lipids, atherosclerotic cardiovascular disease risk scores, and adverse events were longitudinally assessed. Low-density lipoprotein increased early but stabilized, whereas high-density lipoprotein increased, with no change in low-density lipoprotein:high-density lipoprotein ratio. Atherosclerotic cardiovascular disease risk increased modestly (+1.2%). No major adverse cardiovascular events occurred. Two venous thromboembolism events occurred during active disease. In older patients with IBD and baseline cardiovascular risk, upadacitinib was not associated with cardiovascular events over 188 patient-years, supporting appropriate clinical use with risk monitoring.
中文摘要:基于类风湿关节炎人群中?心血管事件增加而发布的Janus激酶抑制剂监管安全警告,引发了对其用于合并心血管危险因素的炎症性肠病患者的担忧。研究纳入50岁及以上、开始使用乌帕替尼的炎症性肠病患者,纵向评估血脂、动脉粥样硬化性心血管疾病风险评分及不良事件。低密度脂蛋白早期升高后趋于稳定,高密度脂蛋白升高,低密度脂蛋白与高密度脂蛋白比值无变化。动脉粥样硬化性心血管疾病风险轻度增加(+1.2%)。未发生主要不良心血管事件。疾病活动期发生2例静脉血栓栓塞事件。在合并基线心血管风险的老年炎症性肠病患者中,乌帕替尼在188患者年观察期内未伴随心血管事件,支持在风险监测下合理临床使用。
基础研究 (1篇)
Mas-related G protein-coupled receptor X2 (MRGPRX2) is a mast-cell-enriched receptor that mediates immunoglobulin E-independent activation by structurally diverse neuropeptides, host-defense peptides, microbial products, and selected cationic drugs. Its biology links tissue stress and neuroimmune signaling to degranulation, vascular responses, pruritus, barrier dysfunction, and inflammatory amplification, but the extent to which individual diseases depend on this pathway remains uncertain. The strongest clinical rationale begins with non-IgE-mediated immediate drug hypersensitivity, for which MRGPRX2 provides a direct mechanistic framework, although rocuronium illustrates the need to distinguish human MRGPRX2 pharmacology from murine Mrgprb2 and from IgE-mediated perioperative allergy. In atopic dermatitis, preclinical and human skin data support a potential amplifier role in type 2 inflammation and itch, but a randomized phase 2b study of EVO756 did not demonstrate efficacy in an unselected population. In chronic urticaria, challenge, biomarker, and genetic studies suggest an MRGPRX2-responsive subgroup within a heterogeneous disease, whereas a randomized phase 2b study of EVO756 in unselected chronic spontaneous urticaria was also negative despite earlier pharmacodynamic activity. Ulcerative colitis provides additional human tissue evidence for an MRGPRX2-associated mast-cell circuit, although murine Mrgprb2 studies show context-dependent protective and pathogenic effects. Emerging evidence in chronic prurigo, allergic contact dermatitis, asthma, mastocytosis, rheumatoid arthritis, synovial inflammation, and neurogenic inflammation is also considered, with explicit separation of human observations from mouse-model evidence. We integrate these findings with receptor pharmacology and early clinical development, emphasizing evidence hierarchy, validated biomarker needs, patient selection, tissue target engagement, safety, and trial design. Current data support MRGPRX2 as an investigational endotype-defining pathway rather than a universal driver of allergic or immune-mediated disease.
中文摘要:Mas相关G蛋白偶联受体X2(MRGPRX2)是一种富集于肥大细胞的受体,可被结构多样的神经肽、宿主防御肽、微生物产物及部分阳离子药物激活,该激活不依赖免疫球蛋白E。其生物学将组织应激和神经免疫信号与脱颗粒、血管反应、瘙痒、屏障功能障碍及炎症放大联系起来,但各具体疾病在多大程度上依赖这一通路仍不确定。最有力的临床依据来自非IgE介导的速发型药物超敏反应,MRGPRX2为其提供了直接的机制框架;不过罗库溴铵的例子说明,需要区分人MRGPRX2药理学、小鼠Mrgprb2以及围手术期IgE介导的过敏。在特应性皮炎中,临床前数据和人皮肤数据支持MRGPRX2可能在2型炎症和瘙痒中起放大作用,但EVO756的一项随机2b期研究在未筛选人群中未显示疗效。在慢性荨麻疹中,激发试验、生物标志物和遗传学研究提示,这种异质性疾病中存在对MRGPRX2有反应的亚组;而EVO756在未筛选的慢性自发性荨麻疹中开展的随机2b期研究尽管早期显示药效学活性,结果同样为阴性。溃疡性结肠炎提供了额外的人体组织证据,支持存在与MRGPRX2相关的肥大细胞环路,不过小鼠Mrgprb2研究显示其保护性和致病性效应取决于具体情境。慢性痒疹、变应性接触性皮炎、哮喘、肥大细胞增多症、类风湿关节炎、滑膜炎症和神经源性炎症中的新证据也纳入讨论,并明确区分人体观察与小鼠模型证据。我们将这些发现与受体药理学及早期临床开发结合起来,强调证据层级、对经过验证的生物标志物的需求、患者选择、组织靶点结合、安全性及试验设计。现有数据支持将MRGPRX2视为一种研究性的、用于界定内型的通路,而非过敏性或免疫介导疾病的普遍驱动因素。
15胰腺疾病 (1篇)
临床研究 (1篇)
Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) have evolved from glucose-lowering agents to foundational therapies for the management of type 2 diabetes mellitus, heart failure, and chronic kidney disease, with substantial benefits for cardiovascular, kidney, and survival outcomes. As their indications continue to expand, a comprehensive understanding of their safety and tolerability has become increasingly important for optimizing patient care. Building on our recent state-of-the-art review of glucagon-like peptide-1 receptor agonists, this review provides a contemporary synthesis of the evidence on the safety and tolerability of SGLT-2is. We critically appraise data from randomized controlled trials, cardiovascular and kidney outcome trials, pharmacovigilance databases, large observational studies, and systematic reviews and meta-analyses. The available evidence demonstrates that SGLT-2is have a favorable overall safety profile, with genital mycotic infections representing the most consistently observed adverse event. Volume depletion and euglycemic diabetic ketoacidosis remain clinically important but are uncommon and are largely preventable through appropriate patient selection, patient education, and temporary treatment interruption during high-risk clinical situations. Fournier's gangrene should be regarded as a very rare but serious complication requiring prompt recognition and treatment. In contrast, randomized trials and meta-analyses generally indicate a reduced risk of acute kidney injury, while evidence concerning fracture, lower-limb amputation, hepatotoxicity, pancreatitis, and cancer is less definitive. Although consistent class-wide increases in these latter outcomes have not been established, uncommon or agent-specific risks cannot be excluded, particularly where event numbers are small or follow-up is limited. Overall, treatment discontinuation because of adverse events is low across major cardiovascular, heart failure, and kidney outcome trials, supporting the excellent tolerability of this therapeutic class. Comparative evidence suggests only modest differences among individual SGLT-2is, although definitive conclusions remain limited by the absence of direct, large, randomized head-to-head trials. We also summarize practical strategies for adverse-event mitigation, monitoring, temporary treatment interruption, and individualized patient selection. As the clinical applications of SGLT-2is continue to broaden, ongoing pharmacovigilance, inclusive clinical trials, and comparative safety studies will be essential to further refine their benefit-risk profile and optimize their safe use across diverse patient populations.
中文摘要:钠-葡萄糖共转运蛋白2抑制剂(SGLT-2i)已从降糖药物发展为2型糖尿病、心力衰竭和慢性肾脏病管理的基础治疗,对心血管、肾脏和生存结局具有显著获益。随着适应证不断扩展,全面理解其安全性和耐受性对优化患者管理日趋重要。在既往关于胰高血糖素样肽-1受体激动剂的最新综述基础上,本综述对SGLT-2i安全性和耐受性证据进行了当代整合,批判性评价了随机对照试验、心血管和肾脏结局试验、药物警戒数据库、大型观察性研究以及系统综述和荟萃分析的数据。现有证据显示,SGLT-2i总体安全性良好,生殖器真菌感染是最持续观察到的不良事件。容量不足和正常血糖性糖尿病酮症酸中毒仍具有临床重要性,但并不常见,通过合适的患者选择、患者教育以及在高危临床情境下暂时中断治疗,大多可以预防。福尼尔坏疽应视为非常罕见但严重的并发症,需要及时识别和处理。相比之下,随机试验和荟萃分析通常提示急性肾损伤风险降低,而骨折、下肢截肢、肝毒性、胰腺炎和癌症方面的证据尚不明确。尽管尚未确立这些后者结局在全类别中一致增加,但不能排除少见或特定药物相关风险,尤其是在事件数较少或随访有限的情况下。总体而言,在主要心血管、心力衰竭和肾脏结局试验中,因不良事件停药的比例较低,支持该治疗类别具有良好耐受性。比较证据提示不同SGLT-2i之间仅存在 modest 差异,但由于缺乏直接、大型、随机头对头试验,确定性结论仍受限。本综述还总结了不良事件缓解、监测、暂时中断治疗和个体化患者选择的实用策略。随着SGLT-2i临床应用不断拓宽,持续药物警戒、具有包容性的临床试验和比较安全性研究对于进一步细化其获益-风险特征并优化不同患者人群中的安全使用至关重要。
16食管疾病 (1篇)
临床研究 (1篇)
Eosinophilic oesophagitis (EoE) is a chronic inflammatory condition requiring repeat endoscopy and biopsy for histological monitoring, which is invasive, resource-intensive and burdensome for patients. The capsule sponge (CS) offers a potential non-invasive alternative. We evaluated the diagnostic accuracy, feasibility and patient acceptability of CS versus endoscopic biopsies for monitoring disease activity in adult patients. A real-world prospective multicentre cohort study was conducted across three NHS sites in England from August 2023 to June 2025. Adults with established EoE without oesophageal strictures underwent same-day endoscopy and CS using the Endosign device. Histological activity was defined as ≥ 15 eosinophils per high-power field or 0.3 mm2 on endoscopic biopsy histology and CS respectively. Symptom burden was assessed using the Dysphagia Symptom Questionnaire, endoscopic severity using the EoE Endoscopic Reference Score and patient acceptability via structured questionnaire. 136 patients (164 paired episodes) from three secondary care hospitals successfully swallowed CS with sufficient sampling; CS swallowing success rate was 92.7%. Median age was 45 years (IQR 34.8-56); 92/136 (67.6%) were male. CS demonstrated sensitivity 76.3%, specificity 89.5%, PPV 80.4%, NPV 87.0% and overall accuracy 84.8% (Cohen's κ = 0.67). AUC was 0.904 (95% CI 0.856-0.953). Patient acceptability recorded 96.7% found CS acceptable, 78.8% preferred it over endoscopy, and 90.8% would repeat the procedure. No complications occurred. CS is a safe, feasible, accurate and highly acceptable less-invasive tool for monitoring EoE. Its implementation could improve care pathways, reducing the need for repeated endoscopic biopsies while maintaining diagnostic reliability, with potential to reduce service burden, carbon emissions and improve patient experience. CoSiE: IRAS number: 314770; ClinicalTrials.gov identifier: NCT06501274; QuBiE: UK Clinical Trial registry identifier: ISRCTN14071734; Trial number: 10083253.
中文摘要:嗜酸性食管炎(EoE)是一种慢性炎症性疾病,需要重复内镜和活检进行组织学监测,这种方式有创、耗费资源且给患者带来负担。胶囊海绵(CS)提供了潜在的非侵入性替代方案。我们评估了CS与内镜活检相比在成人患者中监测疾病活动的诊断准确性、可行性和患者可接受性。2023年8月至2025年6月在英格兰三个NHS中心开展了一项真实世界前瞻性多中心队列研究。已确诊EoE且无食管狭窄的成人同日接受内镜检查和使用Endosign装置的CS。组织学活动定义为内镜活检组织学每高倍视野≥15个嗜酸性粒细胞,CS为每0.3 mm2≥15个嗜酸性粒细胞。症状负担采用吞咽困难症状问卷评估,内镜严重程度采用EoE内镜参考评分评估,患者可接受性采用结构化问卷评估。来自三家二级 care 医院的136例患者(164对配对检查)成功吞咽CS并获得足够采样;CS吞咽成功率为92.7%。中位年龄45岁(IQR 34.8-56);92/136(67.6%)为男性。CS的敏感性76.3%、特异性89.5%、PPV 80.4%、NPV 87.0%、总体准确率84.8%(Cohen's κ=0.67)。AUC为0.904(95% CI 0.856-0.953)。患者可接受性记录显示96.7%认为CS可接受,78.8%较内镜更偏好CS,90.8%愿意重复该操作。未发生并发症。CS是监测EoE的安全、可行、准确且高度可接受的侵入性较低工具。其应用可改善诊疗路径,在保持诊断可靠性的同时减少重复内镜活检需求,并可能降低服务负担、碳排放并改善患者体验。CoSiE:IRAS编号314770;ClinicalTrials.gov标识符NCT06501274;QuBiE:英国临床试验注册标识符ISRCTN14071734;试验编号10083253。
17胃癌 (1篇)
基础研究 (1篇)
Gastric cancer is a multifactorial disease shaped by diverse risk factors and a complex pathogenesis spanning from chronic atrophic gastritis to invasive malignancy. Its global incidence shows marked geographic disparities, and advances in understanding its pathogenic mechanisms have improved diagnosis and treatment. Although the relationship between gastric cancer and macrophages has been extensively investigated, a systematic review integrating the entire clinical and biological continuum of gastric cancer, from epidemiology to management, with a focus on macrophages remains lacking. This review summarizes the epidemiology and multidimensional risk factors for gastric cancer, including infectious, dietary, genetic, microbiome, and metabolite-related factors. We describe the evolution of precancerous conditions, molecular alterations such as miRNA expression, and the bidirectional interactions between gastric cancer cells and macrophages that drive tumor progression within the tumor microenvironment. We also review clinical features, diagnostic approaches based on screening and endoscopy, and current management strategies, including surgery, systemic therapies, targeted therapies, immunotherapy, macrophage-targeted therapies, macrophage metabolic reprogramming, and recent preclinical and clinical advances. Overall, this review integrates evidence from epidemiology, molecular biology, immunology, and pathology to provide a comprehensive framework for understanding gastric cancer pathogenesis and current as well as emerging therapeutic strategies.
中文摘要:胃癌是一种多因素疾病,受多种危险因素影响,其发病机制复杂,涵盖从慢性萎缩性胃炎到侵袭性恶性肿瘤的过程。全球发病率存在明显地域差异,对发病机制认识的进展改善了诊断和治疗。胃癌与巨噬细胞的关系已得到广泛研究,但仍缺乏以巨噬细胞为重点、整合胃癌从流行病学到管理整个临床与生物学连续过程的系统综述。本综述总结胃癌的流行病学和多维危险因素,包括感染、饮食、遗传、微生物组和代谢物相关因素。我们描述癌前病变的演变、miRNA表达等分子改变,以及胃癌细胞与巨噬细胞在肿瘤微环境中的双向相互作用如何驱动肿瘤进展。我们还回顾临床特征、基于筛查和内镜的诊断方法,以及当前管理策略,包括手术、全身治疗、靶向治疗、免疫治疗、巨噬细胞靶向治疗、巨噬细胞代谢重编程及近期临床前和临床进展。总体来看,本综述整合流行病学、分子生物学、免疫学和病理学证据,为理解胃癌发病机制及当前和新兴治疗策略提供综合框架。
18肠道微生态 (1篇)
基础研究 (1篇)
Gut dysmotility is a common long-term effect of enterotoxigenic Bacteroides fragilis (ETBF) colonization but the underlying mechanisms are not clear. Here, using mouse colonization models, we found that ETBF-secreted B. fragilis toxin (BFT) causes loss of colonic myenteric neurons, which are crucial regulators of intestinal motility. BFT induced apoptosis in these neurons through the NOD1-RIPK2-CASP9-CASP3 pathway, leading to gut dysmotility that persisted even after the clearance of ETBF. Analyses of human inflammatory bowel disease and colorectal cancer patient cohorts showed a positive correlation between ETBF and Fusobacterium nucleatum abundance. In mice, F. nucleatum-derived 2-hydroxybutyric acid enhanced BFT production in ETBF by alleviating RprY-mediated suppression and aggravated neurotoxicity and dysmotility. This enteric neuron loss and dysmotility enhanced susceptibility to dextran sulfate sodium-induced colitis in mice. Therapeutically, a Bifidobacterium-based probiotic attenuated neuron toxicity and improved intestinal motility. Our findings reveal bacterial interactions regulating intestinal function and a potential clinical therapeutic approach to preventing outcomes of ETBF colonization.
中文摘要:肠道动力障碍是产肠毒素脆弱拟杆菌(ETBF)定植后常见的长期后果,其机制尚不清楚。研究利用小鼠定植模型发现,ETBF分泌的脆弱拟杆菌毒素(BFT)引起结肠肌间神经丛神经元丢失,而这些神经元是肠道动力的关键调节者。BFT通过NOD1-RIPK2-CASP9-CASP3通路诱导这些神经元凋亡,导致肠道动力障碍,且在ETBF清除后仍持续存在。对炎症性肠病和结直肠癌患者队列的分析显示,ETBF与具核梭杆菌丰度呈正相关。在小鼠中,具核梭杆菌来源的2-羟基丁酸通过减轻RprY介导的抑制增强ETBF的BFT产生,加重神经毒性和动力障碍。这种肠神经元丢失和动力障碍增加小鼠对葡聚糖硫酸钠诱导结肠炎的易感性。治疗上,基于双歧杆菌的益生菌减轻神经元毒性并改善肠道动力。研究结果揭示调控肠道功能的细菌相互作用,以及预防ETBF定植后果的潜在临床治疗途径。
19胆道狭窄 (1篇)
临床研究 (1篇)
BENIGN BILIARY STRICTURES. 1: ESGE suggests temporary insertion of multiple plastic stents (MPSs) to treat postcholecystectomy benign biliary strictures. A fully covered self-expandable metal stent (FCSEMS) can be considered in these patients when the stricture is located >2 cm distally from the main hepatic confluence or for patients who are noncompliant with repeated endoscopic retrograde cholangiopancreatographies (ERCPs). 2: ESGE suggests treating anastomotic biliary strictures following liver transplantation with either MPSs or temporary insertion of an FCSEMS when located >2 cm distally from the main hepatic confluence. 3: ESGE suggests treating biliary strictures secondary to chronic pancreatitis with temporary insertion (6-12 months) of an FCSEMS. 4: ESGE suggests using balloon dilation alone for high grade biliary strictures secondary to primary sclerosing cholangitis. There is no added benefit of stenting following balloon dilation, and stenting may increase the risk of adverse events. 5: ESGE suggests avoiding the insertion of uncovered SEMSs (USEMSs) for the drainage of extrahepatic biliary obstruction of unconfirmed etiology. DISTAL MALIGNANT BILIARY STRICTURES. 6: ESGE recommends the endoscopic placement of a 10-mm diameter SEMS for preoperative biliary drainage (PBD) of extrahepatic malignant biliary obstruction (MBO). 7: ESGE recommends the endoscopic placement of a 10-mm diameter SEMS for neoadjuvant biliary drainage of extrahepatic pathologically confirmed MBO. 8: ESGE recommends endoscopic over surgical or percutaneous biliary drainage for primary decompression of inoperable, extrahepatic MBO. HILAR MALIGNANT BILIARY STRICTURES. 9: ESGE recommends ERCP over percutaneous transhepatic biliary drainage (PTBD) for PBD in hilar malignant obstruction. 10: ESGE suggests palliative drainage of malignant hilar strictures by means of ERCP for Bismuth types I-II. For Bismuth III-IV, ERCP or a combination of ERCP with endoscopic ultrasound-guided biliary drainage (EUS-BD) is preferable over primary PTBD. Complementary drainage using PTBD might be required in some cases. 11: ESGE suggests obtaining drainage of more than 50%, and ideally 70% or more, of the viable nonatrophic liver volume for palliative drainage of proven malignant Bismuth II-IV strictures, using a multimodal approach (EUS-BD/PTBD if needed, as complementary methods to ERCP). 12: ESGE suggests using either plastic stents or USEMSs for palliative drainage of proven malignant hilar obstruction. ESGE suggests a plastic stent when the optimal drainage strategy has not been defined. ESGE suggests using a USEMS in expert centers to reduce the need for revisional procedures based on the patient's expected survival and the likelihood of achieving complete biliary drainage. MALIGNANT BILIARY STRICTURE IN CASES OF FAILED OR UNFEASIBLE ERCP. 13: ESGE recommends EUS-BD over PTBD in cases of malignant biliary stricture following failed or unfeasible ERCP.In patients with distal stricture, ESGE suggests using EUS-guided hepaticogastrostomy (EUS-HGS) where a duodenal stricture is present, and either EUS-HGS or EUS-guided choledochoduodenostomy where there is no duodenal stricture.ESGE suggests using PTBD when EUS-BD fails or is not feasible.
中文摘要:良性胆道狭窄。1:ESGE建议对胆囊切除术后良性胆道狭窄临时置入多根塑料支架(MPSs)。当狭窄位于主要肝管汇合部以远超过2 cm,或患者不能配合重复内镜逆行胰胆管造影(ERCP)时,可考虑使用全覆膜自膨式金属支架(FCSEMS)。2:肝移植术后吻合口胆道狭窄位于主要肝管汇合部以远超过2 cm时,ESGE建议使用MPSs或临时置入FCSEMS治疗。3:慢性胰腺炎继发胆道狭窄,ESGE建议临时置入FCSEMS 6至12个月。4:原发性硬化性胆管炎继发的高级别胆道狭窄,ESGE建议单用球囊扩张。球囊扩张后置入支架无额外获益,且置入支架可能增加不良事件风险。5:病因未明的肝外胆道梗阻引流,ESGE建议避免置入未覆膜自膨式金属支架(USEMSs)。远端恶性胆道狭窄。6:肝外恶性胆道梗阻(MBO)术前胆道引流(PBD),ESGE推荐内镜下置入直径10 mm的SEMS。7:病理确诊的肝外MBO行新辅助胆道引流,ESGE推荐内镜下置入直径10 mm的SEMS。8:不可手术的肝外MBO初始减压,ESGE推荐内镜引流优于手术或经皮胆道引流。肝门部恶性胆道狭窄。9:肝门部恶性梗阻行PBD,ESGE推荐ERCP优于经皮肝穿刺胆道引流(PTBD)。10:Bismuth I-II型恶性肝门部狭窄的姑息性引流,ESGE建议采用ERCP。Bismuth III-IV型,ERCP或ERCP联合内镜超声引导胆道引流(EUS-BD)优于首选PTBD。部分病例可能需要PTBD补充引流。11:对确诊的Bismuth II-IV型恶性狭窄行姑息性引流时,ESGE建议引流超过50%、理想情况下70%或以上的有活力非萎缩肝体积,采用多模式方法,必要时以EUS-BD或PTBD作为ERCP的补充手段。12:确诊恶性肝门部梗阻的姑息性引流,ESGE建议使用塑料支架或USEMSs。最佳引流策略尚未确定时,ESGE建议使用塑料支架。在专家中心,可根据患者预期生存期和实现完全胆道引流的可能性使用USEMS,以减少再次干预的需要。ERCP失败或不可行时的恶性胆道狭窄。13:恶性胆道狭窄在ERCP失败或不可行时,ESGE推荐EUS-BD优于PTBD。远端狭窄患者存在十二指肠狭窄时,ESGE建议采用内镜超声引导肝胃吻合术(EUS-HGS);无十二指肠狭窄时,采用EUS-HGS或内镜超声引导胆总管十二指肠吻合术均可。EUS-BD失败或不可行时,ESGE建议采用PTBD。
20食管癌 (1篇)
临床研究 (1篇)
Esophageal cancer (EC) remains highly lethal partly because many patients are diagnosed at advanced stages, and current diagnostic pathways rely on invasive endoscopy and centralized molecular testing. Circulating microRNAs (miRNAs) are promising minimally invasive biomarkers, yet amplification-based assays can be workflow-intensive and introduce protocol-dependent bias. Here we report an amplification-free, dual-readout gold nanoparticle (AuNP) biosensor for hsa-miR-320b analysis in plasma RNA extracts. Target miR-320b bridges a biotinylated capture probe on streptavidin magnetic beads and a thiolated detection probe on 40-nm AuNPs to form sandwich complexes. A shared magnetic-separation workflow enables two sequential readouts: a colorimetric verification based on AuNP depletion in the supernatant (LOD 0.085 pM) and a digital release-to-count (R2C) mode, in which RNase H selectively cleaves the RNA strand within the DNA/RNA heteroduplex to release AuNP-DNA labels for dark-field single-particle counting (LOD 5.3 fM) without nucleic-acid amplification. The assay demonstrates single-base mismatch discrimination, short-term storage stability, and spike recoveries of 89.8 -92.9% in plasma RNA extracts. In a cohort of 60 clinical plasma samples (20 EC, 20 benign lesions, 20 healthy controls), the R2C digital readout showed an EC-associated elevation of plasma miR-320b relative to benign lesions and healthy controls, with trends consistent with reverse transcription quantitative PCR (RT-qPCR) on the same extracts. This work provides a practical route to amplification-free digital miRNA quantification using countable plasmonic labels and is readily extended to other circulating targets.
中文摘要:食管癌(EC)致死率高,部分原因在于许多患者确诊时已处晚期,现有诊断路径依赖侵入性内镜和集中化分子检测。循环microRNA(miRNA)是有前景的微创生物标志物,但基于扩增的检测流程繁琐,并可能引入依赖操作方案的偏倚。我们报道一种无需扩增、双读数金纳米颗粒(AuNP)生物传感器,用于血浆RNA提取物中hsa-miR-320b分析。目标miR-320b桥连链霉亲和素磁珠上的生物素化捕获探针与40 nm AuNP上的硫醇化检测探针,形成三明治复合物。共享的磁分离流程支持两种顺序读数:基于上清中AuNP耗竭的比色验证(LOD 0.085 pM),以及数字释放计数(R2C)模式,其中RNase H选择性切割DNA/RNA异源双链中的RNA链,释放AuNP-DNA标记用于暗场单颗粒计数(LOD 5.3 fM),无需核酸扩增。该检测显示单碱基错配区分能力、短期储存稳定性,以及血浆RNA提取物中89.8–92.9%的加标回收率。在60例临床血浆样本(20例EC、20例良性病变、20例健康对照)队列中,R2C数字读数显示,相对于良性病变和健康对照,EC相关血浆miR-320b升高,趋势与同一提取物上的逆转录定量PCR(RT-qPCR)一致。这项工作为利用可计数等离激元标记实现无扩增数字miRNA定量提供了实用路径,并可方便地扩展至其他循环靶标。
21肝癌/肝纤维化 (1篇)
基础研究 (1篇)
Long-term liver injury leads to acute hepatitis and chronic liver diseases, including fibrosis and hepatocellular carcinoma (HCC), which frequently necessitate liver transplantation and are associated with poor median survival. Transforming growth factor-β (TGF-β) signalling pathway is a key driver of fibrogenesis and tumor progression. Therapeutic approaches targeting this pathway-via TGF-β receptor blockade or inhibition of its chaperone protein Hsp90- are under pre-clinical and clinical trials, and despite some promising results none of them has been adopted as a definitive therapy. Engineered protein scaffolds have emerged as an attractive alternative owing to their high engineerability and ease of production. In particular, consensus tetratricopeptide repeat (CTPR) proteins are strong candidates because of their modularity, robustness, design flexibility, and amenability to functionalization. Here, we investigate the protein-nanocluster hybrid formulation comprising C390 and nanocluster-stabilizing domain (C390-AuNC) as a Hsp90 inhibitory platform to assess its potential dual anti-fibrotic and anti-tumor activity in two chemically-induced murine liver disease models: acute liver fibrosis and chronic HCC. In the fibrosis model, C390-AuNC markedly suppress the expression of profibrotic markers and promote degradation of collagen fibers in the liver, indicating effective attenuation of fibrogenesis. In the HCC model, C390-AuNC inhibit Hsp90, leading to reduced expression of oncogenic proteins that drive cancer cell proliferation and metastasis, and consequently diminish tumor burden. Collectively, these findings support C390-AuNC as a promising next-generation biotherapeutic platform with low anticipated immunogenicity and high therapeutic potential.
中文摘要:长期肝损伤可导致急性肝炎和慢性肝病,包括纤维化和肝细胞癌(HCC),常需肝移植,且中位生存期较差。转化生长因子-β(TGF-β)信号通路是纤维化生成和肿瘤进展的关键驱动因素。靶向该通路的治疗策略,包括阻断TGF-β受体或抑制其伴侣蛋白Hsp90,正处于临床前和临床试验阶段,尽管取得了一些有希望的结果,尚无一种被采纳为确定性治疗。工程化蛋白支架因可工程化程度高、生产简便而成为有吸引力的替代方案。共识三十四肽重复(CTPR)蛋白尤其是有力候选,因为其模块化、稳健性、设计灵活性和易于功能化。研究考察了由C390与纳米簇稳定域组成的蛋白-纳米簇杂合制剂(C390-AuNC)作为Hsp90抑制平台,在两种化学诱导的小鼠肝病模型中评估其潜在的双重抗纤维化和抗肿瘤活性:急性肝纤维化和慢性HCC。在纤维化模型中,C390-AuNC显著抑制促纤维化标志物表达,促进肝脏胶原纤维降解,表明有效减弱纤维化生成。在HCC模型中,C390-AuNC抑制Hsp90,导致驱动癌细胞增殖和转移的致癌蛋白表达降低,从而减轻肿瘤负荷。这些发现支持C390-AuNC作为有前景的下一代生物治疗平台,预期免疫原性低,治疗潜力高。
22内镜/EMR (1篇)
临床研究 (1篇)
EMR is a well-established treatment for large laterally spreading colorectal lesions. However, recurrence remains a key limitation. Accurate endoscopic evaluation of the post-EMR scar is essential, yet white-light endoscopy (WLE) alone may miss subtle residual neoplasia, contributing to routine biopsies and increased costs. Enhanced imaging modalities, particularly narrow-band imaging (NBI), improve visualization of mucosal and vascular patterns relevant to the detection of recurrence. Despite these advances, the incremental benefit of NBI over WLE for post-EMR scars remains uncertain. We aim to evaluate the diagnostic performance of NBI for the assessment of post-EMR scars, comparing its performance with WLE. We performed a systematic review and meta-analysis using the PubMed, Embase, and Cochrane databases. We searched for randomized and nonrandomized studies comparing WLE with NBI in patients submitted to surveillance colonoscopy after colorectal EMR and reporting at least one of the outcomes of interest. The outcomes assessed were the area under the curve (AUC), sensitivity, and specificity of both endoscopic techniques. Outcomes were reported with their respective 95% CI. This study included 5 studies with 848 scars evaluated. The pooled sensitivity and specificity of WLE for recurrence detection were 0.799 (95% CI, 0.705-0.868) and 0.950 (95% CI, 0.875-0.981), respectively. The pooled sensitivity and specificity of NBI for recurrence detection were 0.904 (95% CI, 0.843-0.942) and 0.936 (95% CI, 0.876-0.968), respectively. The comparison between these AUCs results in a P value of .461. Across 5 studies of 848 post-EMR scars, both WLE and NBI demonstrated high diagnostic performance for scar assessment. When applied in a complementary and sequential approach, with NBI performed after careful white-light evaluation, diagnostic sensitivity and confidence were enhanced, improving the ability to differentiate postresection scars from residual or recurrent neoplasia. This real-world strategy supports a selective and targeted biopsy approach, with the potential to avoid unnecessary biopsies and improve cost-effectiveness in post-EMR surveillance.
中文摘要:EMR是大面积侧向发育型结直肠病变的成熟治疗方式,但复发仍是其主要局限。对EMR后瘢痕进行准确的内镜评估很重要,而单用白光内镜(WLE)可能漏诊细微的残留肿瘤,导致常规活检增加和费用上升。窄带成像(NBI)等增强成像方式可改善与复发检出相关的黏膜和血管形态的显示。尽管有这些进展,NBI相对WLE用于EMR后瘢痕评估的额外获益仍不确定。研究旨在评估NBI对EMR后瘢痕的诊断性能,并与WLE比较。研究者通过PubMed、Embase和Cochrane数据库开展系统评价和meta分析,检索在结直肠EMR后接受监测性结肠镜检查的患者中比较WLE与NBI、且报告至少一项感兴趣结局的随机和非随机研究。评估结局为两种内镜技术的曲线下面积(AUC)、灵敏度和特异度,并报告各自的95%CI。该研究纳入5项研究、评估848处瘢痕。WLE检出复发的合并灵敏度和特异度分别为0.799(95%CI,0.705-0.868)和0.950(95%CI,0.875-0.981)。NBI检出复发的合并灵敏度和特异度分别为0.904(95%CI,0.843-0.942)和0.936(95%CI,0.876-0.968)。AUC比较的P值为0.461。在5项研究、848处EMR后瘢痕中,WLE和NBI对瘢痕评估均表现出较高的诊断性能。采用互补且序贯的方式,即在仔细白光评估后行NBI,可提高诊断灵敏度和信心,改善区分切除后瘢痕与残留或复发肿瘤的能力。这一真实世界策略支持选择性、靶向活检,有望避免不必要的活检并提高EMR后监测的成本效益。
23功能性胃肠病 (1篇)
临床研究 (1篇)
The diagnostic Rome criteria, classify disorders of gut-brain interaction (DGBI) according to the anatomical region of the gastrointestinal (GI) tract from which the predominant symptom are perceived to originate. A study in Asian DGBI patients using an Enhanced Asian Rome questionnaire (EAR3Q) identified symptom clusters involving multiple anatomical section. Our aim was to investigate if DGBI symptom groupings involving more than 1 anatomical region can be found in both Eastern and Western DGBI patients. Physician-diagnosed DGBI patients, recruited from 5 Eastern and 6 Western, completed the EAR4Q. We performed an exploratory and confirmatory factor analysis on questionnaire data to identify symptom groupings, describing distinct DGBI diagnostic entities. In total, 1,074 DGBI patients (66.8% women, 42.6 ± 14.6 years) were recruited. We identified 10 distinct symptom groupings: (i) irritable bowel syndrome predominant diarrhea triggered by a meal and relieved by bowel movement or passing of flatus; (ii) constipation; (iii) upper GI symptoms with predominant regurgitation, nausea and vomiting; (iv) upper and lower GI symptoms relieved by bowel movement or flatus; (v) epigastric pain or burning related to bowel movement or passing flatus; (vi) lower GI symptoms triggered or worsened by bowel movement or passing flatus; (vii) meal-related pain and gas symptoms; (viii) globus and dysphagia; (ix) functional chest pain and heartburn; (x) constipation and belching relieved by bowel movement or passing flatus. Although some symptom groupings aligned with the Rome IV diagnostics, several clearly include multiple anatomical regions, surpassing the scope of the Rome regional subdivision approach. Our study revealed 10 distinct symptom clusters. Some aligned with Rome criteria but other extended beyond its strict anatomical divisions, challenging a key assumption of the Rome classification framework. These results provide novel insight on a multicontinental scale about the complexity of symptom patterns in DGBI and their anatomical relationships.
中文摘要:罗马诊断标准依据主要症状被感知来源的胃肠道解剖区域对肠-脑互动障碍(DGBI)进行分类。一项在亚洲DGBI患者中使用增强型亚洲罗马问卷(EAR3Q)的研究发现了涉及多个解剖部位的症状簇。我们的目标是探讨在东方和西方DGBI患者中是否都能发现涉及一个以上解剖区域的DGBI症状分组。从5个东方和6个西方中心招募由医生诊断的DGBI患者,完成EAR4Q。我们对问卷数据进行探索性和验证性因子分析,以识别症状分组,描述不同的DGBI诊断实体。共纳入1,074例DGBI患者(女性66.8%,年龄42.6±14.6岁)。我们识别出10个不同的症状分组:(i)餐食诱发、排便或排气后缓解的腹泻型肠易激综合征;(ii)便秘;(iii)以反流、恶心和呕吐为主的上消化道症状;(iv)排便或排气后缓解的上、下消化道症状;(v)与排便或排气相关的上腹痛或烧灼感;(vi)由排便或排气触发或加重的下消化道症状;(vii)与餐食相关的疼痛和胀气症状;(viii)癔球感和吞咽困难;(ix)功能性胸痛和烧心;(x)排便或排气后缓解的便秘和嗳气。尽管部分症状分组与罗马IV诊断一致,但若干分组明显包含多个解剖区域,超出了罗马按区域细分方法的范围。我们的研究揭示了10个不同的症状簇。部分与罗马标准一致,另一些则超出其严格的解剖划分,挑战了罗马分类框架的一项关键假设。这些结果在多大陆尺度上为DGBI症状模式的复杂性及其解剖关系提供了新见解。
24食管癌筛查 (1篇)
临床研究 (1篇)
Esophageal cancer (EC) remains a significant public health burden in China. Current diagnostics modalities such as endoscopy and imaging are invasive, poorly accessible, or insensitive for early-stage cases. DNA methylation alterations in circulating free DNA (cfDNA) are promising for non-invasive cancer detection. We aimed to develop and validate a methylation PCR-based assay for EC detection using EC-specific DNA methylation targets. Here, we report myESCAP, a PCR-based assay that amplifies and quantifies levels of EC-specific methylation in cfDNA METHODS: We conducted a multi-center, retrospective case-control study with 489 EC cases and 555 non-malignant controls (benign esophageal/gastric diseases or asymptomatic) to develop myESCAP, a methylation-specific PCR assay containing 11 EC-specific methylation markers from our previous genome-wide methylation screening, selected for strong discriminative performance and PCR compatibility. cfDNA was collected, bisulfite-converted, and tested by myESCAP, and results were analyzed by six modeling strategies (generalized linear model, k-nearest neighbors, C5.0 decision tree, gradient boosting machine, random forest, support vector machine) to train EC-prediction models using 347 EC cases and 349 non-malignant controls, and validated in 142 EC cases and 206 controls. All myESCAP markers demonstrated significant differential methylation between ECs and non-malignant controls, with adjusted p values between 5.8×10⁻3 and 3.1×10⁻88. The six models showed robust performance in the training cohort (average AUC = 0.835, average sensitivity = 76.13%, average specificity = 90.88%). They maintained performance in the validation cohort (average AUC = 0.823, average sensitivity = 75.59%, average specificity = 89%). Specifically, for stage I cases, myESCAP had an average sensitivity of 47.2%, highlighting the challenge of early detection with limited circulating tumor DNA and the need for further optimization. myESCAP accurately differentiated EC from non-malignant controls. The six models collectively confirm myESCAP's robustness and clinical potential as a cost-effective, non-invasive diagnostic tool for EC.
中文摘要:食管癌(EC)在中国仍构成显著公共卫生负担。现有诊断方式如内镜和影像学具有侵入性、可及性差或对早期病例不敏感。循环游离DNA(cfDNA)中的DNA甲基化改变有望用于非侵入性癌症检测。我们旨在利用食管癌特异性DNA甲基化靶点开发并验证一种基于甲基化PCR的食管癌检测方法。此处报告myESCAP,一种扩增并定量cfDNA中食管癌特异性甲基化水平的PCR方法。方法:开展多中心回顾性病例对照研究,纳入489例食管癌病例和555例非恶性肿瘤对照(良性食管/胃疾病或无症状者),用于开发myESCAP;该甲基化特异性PCR方法包含11个食管癌特异性甲基化标志物,来源于既往全基因组甲基化筛查,依据强判别性能和PCR兼容性选出。采集cfDNA,经亚硫酸氢盐转化后由myESCAP检测,结果用六种建模策略(广义线性模型、k近邻、C5.0决策树、梯度提升机、随机森林、支持向量机)分析,以347例食管癌病例和349例非恶性肿瘤对照训练食管癌预测模型,并在142例食管癌病例和206例对照中验证。所有myESCAP标志物均显示食管癌与非恶性肿瘤对照之间存在显著差异甲基化,校正p值介于5.8×10⁻³至3.1×10⁻88。六种模型在训练队列中表现稳健(平均AUC=0.835,平均灵敏度=76.13%,平均特异度=90.88%)。在验证队列中维持性能(平均AUC=0.823,平均灵敏度=75.59%,平均特异度=89%)。对于I期病例,myESCAP平均灵敏度为47.2%,显示在循环肿瘤DNA有限时早期检测的挑战以及进一步优化的需要。myESCAP能准确区分食管癌与非恶性肿瘤对照。六种模型共同证实myESCAP作为食管癌经济、非侵入性诊断工具的稳健性和临床潜力。
25内镜/ESD (1篇)
临床研究 (1篇)
Delayed bleeding after gastric endoscopic submucosal dissection (ESD) remains a significant clinical complication, particularly in patients receiving anticoagulants/ dual antiplatelet therapy (DAPT). However, effective preventive measures are not established and the efficacy of endoscopic shielding using polyglycolic acid (PGA) sheets with fibrin glue in this high-risk population remains unclear. This study prospectively evaluated the efficacy of PGA sheets and fibrin glue shielding in preventing delayed bleeding after gastric ESD in patients receiving anticoagulants/ DAPT. This multicenter, prospective, single-arm confirmatory study was conducted at 13 Japanese institutions. Patients with gastric neoplasms who underwent ESD while receiving anticoagulants/DAPT were enrolled. Following standard ESD and prophylactic coagulation, PGA sheets and fibrin glue were applied to the ulcer beds. The primary endpoint was delayed bleeding within 28 days. Secondary endpoints included late delayed bleeding, transfusion, emergency endoscopy, and thromboembolic events. We included 125 patients in this study. Delayed bleeding occurred in 13 (10.4%) patients (95% confidence interval: 5.7-17.1%), which did not meet the pre-specified threshold of 15% (p = 0.09), and late delayed bleeding occurred in 7.2%. Bleeding rates were higher in DAPT (28.6%) than in anticoagulant users (9.3%). Blood transfusion was required in 5.6% of the patients, and thromboembolic events occurred in 0.8%. The prespecified efficacy threshold was not met. Delayed bleeding occurred in 10.4% of patients receiving anticoagulants or DAPT. Further controlled studies are needed to determine whether PGA shielding provides clinical benefit in this high-risk population.
中文摘要:胃内镜黏膜下剥离术(ESD)后迟发性出血仍是重要临床并发症,尤其在接受抗凝药/双联抗血小板治疗(DAPT)的患者中。有效预防措施尚未确立,聚乙醇酸(PGA)片联合纤维蛋白胶进行内镜下覆盖在该高危人群中的效果仍不明确。本研究前瞻性评估PGA片与纤维蛋白胶覆盖预防接受抗凝药/DAPT患者胃ESD后迟发性出血的效果。这项多中心、前瞻性、单臂确证性研究在日本13家机构开展。纳入接受抗凝药/DAPT期间行ESD的胃肿瘤患者。标准ESD及预防性电凝后,将PGA片和纤维蛋白胶覆盖于溃疡面。主要终点为28天内迟发性出血。次要终点包括晚期迟发性出血、输血、急诊内镜和血栓栓塞事件。共纳入125例患者。13例(10.4%)发生迟发性出血(95%置信区间:5.7-17.1%),未达到预设15%阈值(p=0.09),晚期迟发性出血发生率为7.2%。DAPT组出血率(28.6%)高于抗凝药组(9.3%)。5.6%患者需要输血,血栓栓塞事件发生率为0.8%。未达到预设疗效阈值。接受抗凝药或DAPT的患者中迟发性出血发生率为10.4%。需要进一步对照研究确定PGA覆盖是否在该高危人群中提供临床获益。